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SUMMARY  
 
Much of the promise that human embryonic stem cells (hESCs) hold for 
regenerative medicine is dependent on the development of a feeder-free and 
xenogenic-free culture platform. MatrigelTM and inactivated fibroblasts currently 
dominate as the field culture substrates; however concerns about contamination and 
batch inconsistency are its limitations. Defined substrates that can maintain hESC 
pluripotency are therefore of high interest. Attempts to address these issues have 
centred on the use of peptide/protein substrates.  Of those examined, the adhesive 
extracellular matrix (ECM) protein vitronectin (VN) has been shown to be 
particularly effective. However little is known about either the defining parameters or 
threshold levels of surface-bound VN that are required to maintain hESC 
pluripotency.  
To establish this baseline, a range of VN solution concentrations were 
examined and the minimum amount of tissue culture-treated polystyrene surface-
bound VN able to support long-term propagation of pluripotent cells (> 10 passages) 
determined. Analyses highlighted a particular VN surface threshold, 250 ng/cm2, 
which was able to maintain the growth of pluripotent hESCs.  
If the use of its VN for the culture expansion of hESC is ever to replace 
MatrigelTM or cell feeders as a routine substrate, clearly the coating efficiency needs 
to be greatly improved. To address this issue, a novel strategy was developed based 
on the ionic and sequence-based binding of proteins to heparan sulfate (HS), a 
structural component of the ECM.  
Through the use of its affinity to a synthesized peptide containing the heparin-
binding domain of VN, an HS variant (HS9+ve) was purified by affinity 
chromatography from porcine-derived HS.  The binding avidity of HS9+ve for VN was 
                                                                                             ix 
determined using a combination of biochemistry and capillary electrophoresis assays. 
The data clearly demonstrated the improved specificity of the HS9+ve variant for VN 
as compared to other ECM proteins. Thus a strategy by using a tuned HS as a bound 
substratum to capture and present VN was explored next. 
To develop a substrate-sandwich consisting of tissue culture-treated 
polystyrene (TCPS) surface coated with HS9+ve and VN, the TCPS needed to be made 
positively charged so as to bind the negatively charged HS.  This was achieved by 
plasma polymerization of surface allylamine (AA) polymers. Subsequently, HS 
binding was confirmed by a combination of radiolabeled HS and dye-based assays. 
The coating efficiency and threshold surface density of VN able to support the 
propagation of pluripotent hESC was then re-evaluated with saturating amounts of 
precoated HS9+ve.  
When AA surfaces were coated with HS9+ve, and then VN, they proved to be 
equally effective in all the hESC bioassays as compared to the surfaces at the VN 
threshold density of 250 ng/cm2. Cells cultured on AA+HS9+ve and 5 g/ml of VN 
coating solution retained their pluripotency for > 8 passages, remained karyotypically 
normal and were able to readily differentiate in vitro and in vivo when stimulated. 
Importantly, although the AA+HS9+ve+VN5 surface density (150 ng/cm2) contained 
~ 30 % less VN than that passively adsorbed to TCPS (250 ng/cm2), the hESCs were 
still easily propagated without adversely affecting their pluripotency. This represents 
a significant reduction in the VN surface density needed for hESC maintenance and 
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1.1. Introduction 
 
Human pluripotent stem cells (hPSCs) can be isolated from either the inner 
cell mass of blastocysts, or induced from somatic cells (“induced pluripotent stem 
cells,” iPSCs). These cells have the dual ability to divide indefinitely, and to 
differentiate into lineages characteristic of each of the 3 germ layers, endoderm, 
mesoderm and ectoderm. Hence the clinical potential of pluripotent cells is 
substantial. The usual methods of culturing these cells typically mandates the use of 
either inactivated mouse or human fibroblast cells as feeder layers, or a basement 
membrane extract from mouse cells (MatrigelTM). However, these poorly defined cell 
culture substrates are not suitable for the culturing of clinical grade hPSCs for 
therapy. Clearly, better surfaces need to be explored.  
In response to this constraint, several surfaces have been developed, including 
coatings incorporating extracellular matrix (ECM) proteins (laminin, fibronectin, 
vitronectin, collagen IV), peptides (vitronectin heparin-binding domain peptide, or 
RGD derivatives) and polymers (Table 1.1). The surface density of the active 
ingredients of these coatings is again either poorly defined, or not defined at all. 
Moreover, the method of immobilizing ECM proteins onto culture surfaces involves 
passive adsorption, a method that is both poorly understood and non-specific.  
Of the ECM proteins, vitronectin (VN) is amongst the most promising. It has 
already been shown that it supports hESC culture by engaging V5 integrins on 
their cell surfaces (Rowland et al. 2010) and that cell glycosaminoglycans (GAGs) are 
critical mediators of VN binding via unique heparin-binding peptide domains (Klim et 
al. 2010). Hence the idea of creating a novel surface using a combination of heparan 
sulfate (HS) and VN, and to understand the surface threshold requirement for the 
long-term culture of hPSCs has a rational basis.  
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 Thus, this study set out to determine the surface density of VN that can support 
long-term propagation of pluripotent cells using a natural ECM component, heparan 
sulfate, as a pre-coating to adsorb functional VN efficiently. This is key, because 
unless surfaces can be produced that are scalable, cost effective, reliable and 
reproducible, the possibilities for cultured cells to be of therapeutic value decline 
markedly.  
 
1.2. Pluripotent stem cells 
 
 Precursor cells can be categorized into pluripotent, multipotent or unipotent 
based on their differentiation potential.  Pluripotent cells are defined as being capable 
of dividing and producing all the differentiated cell types; multipotent cells have the 
potential to give rise to cells of multiple, but limited number of lineages; and 
unipotent cells have the capacity to differentiate into only one cell type (Hoffman & 
Carpenter 2005a).  
Human pluripotent stem cells (hPSCs) are not only a promising platform for 
the study of complex human developmental processes, but a source of 
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Figure 1.1. Potential clinical applications of hPSCs. (Evans & Kaufman 1981) 
 
 
1.2.1. Sources of hPSCs 
 
Two groups, Evans and Kaufman, and Martin et al. in the early 1980s were 
the first to isolate mouse embryonic stem cells (mESCs) from the inner cell mass of 
embryos (Evans & Kaufman 1981, Martin 1981).This breakthrough opened the 
possibility of using these cells as a source for the derivation of all the cell types of the 
body (endoderm, mesoderm and ectoderm) (Fig. 1.2). Consequently, human 
embryonic stem cells (hESCs) were isolated from the inner cell mass (Reubinoff et al. 
2000, Thomson et al. 1998), and resembled mESCs in their ability to both self-renew 
indefinitely,  and differentiate into the three germ layers in vivo and in vitro (Ben-Hur 
et al. 2004, D'Amour et al. 2006, Lavon et al. 2004, Mummery et al. 2003, Phillips et 
al. 2007, Reubinoff et al. 2001, Xu et al. 2001a).  
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Figure 1.2. Sources and differentiation potential of hESCs (Hyslop et al. 2005a). 
 
Although hESCs promise much, many ethical and legal challenges remain. 
Embryos must be destroyed to obtained hESCs. In 2006, Yamanaka et al. overcame 
this obstacle by demonstrating the ability of mouse fibroblasts to be reprogrammed 
back to pluripotent states by retrovirally introducing stem cell-associated genes (OCT-
4, Sox2, c-myc, and Klf4); these cells were dubbed induced pluripotent stem cells 
(iPSCs) (Takahashi & Yamanaka 2006). This discovery abrogated the ethical 
concerns and opened a whole new field for regenerative medicine.   
 However, several challenges are also associated with these improved 
techniques; in particular, retroviruses have major safety concerns. In addition, the 
introduced c-myc is an oncogene which can cause cancer (Marion et al. 2009). 
Overall, reprogramming has low efficiency (0.01-1 %) (Takahashi et al. 2007) and the 
possibility that cells with incomplete reprogramming will form a teratoma are 
problematical (Zhao et al. 2009). Yamanaka et al. reported that about 20 % of the 
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mice they tested developed tumours from iPSCs. In a later study they reported that 
iPSCs can be generated without c-myc, but the process takes longer and is not 
efficient (Aoi et al. 2008, Takahashi et al. 2007). Many other groups have addressed 
these problems by either using small compounds that mimicked the effects of the 
transcription factors (Huangfu et al. 2008, Shi et al. 2008), or using alternate vectors 
such as plasmids (Zhou & Freed 2009) or micro RNA molecules (Judson et al. 2009).  
Both human and mouse iPSCs resemble embryonic stem cells in every aspect 
tested: gene expression, chromatin methylation patterns, doubling time, embryoid 
body formation, teratoma formation and viable chimera formation  (reviewed by 
(Amabile & Meissner 2009, Kiskinis & Eggan). Although the sources of iPSCs are 
not as controversial as ESCs, the field is still in its infancy, and many technical issues 
remain to be addressed.  Other methods that do not rely on the integration of 
transgenes have proven inefficient (0.0001 to 1 %), while those that do rely on the 
integration of transgenes face the problems of incomplete reprogramming and 
tumourigenesis. Thus it is still premature to dispense with the advantages of ESCs; 
hence the focus of this thesis will be on hESCs and the way they react to defined 
environments.  
 
1.2.2. Characterization of hESCs 
 
 The most reliable way of determining the pluripotent state of hESCs is by 
monitoring the expression of a set of phenotypic markers with fluorescence-activated 
cell sorting (FACS). These markers can be broadly categorized into cell surface 
markers and intracellular markers, including transcription factors.  
 Unique surface markers are used to characterize the state of ESCs, the 
antigens predominately identified from previous studies of embryonic carcinoma (EC) 
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cells. At present, amongst the key markers are the stage-specific embryonic antigens 
SSEA-3 and SSEA-4, Tra-1-60 and Tra-1-80. More recently, the successful 
generation by several groups of monoclonal antibodies (mAbs) specific to hESCs has 
added to the list of useful markers. The antigens that have proved most useful are the 
heat shock 70-kDa protein 8 isoform (HSPA8) (Son et al. 2005), podocaylxin-like 
protein-1(PODXL) (Choo et al. 2008) and the epithelial cell adhesion molecule 
(EpCAM) (Ng et al. 2010). 
A network of transcription factors, chiefly octamer-binding transcription 
factor 4 (OCT-4), SRY (sex determining region Y)-box 2 (Sox2), and Nanog have 
been found to be critical for efficient maintenance of ESC self-renewal (Bowles et al. 
2000, Chambers et al. 2007, Mitsui et al. 2003, Parslow et al. 1984). The first of 
these, OCT-4, which binds to the octamer sequence ATGCAAT, is highly expressed 
in both mouse and human ESCs (Parslow et al. 1984). This is the most widely 
accepted molecular marker of undifferentiated ESCs. Knockdown of OCT-4 in human 
and mouse ESCs with RNA interference (RNAi) triggers a rapid differentiation into a 
trophoblast lineage (Hay et al. 2004, Matin et al. 2004). This transcription factor has 
been employed by several groups as one of the genes in the reprogramming cocktail 
that re-specifies somatic cells to iPSCs (Shi et al. 2008).  
Sox2 is a target gene of OCT-4, a member of the high mobility group (HMG) 
box DNA-binding protein family (Bowles et al. 2000). Together with OCT-4, Sox2 
helps to regulate downstream target genes; it also shares an expression pattern similar 
to OCT-4 in mouse pre-implantation development (Avilion et al. 2003). Repression of 
Sox2 using RNAi in mESCs results in trophectoderm differentiation in a manner that 
resembles the RNAi knockdown of OCT-4 (Masui et al. 2007). In contrast, over-
expressing Sox2 in cells triggers the differentiation of mESCs (Kopp et al. 2008). 
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However, the loss of Sox2 does not greatly affect downstream Oct/Sox target genes, 
making Sox2 dispensable if OCT-4 levels are elevated (Masui et al. 2007). Despite 
this potential redundancy, Sox2 is one of the most widely used of the reprogramming 
genes.   
 Nanog was first identified through in silico analysis of mESC-specific 
transcription by two independent groups (Chambers et al. 2003, Mitsui et al. 2003). It 
is a homeobox-containing transcription factor thought to play a key role in 
pluripotency. Over-expression of Nanog in mESCs can maintain cells in an 
undifferentiated state in the absence of leukaemia inhibitory factor (LIF) (Mitsui et al. 
2003) and also enables hESCs to grow in the absence of feeder layers (Darr et al. 
2006). Knockout of Nanog causes both mESCs and hESCs to differentiate into other 
cell types (Chambers et al. 2007, Hyslop et al. 2005b, Mitsui et al. 2003, Zaehres et 
al. 2005). Notably, Nanog is absent in Yamanaka’s cocktail of reprogramming genes, 
because although it stabilizes cells in an undifferentiated state, it is not central to the 
maintenance of pluripotency (Chambers et al. 2007).    
 As well as FACS analysis, other assays such as chromosomal stability, 
chromatin methylation pattern, doubling time, in vivo and in vitro differentiation 
potential and chimera formation are also standard methods for the characterization of 
ESCs. Karyotypic stability is a major concern with the clinical use of these cells. 
There have been many reports that chromosomal abnormalities, including aneuploidy 
(trisomy 12 and amplification of 17q) and other translocations may provide a selective 
advantage to hESCs over the long term. Interestingly, the Nanog gene is located on 
12p (Baker et al. 2007). A study by The International Stem Cell Initiative analyzed 
125 hESC lines from 11 laboratories world-wide and found that cells adapted to 
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culture tend to acquire changes on chromosomes 1, 12, 17 and 20, with the BCL2L1 
gene emerging as a strong candidate for driving culture adaptation (Amps et al. 2011).  
 One of the hallmarks of ESCs is their ability to differentiate in vitro as 
embryoid bodies (EBs) and give rise to all 3 germ lineages, and when injected into 
SCID mice, they are able to form teratomas containing structures from all 3 lineages 
(Reubinoff et al. 2000, Wobus et al. 1984). Thus, before ESCs are cultivated in vitro, 
their pluripotency must be verified both by their ability to form EBs when cultured, 
and to form multi-germline teratomas in vivo.   
 
1.2.3. Defined hESC culture platforms   
 
 The clinical possibilities for stem cells rest on the ability to generate them in 
large numbers. This requirement has prompted the FDA to set out requirements for 
stem-cell based therapies to ensure that downstream processing does not pose a risk 
for either contamination or harm (Halme & Kessler 2006).  
Human ESCs derived from the inner cell mass of blastocysts have been most 
often grown in laboratories in co-culture systems with mitotically-inactivated mouse 
embryonic fibroblast (MEF) cells (Lee et al. 2011, Reubinoff et al. 2000, Thomson et 
al. 1998). This feeder layer supports the growth of hESCs in the presence of 20 % 
fetal calf serum (FCS) (Whateley & Knox 1980). Many of the cell lines available in 
cell banks are derived using this standard method. Although this co-culture platform 
can support hESCs, it is labour-intensive and imposes significant limitations on 
subsequent large-scale expansion. As well as this, the presence of FCS and mouse 
feeders is not suitable for the development of clinical-grade hESCs, due to the 
xenogenic risks they introduce. Non-human sera (such as FCS) are potential sources 
of contamination via prions or viruses, or may induce immune reactions to the foreign 
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proteins (Lim & Bodnar 2002). Thus the removal of FCS as a serum source and MEFs 
as feeders would represent a major advance. While human feeders have been 
developed that can successfully replace MEFs (Choo et al. 2004, Genbacev et al. 
2005), these cells may carry-over during hESC removal and thus adversely affect 
hESC purity. Feeders thus limit experimental interpretation as the data generated may 
in fact be a combined response from cells and feeder layers to any stimuli or treatment 
(Moore 2006).  
 The other problem is that spontaneous differentiation occurs frequently under 
these conditions. Thus, Amit and co-workers developed the use of KnockOutTM 
Serum Replacement (KSR) in combination with recombinant basic fibroblast growth 
factor (FGF-2) as an alternative cocktail to replace serum in media (Amit et al. 2000). 
KSR contains AlbuMAX I, a lipid-rich serum albumin derived from bovine plasma, 
which is markedly less complex than the protein mix of FCS. Amit et al. also 
introduced the use of enzymatic treatment with Collagenase IA for the subculturing of 
cells, allowing a method of culturing them at much higher density and lesser 
differentiation (Amit et al. 2000). This marked the beginning of rational, larger scale 
culturing of hESCs, albeit still requiring the use of feeders as supporting cells.   
To produce clinical-grade hESCs for therapeutic application, hESCs will need 
to be cultured in a feeder-free platform (Halme & Kessler 2006). Some feeder-free 
platforms have been developed. Xu et al. demonstrated the use of MatrigelTM; a 
gelatinous basement membrane extract derived from mouse Engelbreth-Holm-Swarm 
tumour cells, as an alternative substrate (Xu et al. 2001a). Xu and co-workers 
successfully cultured hESCs on MatrigelTM together with conditioned media (CM) 
from MEFs supplemented them daily with FGF-2 and used collagenase to passage 
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cells. This form of passaging has since become a common technique in many 
laboratories.  
Despite these advances, the use of MatrigelTM is plagued by batch-to-batch 
variability, and the possibility of transferring the highly immunogenic non-human 
sialic moiety, N-glycolylneuraminic acid (Neu5Gc), to the hESCs (Nasonkin & 
Koliatsos 2006). MatrigelTM is also known to contain a diverse and variable number 
of factors that include laminin-111, entactin, HS proteoglycans (HSPGs) as well as 
several growth factors (Xu et al. 2001a). This variability is problematical. As well as 
this, the CM from MEFs can also contain contaminants, particularly xenogenic 
antigens, which could possibly be transferred to the hESCs. It has been recently been 
shown that as many as 136 unique proteins can be identified in the CM from MEFs, 
including proteins that trigger cell growth and differentiation (Lim & Bodnar 2002). 
Indeed these results have yielded several more candidates for testing in attempts to 
construct a fully defined culture platform. 
Several defined media to replace the CM, including XVIVO-10 (Lonza) (Li et 
al. 2005), DMEM/F12 (Invitrogen) (Li et al. 2005), IMDM/F12 (Invitrogen) (Vallier 
et al. 2005), hESF9 (CSTI) (Furue et al. 2008), StemPro (Invitrogen) (Wang et al. 
2007) and mTeSRTM1  (Stem cell technologies) have also been developed (Ludwig et 
al. 2006a). A comparative study by 5 separate laboratories assessed the different cell 
culture media for their ability to support 10 different hESC lines over 10 passages. Of 
the eight culture systems, only the two commercial media, mTeSRTM1 and 
STEMPRO, supported maintenance of the majority of the cell lines over 10 passages 
(Akopian et al. 2010). Hence, mTeSRTM1 will be used to culture hESCs in attempts to 
maintain cells in a more pluripotent state in this thesis.   
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A further development was described by Ludwig and colleagues, who reported 
that a combination of human collagen IV, fibronectin (FN), laminin (LN) and 
vitronectin (VN) was able to support hESCs over several passages when combined 
with a xeno-free culture medium (TeSR1) (Ludwig et al. 2006b). However this relies 
on four different human matrix proteins as a substrate, adding significantly to the cost 
of scale-up.  Moreover, the cells were found to be karyotypically abnormal (Ludwig 
et al. 2006b), which may explain their ready adaptation to these conditions. In other 
approaches, hESCs have been shown to propagate on separate matrices of FN, LN, 
LN-511, E-cadherin and VN (Amit & Itskovitz-Eldor 2006, Braam et al. 2008, 
Miyazaki et al. 2008, Rodin et al. 2010). Such findings suggest that a defined, 
scalable substrate to propagate hESCs may be a possibility. Also, the iPSC line 
IMR90 has recently been successfully propagated on plasma-purified VN (Rowland et 
al. 2010). Manton et al. have demonstrated that a chimeric VN: insulin-like growth 
factor 1 (IGF-1) complex, when added into serum-free media, could maintain 
pluripotent hESCs. However in their study, hESCs were cultured on a substrate of 
murine Laminin, which does not meet the requirements for a xeno-free culture 
platform (Manton et al. 2010). The experiments in fact suggested that VN, of the 
several ECM proteins being investigated, may be most useful for the propagation of 
pluripotent stem cells. 
 Although these surfaces are able to support hESC propagation, the method of 
immobilizing ECM proteins is problematical; in almost all cases it is by passive 
physical adsorption, which gives no control over the amounts or activity of the 
proteins once on the surface.   
Defined model surfaces, in the form of immobilized peptide arrays, have been 
used previously as substrates for hESC adhesion and expansion (Derda et al. 2007, 
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Liu et al. 2011, Orner et al. 2004). While dilution is used to tune the peptide surface 
density, the actual amounts of peptide that attach to the substrate are almost never 
quantified or even measured. Furthermore, the analysis of hESC pluripotency is 
limited to detecting endogenous alkaline phosphatase and OCT-4 expression, without 
any examination of karyotypic stability or the differentiation potential of the 
expanded hESCs. In a study by Kolhar et al., cyclic RGD peptide sequences 
immobilized using the Michael addition reaction were shown to be capable of 
promoting hESC attachment and propagation (Kolhar et al. 2008). Using this 
platform, hESCs could be cultured for > 10 passages, without adversely affecting 
karyotype or differentiation potential. Although indirect estimates of final peptide 
surface density (10-30 fmol/cm2) were obtained from fluorescence measurements and 
enzyme-linked immunosorbant assay (ELISA), no direct quantification of the peptide 
surface density or other surface characterization was carried out. 
Other than recombinant, truncated or whole ECM protein as a possible 
substrate, studies by Villa-Diaz et al., Irwin et al., Brafman et al., Melkoumian et al. 
and Klim et al. have all demonstrated the ability of synthetic polymers poly[2-
(methacryloyloxy)ethyl dimethyl-(3-sulfopropyl)ammonium hydroxide] 
(PMEDSAH), N-(3-Aminopropyl)methacrylamide hydrochloride (APMAAm), 
poly(methyl vinyl ether-alt-maleic anhydride (PMVE-alt-MA), peptide-acrylates 
(BSA-PAS, VN-PAS), and alkanethiol-conjugated peptides (VN-HBD) to support 
hESCs over the long-term in culture (Table 1.1) (Brafman et al. 2010, Irwin et al. 
2011, Klim et al. 2010, Melkoumian et al. 2010, Villa-Diaz et al. 2010). Although 
these defined surfaces are promising, these methods are still in their infancy, and they 
are yet to be proven as robust or as stimulatory as MatrigelTM or other protein-based 
methods. The common theme for both peptide-acrylates and the peptide conjugates is 
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the requirement for VN, either whole or in part, to be immobilized onto the cell 
culture surface, in some cases via biotinylation to streptavidin-coated surfaces. It is 
clear that the means of immobilizing VN to retain its native conformation is of crucial 
importance hence better immobilizing strategy is needed.  
Hakala et al. compared the use of MatrigelTM with different feeder-free hESC 
culture substrates including various biomaterials, human ECM proteins, human and 
animal sera matrices. In this study, MatrigelTM was superior in terms of the maximum 
passage number attained, as well as hESC morphology and the pluripotent markers 
expressed (Hakala et al. 2009). Therefore, MatrigelTM is used as a positive surface for 
the culture of hESC in this thesis. These results thus set the background for this study 
to combine engineering and biology to generate better-defined, VN-based surfaces. 
 
Table 1.1 Defined substrates developed for long-term growth of hESCs in a 
feeder-free microenvironment. 
  Method of preparation 
Biological components 
  Recombinant E-cadherin 
 
Absorption by surface (Nagaoka et 
al. 2010) 
  Recombinant laminin-511 
 
Absorption by surface (Rodin et al. 
2010) 
  Recombinant vitronectin 
 
Absorption by surface (Braam et al. 
2008) 
  RGD and vitronectin heparin-binding peptide 
 
 
Biotinylated peptides bound to 
streptavidin-coated surface (Klim et 
al. 2010) 
  RGD domains of bone-sialoprotein and vitronectin 
 
Peptides bound to acrylate-coated 
surface (Melkoumian et al. 2010) 
Synthetic components 
       PMEDSAH 
 
Polymer synthesis by surface-
initiated graft polymerization (Villa-
Diaz et al. 2010) 
 
      APPMAAm Polymer synthesis by photoinitiated 
radical addition polymerization 
(Irwin et al. 2011) 
 
      PMVE-alt-MA                 
 
Polymer synthesis by free radical 
polymerization (Brafman et al. 2010) 
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 The overall progress towards a fully defined culture system only addresses a 
variant of the multi-faceted set of problems surrounding the translation of hESCs into 
the clinic. Another challenging problem is to be able to achieve sufficient cell 
numbers for stem cell transplantation. Only limited numbers of cells can be cultured 
on 2-dimensional (2-D) TCPS in a cost-effective manner, and thus other scalable 
methods need to be explored. The problem can be overcome by growing cells in 
controlled bioreactors at industrial scales. Oh et al. have demonstrated the successful, 
robust, serial culturing and passaging of hESCs on microcarriers (MC) in such a way 
that retains their pluripotency. MCs allow cells to grow in much higher numbers in 
bioreactors as compared to 2-D cell culture (Oh et al. 2009). Recently Heydarkhan-
Hagvall et al. created a 3-dimensional (3-D) microenvironment by electrospinning 
gelatin type B and PCL together (Heydarkhan-Hagvall et al. 2012). These scaffolds 
were used to culture mESCs after their adsorption with collagen IV, FN, LN, VN, 
MatrigelTM or gelatin. He observed that cell numbers were higher in scaffolds coated 
with LN or VN as compared to the other factors. His results are consistent with the 
many previous studies that demonstrated VN can serve as a very promising substrate 
for the 2-D and 3-D culture of hESCs (Braam et al. 2008, Li et al. 2010, Rowland et 
al. 2010, Yap et al. 2011).  
 
1.3. Extracellular Matrix proteins 
 
 During embryonic development, the ECM plays a critical role in directing the 
proliferation, differentiation and migration of cells, particularly at the blastocyst, and 
later stages. In tissue culture, cells avidly interact and respond to specific ECM cues 
to attach, proliferate and differentiate (Evseenko et al. 2009, Hakala et al. 2009, Kato 
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et al. 1995). Thus, the ECM remains an indispensible component for any culture 
surface development. 
 The central importance of ECM was first established by Gospodarowicz and 
colleagues, when they published in their seminal study “The permissive effect of the 
ECM on cell proliferation in vitro” (Gospodarowicz et al. 1980). He reported the 
superior proliferation with a coincident, increased growth factor sensitivity of bovine 
granulosa and adrenal cortex cells cultured on detergent-exposed ECM, produced by 
corneal endothelial cells, compared to tissue culture plastic. He also discovered that 
cells cultured on this decellularized matrix proliferated without exogenous FGF-2, the 
key mitogen for cells cultured on plastic. Further research revealed that bovine bone 
cells normally synthesize FGF-2 and store it in their ECM (Globus et al. 1989). A 
further comparison using hepatocarcinoma cells cultured on either the decellularized 
matrix or the plastic revealed differences in their morphology, doubling time and 
migratory activity, confirming the superiority of ECM for cell culture 
(Gospodarowicz et al. 1978, Vlodavsky et al. 1980). Grunert et al. also showed that 
the decellularized matrix of osteoblastic cells contained glycosaminoglycans that 
regulated bone-morphogenetic protein 2 (BMP-2) activities (Grunert et al. 2007). 
 ECM consists of proteoglycans, non-proteoglycan polysaccharides, fibres and 
ECM proteins (Aumailley & Gayraud 1998). It sequesters a wide range of growth 
factors within the saccharide compartment, so serving as the external protein reservoir 




Vitronectin (VN) is a 459 amino acid, multifunctional, 75 kDa (Schvartz et al. 
1999a) glycoprotein that is found in abundance in the ECM and serum (Hayman et al. 
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1983). Carbohydrates account for about 30 % of VN’s total mass (Schvartz et al. 
1999a). It was first discovered as a “serum spreading” factor that could adhere to 
glass (Hayman et al. 1983, Stanley 1986). Its amino acid sequence was deduced from 
a human liver complementary DNA (cDNA) library (Solem et al. 1991), and human 
VN shares about 80% homology with mouse and rabbit forms (Preissner et al. 1997). 
VN is involved in various functions, and interacts with glycosaminoglycans 
(GAGs) to assist in the processes of cell adhesion and cell spreading (Francois et al. 
1999). It also binds to plasminogen, plasminogen activator inhibitor-1 (PAI-1), 
thrombin-antithrombin (TAT) complexes, several collagens and the urokinase-type 
plasminogen activator (uPAR) (Francois et al. 1999, Morris et al. 1994, Schvartz et 
al. 1999b) that participates in the blood clotting cascade. It also inhibits the 
membrane-rupturing effects of the cytolytic complement pathway by binding to serine 
protease inhibitors, so promoting cell survival (Declerck et al. 1988, Milis et al. 1993, 
Schvartz et al. 1999a).   
This ECM protein is primarily synthesized in the liver, and secreted into the 
circulation together with a 19 amino acid signal peptide which is cleaved during 
processing (Schvartz et al. 1999b).  VN is heterogenic, presenting in two structurally 
and functionally distinct forms: the monomeric form, found in the circulation in 
significant concentrations (0.4 mg/ml) (Schvartz et al. 1999b) and then deposited 
extra-vascularly into many tissues and ECM. This ECM association triggers the 
second heparin-binding multimeric form (Francois et al. 1999, Gibson & Peterson 
2001, Izumi 1989, Podor et al. 2002, Seiffert & Schleef 1996).  
VN is made up of 5 domains: the N-terminal somatomedin B domain (residues 
1-39) which was originally thought to be mitogenic, and contains binding sites for 
PAI-1 and uPAR; the connecting region, containing an arginine-glycine-aspartic acid 
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(RGD) sequence (residues 45-47), which mediates the attachment of hESCs via  
V5 integrin (Braam et al. 2008); the ‘linker’ region (residues 45 - 130) which 
contains both a TAT complex and collagen binding sites within a highly unstructured 
domain (Xu et al. 2001b); a central domain with hemopexin homology (residues 131-
286) that has been proposed to contain a secondary heparin-binding site (Liang et al. 
1997); and finally a C-terminal domain which also has hemopexin homology 
(residues 269-459), and contains sites for plasminogen binding and the primary 
binding site for heparin (Fig. 1.3). It was also found that heparin-binding domain 
(HBD) of insulin-like growth factor binding protein 3 and 5 (IGFBP-3 and IGFBP-5) 
enhance IGF-1 binding to VN (Firth et al. 1998, Grulich-Henn et al. 2002). 
 
Figure 1.3. Structure of vitronectin, encompassing N-terminal Somatomedin B, 
hemopexin and heparin-binding domains (Schvartz et al. 1999b). The underlined 
residues are the basic amino acids involved in the electrostatic binding to negatively-
charged heparin. 
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The RGD sequences in VN interact with the integrins on cell surfaces, which 
in turn triggers a cascade of cellular events (Jones & Walker 1999) such as allowing 
cells to migrate through ECM to new locations (Germer et al. 1998, Zanetti et al. 
1994). Association of VN with integrins enhances both the survival of glioma cells 
under insult from drug-induced apoptosis (Uhm et al. 1999), and protects 
microvasular endothelial cells from apoptosis via V3 and V5 integrins (Isik et 
al. 1998). Such data suggests that the V integrin subunit is important for VN-
induced anti-apoptotic response. The integrin receptor activation also led to clustering 
and formation of focal adhesion contacts on the cell membrane which link 
extracellular signalling to the cell cytoplasm.  Optimal cell response to growth factors 
is also known to depend on prior integrin-mediated cell attachment to the ECM 
(Eliceiri 2001, Giancotti & Ruoslahti 1999) . It is clear that integrin engagement is 
important for the optimization of growth-factor induced biological processes, as there 
is a great deal of cross-talk between the two systems. 
Suzuki et al. used the cyanogen bromide technique to chemically sequence 
VN, and revealed a highly basic region near the C-terminus. This region incorporates 
the heparin-binding domain (HBD) and occurs at residues 362-395; 
(RPSLAKKQRFRHRNRKGYR SQRGHSRGRNQNSRR, Figure 1.3)  (Suzuki et al. 
1984). The basic amino acids arginine, lysine and histidine in the VN-HBD play key 
roles in this interaction, and engage the precisely spaced, negatively charged sulfate 
and carboxylate groups within GAGs (Cardin & Weintraub 1989). The binding of VN 
to heparin also induces structural changes to the molecule, whereby cryptic sites are 
revealed, exposing extra loci for other ligands (Morris et al. 1994, Seiffert & Smith 
1997). The “true” position of the HBD in VN has been much debated over the years 
(Fig. 1.4). Studies by several authors have shown that the HBD is buried in the native 
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molecule, stabilized by a cluster of negative charges. This cryptic binding site 
becomes exposed when VN undergoes heating or chemical denaturation (Hayashi et 
al. 1985, Izumi 1989, Preissner & Mullerberghaus 1987). However, other studies 
support another model, wherein the HBD is actually exposed in the native and 
denatured VN protein, not hidden, so allowing the binding of GAGs without 
denaturation and exposure of any cryptic binding site (Gibson et al. 1999, Xu et al. 
2001b, Zhuang et al. 1997). These models are summarized in Figure 1.4.   
 
Figure 1.4. The two proposed models for the HBD in VN. (A) HBD basic residues 
are buried in native VN, and are stabilized by the acidic residues at the N-terminal. 
The HBD domain gets exposed by heat or chemical denaturation. (B) The HBD is 
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exposed on the surface of native VN, and denaturation is accompanied by the self-
association of VN into its multivalent form (Zhuang et al. 1997). 
 
These contradicting positions will only be resolved with the 3-D structural 
resolution of VN. However, attempts to crystallize the whole protein have been 
unsuccessful, due to its large size and extensive glycosylation. Moreover, the protein 
is too large for high-resolution structural determination by nuclear magnetic 
resonance.  Lynn and colleagues used computational analysis to predict the 3-D form 
for the complete protein (Lynn et al. 2005). They surmised that VN is a bi-lobed 
cylinder, with the N-terminal within the upper smaller lobe, a hemopexin-like domain 
(containing the HBD) filling the lower lobe, and the flexible linker domain between 
them. They found that all domains were both presented and accessible on the surface 
of the molecule, which supported the latter model of the VN-HBD. It is best 
envisaged with a radius of 30.3 + 0.6 Å and a length of 110 Å (Fig. 1.5) (Lynn et al. 
2005). Xu et al. also employed computational analysis to predict a 3-D structure for 
VN, and then used docking experiments to provide clues for the binding of heparin to 
it (Fig. 1.6) (Xu et al. 2001b). This computed structure predicts that the central and C-
terminal domains form a groove wherein the HBD lies. Together these results tend to 
support the model that the VN in solution is open-faced with little interaction between 
the acidic and basic residues.  
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Figure 1.5. Two orthogonal views of the proposed 3-D VN model produced by 
CONTRAST docked into the GA_STRUCT software. The somatomedin B domain 
is coloured cyan, the linker region amber, the central domain green, the heparin-
binding domain red, and the carbohydrates blue. The consensus envelope is coloured 
violet. Binding sites for ligands are indicated with arrows and labels: P for PAI-1, 
RGD for integrins, and H for heparin (Lynn et al. 2005). 
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Figure 1.6. Two different views of computed docking conformation between 
heparin and VN. Heparin is in red; the combined structure of the central and C-
terminal are in blue and yellow respectively (Xu et al. 2001b). It predicts a groove 
between central and C-terminal domains for the binding of heparin.  
 
In a landmark paper, Braam et al. reported the successful culture of hESCs, for 
at least 10 passages, on surfaces precoated with 5 g/ml of recombinant VN (Braam 
et al. 2008). They also identified V5 integrin as the VN receptor. A study by Isik et 
al. showed that V integrin receptors are important for VN-induced anti-apoptotic 
survival responses (Isik et al. 1998). Rowland et al. and Prowse et al. both reported 
using a 10 g/ml coating of plasma-purified VN for the culture of iPSCs and a 
17.5 g/ml coating of recombinant VN for hESC culture respectively (Prowse et al. 
2010, Rowland et al. 2010). However, neither of these reports determined the 
threshold amount of VN necessary for the long-term propagation of hESCs, indicating 
a need to quantify VN substrates (Oh & Choo 2008, Skottman et al. 2006, Unger et 
al. 2008). The combination of the ability of VN to support hESC culture, and the 
presence of an HBD makes VN particularly amenable to further manipulation.   
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1.3.2. Other ECM proteins  
 
The laminins are a family of glycoproteins with a Mr of ~106 that are an 
integral part of the ECM, particularly the basement membrane. Each of the isoforms 
contain an α-chain, a β-chain, and a γ-chain, with five, four, and three genetic variants 
respectively (Timpl et al. 1979). Xu et al. observed that hESCs are able to avidly 
attach and proliferate on LN (Xu et al. 2001a) and Rodin and colleagues demonstrated 
that the recombinant LN-511 variant can be used to successfully culture hESCs over 
many passages (Rodin et al. 2010).  
 Fibronectins (FNs) are a class of structural glycoproteins, with a molecular 
weight of ~440 kDa, that are found in loose, mesenchymal ECM and exist as protein 
homodimers linked by disulfide bonds (Hynes 1985). They consist of repeating 
homologous units of 40, 60 and 90 amino acids. FN binds to cells primarily via the 
α5β1 integrin and also participates in cell growth, migration and differentiation 
(Ruoslahti 1988). FN, together with fibrin, plays a critical role in wound healing, 
contributing to the formation of the blood clots that stop bleeding  (Ruoslahti 1988). 
A key feature of FN-FN assembly is the conformational change from a compact 
soluble form into the extended, activated dimer via heparin binding (Bushuev et al. 
1985, Khan et al. 1990).  
 Collagens are the most abundant structural fibres of the ECM, and account for 
> 90 % bone matrix protein content (Kern et al. 2001). They have either a homo- or 
heterotrimeric  chain structure containing collagenous and noncollagenous domains. 
The  chain differs in its primary sequence (the Gly-X-Y motifs) and alternative 
splicing adds to the diversity of this molecule. The collagenous portion of the three  
chains forms a coiled-coil structure which constitutes the basic building block. The 
most abundant form in basement membrane is collagen IV, with its 6 genetically 
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different  chains. Ludwig et al. demonstrated the culturing of hESCs underlayed by 
a combination of human collagen IV, FN, LN and VN. However, the resulting 
abnormal karyotype in these cells implied that this complex substrate is not sufficient 
for such cells (Ludwig et al. 2006a).  
 A comparison of the HBDs in VN, LN and FN is illuminating. The HBDs in 
LN and FN are juxtaposed to RGD sequences (Aumailley & Gayraud 1998, Timpl & 
Brown 1994). However, the HBD and RGD motif in VN are at either ends of the 
protein. This suggests that the act of heparin binding to VN does not directly affect 
integrin binding. Thus the novel strategy of immobilizing VN via its HBD to GAG-
substrates in this thesis deserves a thorough examination of its potential.    
	
1.3.3. Protein immobilization strategies	
There are many strategies for immobilizing proteins onto surfaces. These 
include the non-covalent adsorption of proteins by hydrophobic or electrostatic 
interactions; classical chemoligation; bioorthogonal site-specific chemoligation; non-
covalent biologically-mediated immobilization; covalent immobilization via 
enzymatically-active fusion proteins; enzyme-catalyzed labelling and immobilization; 
and non-enzymatic biologically mediated covalent immobilization (Wong et al. 
2009). However, these methods have their limitations, including reduced or altered 
protein activity after fixation, low selectivity and/or low immobilization yields. In 
particular, Marson et al. has shown that immobilization of proteins onto surfaces can 
lead to loss-of-function via steric hindrance or conformational perturbation (Marson et 
al. 2005).  
There is thus a need for a process to immobilize sufficient amounts of 
functional VN on surfaces without deleterious chemical modification. As VN contains 
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HBD, exploiting this inherent property to immobilized VN onto a heparan 
glycosaminoglycans substrate is possible.  
 
1.4. Glycosaminoglycans (GAGs) 
 
 Together with DNA and protein, carbohydrates are the third class of  
informational biopolymers that play key roles over a broad range of biological 
activities (Bertozzi & Kiessling 2001). Carbohydrates can exist as simple sugars 
(glucose, fructose and galactose) or as glycans, complex conjugates of many simple 
sugars. In the development and function of complex organisms, glycans play 
particularly important roles in cell-cell and cell-matrix interactions. Understanding the 
function and structure of complex sugar molecules with the new analytical techniques 
that have become available has opened a new frontier, dubbed ‘glycobiology’, over 
the past two decades (Rademacher et al. 1988). As the informational content of 
carbohydrates is vastly greater than DNA per unit of structural backbone, a whole 
new field of “glycomics” has also arisen (Rademacher et al. 1988). 
 
1.4.1. Basic features and function of GAGs 
 
 Glycosaminoglycans are complex, linear, highly charged carbohydrates that 
interact with a wide range of proteins (Casu & Lindahl 2001, Jackson et al. 1991). 
These molecules are found on all animal cell surfaces, usually attached to core 
proteins, and throughout the ECM. They are known to both bind and regulate the 
function of chemokines, growth factors, morphogens, enzymes and adhesion 
molecules (Conrad 1998, Jackson et al. 1991). GAGs in vivo are always surrounded 
by a shell of water molecules, which causes them to fill space, hydrate tissue and 
provide resistance to pressure (Champe & Harvey 1994).  
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1.4.2. Proteoglycans  
 With the exception of hyaluronic acid, most GAGs are found covalently linked 
to a core protein to yield a proteoglycan (PG). The protein-sugar linkage involves a 
specific trisaccharide, composed of two galactose (Gal) residues and a xylose (xyl) 
residue. It binds to a core protein through an O-glycosidic bond (GAG-GalGalXyl-O-
CH2-protein) on those serine residues that are followed by a glycine (Gandhi & 
Mancera 2008, Jackson et al. 1991). All animal cells produce PGs and either secrete 
them into the ECM, insert them into plasma membrane, or store them in secretory 
granules. The complexity of PGs is high due to many factors such as differential 
expression of genes encoding the core proteins and differential exon usage, as well as 
variations in the length and type of GAG attached (Varki 1999). Of particular interest 
are the heparan sulfate proteoglycans (HSPGs). 
HSPGs include aggrecan, perlecan, the syndecans and the glypicans, all 
classified by virtue of their core protein. Aggrecan, the major PG secreted into 
cartilage, aggregates into hydrating super-complexes; the syndecans, which are made 
up of four types of transmembrane core capable of carrying both HS and CS; and the 
glycosylphosphatidylinositol-attached glypicans (Gandhi & Mancera 2008). PGs have 
long been known to have affinity for growth factors, cell adhesion molecules and 
enzymes (Conrad 1998). A particularly well established function of HSPGs is the 
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1.4.3. HSPG in stem cells culture 
 
Studies by Levenstein et al. demonstrated that the major components secreted 
by MEFs that support hESC growth are the HSPGs (Levenstein et al. 2008). These 
HSPGs are able to stabilize and extend the half-life of FGF-2 and are required by 
hESCs to remain pluripotent. Another study by Abraham et al. also identified the 
importance of  HSPGs in feeder layers (Abraham et al. 2010), and demonstrated that 
they were able to maintain hESC lines on a combination of mouse sarcoma HSPG and 
combinations of ECM proteins. Two other studies by Sasaki et al. and Furue et al. 
demonstrated the importance of HS and heparin in promoting hESC self-renewal and 
growth (Furue et al. 2008, Sasaki et al. 2008). Chillakuri et al. also reported that the 
heparin-binding domain of VN is required for its oligomerization, which reinforces 
VN activity during cell adhesion and spreading (Chillakuri et al. 2010). Together, 
these studies provide support for the need to further explore how HS and VN 
interactions can be manipulated.  
 Other than hESCs, HS has also been shown to be a critical factor for the 
proliferation and differentiation of other stem cells such as mouse embryonic stem 
cells, mesenchymal stem cells, hematopoietic stem cells and neuronal stem cells 
(Brickman et al. 1995, Hagihara et al. 2000, Holley et al. 2011, Manton et al. 2007). 
Holley et al. have shown that soluble heparin and HS can influence the differentiation 
potential of mESCs (Holley et al. 2011). Bramono et al. recently showed that human 
bone marrow stroma-derived HS helps in the expansion of hematopoietic stem cells 
(Bramono et al. 2011). Taken together, these studies act as motivators to explore how 
HS and VN are able to interact. 
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1.4.4. Classification of GAGs 
 Carbohydrate chains on HSPGs are often digested by endogenous heparinase 
to become soluble GAGs in vivo. GAGs are long, unbranched polysaccharides of 
varying length consisting of characteristic repeating disaccharide units with a wide 
range of molecular weight (10-100 kDa) (Gandhi & Mancera 2008). The repeating 
units are made up of uronic acid (D-glucuronic acid or its epimer L-iduronic acid) and 
an amino sugar (D-galactosamine or D-glucosamine). There are two main types of 
GAGs: non-sulfated and sulfated (Fig. 1.7). Non-sulfated GAGs include hyaluronic 
acid (HA), which is synthesized without a core protein and is digested by enzymes at 
the cell surface directly into the extracellular space. Hyaluronan is the major 
component in the synovial fluid lubricant within body joints (Itano 2008, Laurent et 
al. 1996). As HA is both non-sulfated and unable to bind VN, this molecule is not 
able to address the problem of efficient immobilization of VN to culture surfaces, and 
will thus be dismissed from further consideration. 
 In contrast, sulfated GAGs include chondroitin sulfate (CSs), dermatan sulfate 
(DS), keratin sulfate (KS), heparin and heparan sulfate (HS). These sulfated GAGs 
are secreted covalently attached to a core protein on the cell surface to yield the 
various species of PG described above. This is summarized in Figure 1.7. 
 The CSs are chains of the alternating sugars N-acetylgalactosamine and 
glucuronic acid.  They have a molecular weight of 5-50 kDa, and are the most 
abundant GAGs in the mature vertebrate body. They are found particularly in 
cartilage, tendon, ligament and aorta (Varki 1999). DS is most common GAG in skin, 
blood vessels and heart valves, with a molecular weight of 15-40 kDa (Trowbridge & 
Gallo 2002, Varki 1999). KS is the most heterogeneous GAG, and can be found in 
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cartilage and cornea. It has a molecular weight of 4-19 kDa and may be fucosylated 
(Funderburgh 2000, Varki 1999).  
Of all the many forms of HS, heparin has the highest negative charge of any 
biological molecule known, and is synthesized and stored exclusively in connective 
tissue mast cells. In contrast, HS contains higher levels of acetylated glucosamine, 
and is thus less sulfated than heparin. It is expressed on all mammalian cell surfaces 
and ECM (Lindahl & Kjellen 1991, Varki 1999). Therefore HS was the GAG of 
choice in this thesis for the capture of VN.   
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Figure 1.7. Structures and properties of various glycosaminoglycans. Adapted 
from Gandhi et al. (Gandhi & Mancera 2008).  
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1.4.5. Sulfated GAGs: heparin/heparan sulfate 
 
 Heparin, a hypersulfated variant of the HS family, has been studied 
extensively because of its well known function in anti-coagulation (Capila & Linhardt 
2002). Heparin was first discovered in 1916 in liver extracts; it was discovered 
through its ability to prolong the process of blood clotting. It went into widespread 
clinical use as an anti-coagulant in 1935, after its production become industrialized 
(Best 1959). It has gone on to become one of the most important ever products of 
medical science (Serruys et al. 1998). It provides a reason why other heparin-like 
sugars may have therapeutic utility (Bramono et al. 2012). HS, on the other hand, has 
a more recent history. It was first identified as an impurity in heparin production, but 
has since been found to be critically involved in a variety of biological processes 
(Linker et al. 1958).  
 Heparin and heparan sulfate (HS) consist of repeating uronic acid-(14)-D-
glucosamine disaccharide subunits. Unlike other GAGs, the highly variable pattern of 
substitutions on their subunits gives rise to different, highly complex N-sulfation, O-
sulfation and N-acetylation sequences (Fig. 1.8).  
 
 
Figure 1.8. Diagram of the various N-, O- and N- substitutions on a 
monosaccharide subunit of heparin and HS (Ori et al. 2008). 
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The most abundant disaccharide in heparin is the trisulfated IdoA(2S)-(1 4)-
GlcNS(6S) unit, which gives rise to the extraordinarily high charge density of these 
chains (an average 2.5 sulfate groups per disaccharide) (Linhardt et al. 1992). One 
corollary of this density is heparin’s propensity to promiscuously bind a vast range of 
proteins. In contrast, the most common disaccharide in HS is the unsulfated GlcA-
(14)-GlcNAc, which in turn is organized in such a way as to give rise to segregated 
blocks of unsulfated N-acetyl (NA) residues and “domains” of highly sulfated, 
heparin-like IdoA-(14)-GlcNS disaccharides. It thus has an average of less than 1 
sulfate per disaccharide (Lane 1989).  This classic domain structure was first 
proposed by Gallagher and colleagues (Lyon et al. 2000). The N-acetyl (NA) and 
heparin-like N-sulfated (NS) domains are separated by NA/NS transition domains 
(Fig. 1.9). Thus, the functionally significant, protein-binding sequences of HS are 
encompassed in the highly sulfated NS domains spaced out by the intervening 
unsulfated NA domains such that at least one, and up to 6 distinct protein-binding 
sites may reside on one chain. Thus HS is a key way of integrating combinations of 
extracellular signalling on cell surfaces to drive specific patterns of gene expression. 
The problem of using heparin (which displays low selectivity for proteins) as a model 
for tissue-relevant HS, (which displays much higher selectivity) becomes apparent. 
This diversity of HS structure in turn gives rise to a wide range of biological 
function. In rare cases, the R1 position of the D-glucosamine subunit is neither 
sulfated nor acetylated, which affords the possibility of utilizing naked primary amine 
groups for immobilization reactions (Fig. 1.8). Table 1.2 summarizes the differences 
between HS and heparin. 
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Figure 1.9. Diagram of the sulfated (NS) and non-sulfated (NA) domains in 




Table 1.2. Differences between heparin and heparan sulfate (adapted from 
Gandhi et al.) (Gandhi & Mancera 2008).  
 
 
 The binding of proteins to heparin or HS is primarily electrostatic, involving 
interactions between functional cationic groups of the protein and the abundant 
anionic sites on heparin or HS. The other interactions, such as the van der Waals 
forces, hydrogen bonding and the hydrophobic interactions with the carbohydrate 
backbone, are comparatively minor in extent (Caldwell et al. 1996). The numbers of 
proteins with heparin-binding propensities number at least several hundred (Table 
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1.3). Such proteins usually possess a variation on the Cardin-Weintraub consensus 
sequence XBBBXXBX (where B is lysine, arginine or histidine and X is a 
hydropathic residue). The proposed sequence arose from an analysis of the structures 
of 21 heparin-binding proteins (Cardin & Weintraub 1989). There has been an 
increasing realization over the last 20 years that the specific sequences in the NS and 
NA/NS domains have been selected for their ability to interact with targeted proteins, 
which results in regulation of that protein’s activity (Lindahl et al. 1998, Salmivirta et 
al. 1996, Turnbull et al. 2001). What is most notable from examination of such 
heparin-binding sequences is that each sequence is different (Table 1.3), implying that 
there is a different, specific sugar domain for each protein. On the other hand, the 
non-selective binding of proteins to heparin is almost certainly due just to the sheer 
charge density of the sulfate groups (Salmivirta et al. 1996). 
  
Table 1.3. A small subset of the heparin-binding proteins that contain variations 





Proteins                                                                 XBBBXXBX 
Annexin II   KIRSEFKKKYGKSLYY  
Vitronectin  QRFRHRNRKGYRSQRG  
ApoB  KFIIPSPKRPVKLLSG  
FGF-2 GHFKDPKRLYCKNGGF  
NCAM  DGGSPIRHYLIKYKAK  
Protein C inhibitor  GLSEKTLRKWLKMFKK  
AT-III  KLNCRLYRKANKSSKL  
ApoE  SHLRKLRKRLLRDADD  
Fibrin  GHRPLDKKREEAPSLR  
FGFR-1  AAPVAHLKKEMK  
B-thromboglobulin PDAPRIKKIVQKKLAG  
Insulin-like growth factor-binding protein-3  DKKGFYKKKQCRPSKG  
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Historically, the most stereotypical heparin-binding protein has been FGF-2. 
Work on this interaction has progressed to a stage where X-ray crystal structures of a 
2:2:2 dimeric ternary complexes of FGF-2, fibroblast growth factor receptor-1 
(FGFR1) and a heparin decasaccharide has been resolved (Schlessinger 2000, 
Turnbull et al. 1992). A more physiological model was proposed by Pellegrini et al., 
who reported a crystal structure with the stoichiometric ratio 2:2:1 of 
FGFR2:FGF1:heparin decasaccharide underlying the conformational activation of the 
receptor by the sugar (Pellegrini et al. 2000). The crystal structures revealed the 
precise binding surfaces of FGF-2 for heparin and confirmed a role for heparans in 
FGF-2-FGFR1 interactions.  
The processes of cell attachment, spreading and motility involve HS in the 
ECM collaborating with cell-surface receptor integrins (Fig. 1.10). In analogy to FGF-
2, the large multidomain ECM proteins such as FN, LN and VN all have HBDs, 
which have allowed for the isolation of ECM-targeted HS isoforms in our laboratory. 
FN binds to HS chains on the cell surface, so enabling an appropriate integrin to 
induce cell spreading and focal adhesion formation (Couchman et al. 2001). The 
balance between adhesion and motility in cell depends on the integration of signals 
mediated through binding to PGs and integrin-based adhesion mechanisms. 
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Figure 1.10. Role of HS in cell physiology (Bishop et al. 2007). 
 
1.4.6. Structural characterization of heparin/ HS 
 
 The development of rapid and reliable methods for the sequencing and 
synthesis of oligonucleotides and peptides have made the study of protein and DNA 
structure and function routine. However, the lacks of analogous techniques for the 
study of complex carbohydrates have made their study exceptionally difficult. 
Moreover, most oligosaccharides are branched structures and usually present as a 
heterogeneous population; this further complicates their elucidation. Therefore, 
glycobiology faces more fundamental challenges than do protein or DNA research.  
A complete structural analysis of heparin/HS would involve identification and 
quantification of the uronic acid (14) glucosamine disaccharide building blocks, 
determination of their sequence within their functional domains, and characterization 
of the 3-D conformations of the polysaccharide chain, especially after protein 
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docking. The importance of this is underlined by the first functional HS sequence ever 
deduced, the pentasaccharide sequence in heparin that is responsible for its anti-
thrombolytic activity (Lindahl et al. 1979).   
 The disaccharide composition of HSs can be elucidated through a series of 
enzymatic cleavages of the glycosidic bond (Desai et al. 1993b, Shriver et al. 2000, 
Venkataraman et al. 1999) or by deaminative hydrolysis by nitrous acid (Bienkowski 
& Conrad 1985, Shively & Conrad 1976). The Flavobacterium heparinium enzymes 
heparinase I, II and III have been shown to cleave glucosamine-(14) uronic acid 
glycosidic bonds of differing structure. Heparinase I (Enzyme commission number 
(E.C. 4.2.2.7)) has high selectivity for IdoA (2S) glycosidic bonds, where the 
glucosamine can be either GlcNS, GlcNS (6S) or GlcNS (3,6S), and a secondary 
specificity for GlcA (2S) in highly sulfated regions (Desai et al. 1993b, Venkataraman 
et al. 1999). Heparinase II (no E.C. number) will cleave glycosidic bonds containing 
both 2-O-sulfated and 2-OH uronic acids; hence these two enzymes cut within 
sulfated domains (Venkataraman et al. 1999). Heparinase III (E.C. 4.2.2.8) has high 
selectivity for 2-OH GlcA-containing glycosidic linkages (Desai et al. 1993b, Shriver 
et al. 2000), and thus cleaves between highly sulfated domains to liberate functional 
domain units. The digestion sites for the heparinases are summarized in Figure 1.11. 
When all 3 heparinases are used in combination, they can degrade heparin or HS to > 
90% completion (Karamanos et al. 1997, Vynios et al. 2002) (Fig. 1.12). Digestion 
products can be separated chromatographically by size and degree of sulfation, and a 
crude compositional analysis performed. However, HS sequence analysis or 3-D 
structure determination both remain extremely problematical (Skidmore et al. 2009, 
Turnbull et al. 1999). Compositional analysis can provide important information 
about the relative amounts of the disaccharides present in HS. The disaccharides can 
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be analyzed by strong anionic exchange high performance liquid chromatography 
(SAX-HPLC) (Skidmore et al. 2009), polyacrylamide gel electrophoresis (PAGE) 
(Hampson & Gallagher 1984) or capillary electrophoresis (CE) (Lamari et al. 2001) 





Figure 1.11. Heparinase I, II and III digestion sites on heparin and HS (Malavaki 
et al. 2011). 
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Figure 1.12. The 8 disaccharides generated after digestion of heparin with 
heparinase I, II and III (Ruiz-Calero et al. 1998). 
 
 The most convenient mode for disaccharide analysis is CE, which is not only 
the most sensitive technique but which uses only very small amounts of sample as 
compared to HPLC and PAGE (Lamari et al. 2001). In CE, disaccharides are 
separated by a voltage through an uncoated fused-silica capillary with reverse polarity 
and low pH (3.5). When voltage is applied, the walls of the capillary became 
negatively charged, which causes an electro-osmotic flow (EOF) of the buffer species 
towards the anode because of the reverse polarity separation. The EOF thus moves all 
analytes to the anode and the separation of the solutes is by the vector sum of EOF 
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and electrophoretic mobility (EM), which is proportional to the charge density of the 
molecule. Disaccharides are negatively charged, so the EM is towards the anode. As 
these two driving force counteract each other, migration depends on the net difference 
between the two forces and can be detected at 232 nm. Karamanos et al. first 
described the separation of heparinase-digested disaccharides by 20 kV reverse 
polarity CE. He was able to distinguish 12 different disaccharides species (Karamanos 
et al. 1996). Ruiz-Calero et al. subsequently also demonstrated the separation and 
quantification of 8 heparin disaccharide species using a formic acid buffer, 15 kV 
reverse polarity at pH 3 (Ruiz-Calero et al. 1998). Militosopoulou et al. also described 
a 30 kV reverse polarity separation of 12 heparinase-digested heparin and HS species 
in phosphate buffer, pH 3.5 (Militsopoulou et al. 2002). An example of just such a CE 
electropherogram is depicted in Figure 1.13. The latter authors also detected specific 
fragments of HS disaccharides that bind to FGF2 by incubating the digested species 
with FGF2 and re-electrophoresing of the mixture. Even higher sensitivities can be 
obtained by derivatization of digested disaccharides with a-aminoacridone (AMAC) 
and combining it with laser-induced fluorescence (LIF) detection (Militsopoulou et al. 
2002).  
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Figure 1.13. An example of CE electropherogram isolated with 60 mM formic 
acid buffer, reverse polarity of 15 kV at pH 3 (Ruiz-Calero et al. 1998). Each peak 
represents the individual disaccharide units shown in Figure 1.12.    
 
Mass spectrometry (MS) is another method that can provide enormous 
amounts of information about HS structures. Studies have involved fast-atom 
bombardment, electrospray ionization, liquid secondary desorption/ ionization MS or 
matrix-assisted laser desorption ionization (MALDI) MS to determine the mass of 
sulfated oligosaccharides (Chai et al. 1995, Chai et al. 1998, Desaire & Leary 2000, 
Khoo et al. 1993, Mallis et al. 1989, Rhomberg et al. 1998). Chemically discrete 
oligosaccharides that were produced from the depolymerization of heparin with 
nitrous oxide or heparinase I and III, followed by two-step separation by size and 
charge, have also had their masses determined by 2-D 1H-nuclear magnetic resonance 
(1H-NMR). A major limitation of 1H-NMR is however the large amount of sample 
required (~0.1 mol).  
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As CE is the most sensitive and straight-forward method to determine the 
composition of HS, this study will employ it to elucidate the composition of each 
sulfated disaccharide present in heparinase-digested HS samples.   
 
1.5 Methods of immobilizing GAGs  
 
 Owning to its avidity for proteins, various heparin-immobilized matrices and 
surfaces have been developed for both scientific and medical applications (Cox et al. 
1992, Lincoff et al. 1997). For example, polymer-coated stents are being used as 
controlled release systems for heparin with or without therapeutic proteins, in order to 
treat the plaques that characterize cardiovascular disease (Serruys et al. 1996).   
Two broad methods of immobilization of HS, covalent and electrostatic, to 
couple free GAGs chains to plastic, will now be considered. 
 
1.5.1. Covalent Schiff base chemistry 
 
 Heparin oligosaccharides can be produced and readily tethered to amine-
coated surfaces with nitrous acid (de Paz et al. 2006). The nitrous acid serves to 
cleave the heparin chain at N-unsubstituted or N-sulfated glucosamine residues, 
giving rise to a 2,5-anhydromannose unit that contains a reactive aldehyde group at 
position 1. This aldehyde group is more reactive than the aldehyde group on the 
reducing end of the sugar, thus allowing Schiff base formation with the amine surface. 
This method requires an amine-modified surfaces rather than normal tissue culture-
treated polystyrene (TCPS) surfaces. The more complicated and specialist processing 
needed for this precluded this method from our study.  
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1.5.2. Covalent NHS chemistry 
 
 In 2001, Seeberger and colleagues pioneered chemical methods for the 
automated synthesis of complex carbohydrates directly onto surfaces, in a manner 
analogous to the printing of DNA and peptide arrays (Plante et al. 2001).  He utilized 
1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) chemistry to 
tether the disaccharide unit through an amine added at the reducing end of the 
synthetic sugar. From this, synthesis is carried out by changing conditions to allow the 
lengthening of the chains in a step-wise manner by adding extra disaccharide units to 
produce heparin fragments of a desired length. Such fragments can be used for the 
study of specific protein interactions with such synthetic HS. It was shown by de Paz 
et al. that protection of the sulfates on chains by azide is important during synthesis 
and binding of heparin fragments, as the sulfates are critical to FGF-2 binding (de Paz 
et al. 2001).  
 The process involves mixing small amounts of N-hydroxysuccinimide (NHS) 
with carboxylic acid on the modified surface in a water-free solvent, typically 2-(N-
morpholino) ethanesulfonic acid (MES) buffer. EDC is then added to form an 
unstable active intermediate. EDC is a zero-length cross-linking agent used to couple 
carboxyl groups to primary amines. This crosslinker has been used in a number of 
diverse applications, such as forming amide bonds in peptide synthesis, attaching 
haptens to carrier proteins to form immunogens, and creating amine-reactive NHS-
esters of biomolecules (Gao et al. 2003, Kimura et al. 1991, Mera et al. 2008). It 
reacts with carboxyl to form an amine-reactive O-acylisourea intermediate, and, if this 
intermediate does not encounter an amine, will hydrolyze and regenerate the carboxyl 
group (Fig. 1.14). Such a technique may prove attractive for fundamental studies, but 
over the long-term, the cost and the many steps involved, including the sequential 
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protection and deprotection of functional groups, render the technique just too 
inefficient and complicated for large-scale cell culture. 
 
 
Figure 1.14. EDC reaction scheme (Zhao et al. 2010). 
 
 In this study, the immobilization of HS onto TCPS was explored using EDC 
chemistry as a first strategy, primarily because of the domain structure of HS. HS 
contains ~ 30% primary amines on the glucuronic acid, many of which are available 
to form covalent amide linkages between the amine and carboxyl group on TCPS.   
 
1.5.3. Coupling of GAGs with BSA 
 
 Several groups have reported the covalent coupling of heparin, HS or CS with 
BSA to facilitate the immobilization of heparin onto surfaces (Feng et al. 2004, Hasan 
et al. 1999, Higai et al. 2011, Najjam et al. 1997, Nishioka et al. 2007). It facilitates 
the immobilization of heparin by utilizing its reducing end and covalently binding it 
to an acceptor protein via sodium cyanoborohydride. The heparin-BSA complex is 
then coated onto ELISA plate wells overnight. However, the BSA, being large and 
globular, is prone to interfering with the steric freedom of the sugar (Rees et al. 2004). 
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1.5.4. Biotinylated GAGs 
 
 Another approach for the immobilization of GAGs is their biotinylation and 
coupling to streptavidin-coated surfaces (Foxall et al. 1995, Hasan et al. 1999, Najjam 
et al. 1997, Parker et al. 2009, Roy et al. 2011). A few groups have used this method, 
either by attaching the biotin to the GAG’s carboxylate (Boucas et al. 2008, Parkar & 
Day 1997, Yang et al. 1995) or amino groups (Harris et al. 2008, Mahoney et al. 
2005, Nadesalingam et al. 2003). However, the efficiency of biotinylation is variable 
and cannot be controlled; this can have negative effects on GAG function. A study by 
Roy et al. has shown that modifying the sequences of heparin, particularly the N-
domains, can have a major impact on its biological activities (Roy et al. 2011). Saito 
et al. demonstrated that DS has higher protein-binding activity when biotin is attached 
to the free amino group instead of the uronic acid (Saito & Munakata 2005). 
However, other studies have shown that labelling hyaluronan is more effective if the 
carboxylate group was used, notwithstanding that this reaction is known to alter the 
activity of heparin (Yang et al. 1995). The contradictions kicked up by such studies 
highlight the fact that any method for immobilizing GAG via biotinylation needs to be 
carefully optimized, and is GAG-specific.  
 
 
1.5.5. Passive adsorption to TCPS 
 
 Both proteins and GAGs are polyelectrolytes that contain functional groups 
that can fully dissociate in solution. Heparin has an average of 2.5 sulfates (SO3-) per 
disaccharide unit. In a solution containing uncharged entities, the chain will adopt a 
random conformation. However, in heparin, the combination of the high negative 
charge and restriction of the rotation of glycosidic bonds in each disaccharide repeats 
acts to cause repulsion, thus keeping the structure in an open right-handed twist 
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conformation when in water (Ferro et al. 1990, Mikhailov et al. 1997). If high salt is 
added, it acts to screen the negative charge and lessen the effect of repulsion, allowing 
a more coiled structure. In physiological solutions, GAGs do not bind to plastic 
surfaces, as shown by both Mahoney et al. and Robinson et al., thus restricting its 




1.5.6. Plasma polymer films 
 
 Plasma-based approaches have gained popularity for the creation of surfaces 
designed to be in contact with biological environments; such surfaces are known as 
bio-interfaces. This method inserts chemically reactive groups onto non-reactive 
substrates. Plasma methods can be classified into 3 broad categories: plasma 
treatment, plasma etching and plasma polymerization. Plasma treatment utilizes gases 
such as argon, nitrogen, oxygen or methane in order to insert or substitute chemical 
functionalities onto substrates or to create radicals for crosslinking or surface grafting. 
Plasma etching is the bombardment of surfaces with high speed positive charge, so 
creating charged species on the surface of the material. Plasma polymerization 
involves the fragmentation of the precursor and deposition of organic monomers, so 
creating a coated polymer film on surfaces that do not contain regular repeats such as 
conventional polymers (Ward & Short 1993, Ward & Short 1995). It is done under 
reduced pressure, and highly functionalized surfaces can be produced (Beck et al. 
2001, Rinsch et al. 1996). This study will utilize plasma polymerization of amine-
containing groups onto TCPS surfaces to create a net positive charge surface 
(Chatelier et al. 1997) for the immobilization of negatively charged HS. 
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 Amine polymers are easy to fabricate, and a good coating can be obtained over 
a broad range of plasma parameters. Amine-containing surfaces can be prepared via 
either ammonia plasma treatment or plasma polymerization of allylamine (AA) 
monomers.  Ammonia plasma treatment has the drawback of the short-lived nature of 
the treatment on some polymer substrates, such that the treated substrate reverts back 
to its original state (Chatelier et al. 1995a, Chatelier et al. 1995b, Xie et al. 1992). 
Therefore, plasma polymerization with AA monomers is the method utilized in this 
study. Although it is also possible to create amine groups on TCPS using nitrogen 
plasma treatment, its efficiency and selectivity is low (Meyer-Plath et al. 2003). Barry 
et al. have shown that plasma polymerization of scaffold matrices can encourage cells 
to migrate into the pores and increase the population density of cells throughout the 
scaffold (Barry et al. 2005). This demonstrated that plasma polymerization is cell 
culture-compatible. 
 Many different aminated monomers have been used to create positively-
charged surfaces, including allylamine (Gancarz et al. 2003, Mahoney et al. 2004, 
Robinson et al. 2012, Swaraj et al. 2005), diaminocyclohexane (DACH) (Lassen & 
Malmsten 1997), heptylamine (Gengenbach et al. 1994, Kingshott et al. 2002) and 
ethylenediamine (Gengenbach et al. 1996). This study will focus on allylamine 
polymerization, because the density of amine groups created by each methods is such 
that DACH > allylamine > heptylamine (Kingshott et al. 2002, Muller & Oehr 1999). 
Even though DACH yields higher amine group density, measurements done with 
surface fluorescence spectroscopy neither correlate with the percentage of nitrogen 
measured by XPS nor the content of primary amino groups with apparent 
fluorescence.   
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Allylamine (C=C-C-NH2) has a double bond that encourages higher 
deposition rates through a combination of plasma polymerization and conventional 
radical addition polymerization. The density of amine groups on substrates can be 
controlled using octa-1,7-diene (France et al. 1998).  
There are many studies that show bioactive molecules can be successfully 
immobilized onto plasma-treated amine groups, including DNA (Zhang et al. 2005, 
Zhang et al. 2003), Protein A (Sano et al. 1993), hyaluronic acid (Mason et al. 2000), 
heparin (Steffen et al. 2000) and enzymes (Gancarz et al. 2003, Muguruma et al. 
2000) using EDC chemistry. However, there are drawbacks to using EDC to 
covalently link carboxyl and amine groups onto surfaces. The EDC can activate 
carboxyl groups in such a way that they bind to amine groups on the same molecule, 
or molecules other than the amine groups on the designated surface. This leads to the 
aggregation of molecules, and adsorption to surfaces and thus biological function 
being compromised. Thus using EDC to link HS onto amine surfaces is a risky option. 
For this reason, we will employ here non-covalent methods for immobilizing HS onto 
amine surfaces.   
A recent study by Robinson et al. demonstrated that AA could be coated onto 
the internal surfaces of microplates using plasma polymerization (Fig. 1.15) 
(Robinson et al. 2012). This surface is able to bind GAGs electrostatically without 
affecting biological function. This was shown when the GAGs retained the ability to 
bind osteoprotogerin and the tissue inhibitor of metalloproteinases-3. Other studies 
also confirmed this finding using ELISA (Mahoney et al. 2004, Marson et al. 2005).  
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Figure 1.15. A schematic of the plasma reactor. The plates are placed inside the 
chamber and the generator creates an electromagnetic field that ionizes the allylamine 
to create plasma. The activated molecules are polymerized onto the plate surface. The 
gauge serves to isolate the chamber during the reaction and the liquid nitrogen trap 
acts as waste collection (Robinson et al. 2012).  
 
 
1.6. Surface characterization 
 
For the reliable interpretation of such complicated interactions as the bio-
interfacial junctions between adsorbed protein and applied cells, detailed surface 
analyses of biomaterials is necessary (Castner & Ratner 2002). Therefore, a 
combination of surface chemical analysis methods and X-ray photoelectron 
spectroscopy (XPS) will be used in this study to analyze the nitrogen: carbon (N:C) 
ratio after generating the allylamine polymer coating on TCPS, together with 
measurements of  VN surface density. XPS is a unique and valuable tool for such 
surface analysis and able to measure the elemental composition of materials at 1 - 10 
nm distances from the surface (Delgass et al. 1970). Robinson et al. used XPS to 
quantify the amount of carbon, nitrogen and oxygen on AA polymerized surfaces 
(Robinson et al. 2012). 
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Atomic force microscopy (AFM) will also be used to test the physical 
roughness of the VN-coated surfaces. AFM is a high resolution (nm) microscope that 
consists of a cantilever with a sharp tip that scans the material surfaces (Meyer 1992). 
The forces between the tip and sample lead to the deflection of the cantilever 
according to Hooke’s law and is measured with a suitable detector.  
 
1.7. Thesis outline 
1.7.1. Motivation 
There is a strong correlation between the global economic burden of critical 
illness to society and the potential for stem cells to alleviate such problems (Fig. 1.16) 
(Boston 2001). This is driving stem cell therapy sales exponentially, despite their 
limited effectiveness (Summit 2007). The potential for hESC therapy to contribute to 
this growing market are substantial. 
 
 
Figure 1.16. Stem cells market research analysis (Adapted from Boston Consulting 
Group and Stem cell summit, 2007 http://www.stemcellsummit.com/2007/stem-cell-
fact-sheet.pdf) 
 
Human PSCs have been posited as being central to such therapeutic strategies 
if their provision can be made reliable (Goldring et al. 2011). The directed 
differentiation of hESCs down the cardiomyocyte, hepatocyte or insulin-producing 
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cell lineages carries much promise for regenerative medicine. For example, in 2009 
and 2010, the U.S. Food and Administration (FDA) approved two clinical trials for 
the treatment of grade A thoracic spinal cord injury (NCT01217008 and 
NCT01344993) (Alper 2009) as well as for macular dystrophy and dry-aged related 
macular degeneration (NCT01345006 and NCT01344993) (Schwartz et al. 2012) that 
employed cells derived from human embryonic stem cells. Although it is an exciting 
time for stem cell research, the problem remains that it is still very difficult to 
continuously preserve these cells in their pristine state prior to differentiation, a 
property that is essential to ensure subsequent directed differentiation to meet future 
clinical demands. 
However several challenges remain. The first and most important is to remove 
the reliance of inactivated mouse or human feeder cell layers to culture hESCs. The 
second is to eliminate the use of MatrigelTM, which is a poorly defined product from 
murine sarcoma basement membrane. Thirdly, we need to dispense with bovine 
serum albumin (BSA) and fetal calf serum (FCS) from cell culture media. Lastly, we 
need to be able to propagate the cells in a naïve state in large numbers.  
Cell culture media formulation has made rapid progress, and a number of 
chemically-defined media such as XVIVO-10, hESF9, mTeSRTM1 and STEMPRO 
are now available. (Furue et al. 2008, Li et al. 2005, Ludwig et al. 2006b, Wang et al. 
2007) However, in the area of defined cell culture surfaces, there is still much work to 
be done.  Although many research groups have proposed ways of culturing hESC, 
including laminin (LN) (Rodin et al. 2010, Xu et al. 2001a), vitronectin (VN) (Braam 
et al. 2008), fibronectin (FN) (Amit et al. 2003), E-cadherin (Nagaoka et al. 2010), 
peptides (Klim et al. 2010, Melkoumian et al. 2010) or PMEDSAH polymers (Villa-
Diaz et al. 2010), none of these studies calculated the actual surface density of the 
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applied compounds, nor their economic cost benefits for commercial scale hESC 
propagation.   
The most widely used method to immobilized ECM protein for cell culture is 
by passive adsorption onto culture surfaces. This method had been shown by 
Marson et al. to lead to steric hindrance or conformational perturbation, resulting in 
the loss-of-function to the protein (Marson et al. 2005). Therefore, utilizing this 
method to present sufficient VN for hESC culture is not efficient. Instead of 
modifying the protein, which might lead to deleterious effects, modifying the surface 
for efficient VN immobilization is a more rational approach. Therefore, this thesis is 
aimed at exploring the various strategies that allow the capture of sufficient 
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1.7.2. Specific Aims 
 
In order to provide a scalable surface for the expansion of pluripotent hESC, 
the major aim of this thesis is to engineer an effective substrate capable of binding 
unmodified VN without compromising its biological utility. The hypothesis of this 
thesis is to increase the surface density of functional VN by using a HS fraction tuned 
to VN binding. In doing so, considerations of features including cost, simplicity, 
safety and efficacy will contribute to key characteristics for the development of this 
substrate. The specific aims of this thesis are to:  
1. Establish the optimal VN coating density needed for the expansion of 
pluripotent hESC. 
2. Develop a substrate capable of binding unmodified VN based on its 
affinity for heparan glycosaminoglycans.   
3. Determined the ability of heparan-bound substrates to capture VN and to 
promote the expansion of pluripotent hESC.     
 
1.7.3. Thesis Organization 
 
This thesis is comprised of five chapters: 
Chapter 1 presents a review of literature focusing on four main areas: (1) the 
culture and characterization of pluripotent hESCs, (2) VN, (3) GAGs and (4) methods 
for immobilizing GAGs. It will also describe the background, motivation, and 
objectives of this research. 
Chapter 2 presents the initial study of the propagation of hESC lines (HES-3, 
H1) on TCPS coated with VN solution. This coating was analyzed using a 
combination of X-ray photoemission spectroscopy (XPS), atomic force microscopy 
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(AFM), quantification of the VN surface density with Bradford protein assay and 125I-
VN binding assays.  
 Chapter 3 documents the work on the isolation and characterization of VN-
binding HS species using VN-HBD peptide affinity chromatography. Various 
characterization assays, including ELISA, dot blot, heparin-Sepharose competition, 
isotope labelled-VN binding and capillary electrophoresis (CE) are employed. It also 
describes the various methods of immobilizing HS variants onto TCPS. The three 
immobilization methods used were amide bond formation between the carboxyl 
groups of TCPS and the rare primary amine groups within HS; the electrostatic 
interaction between PLL and the negative charge of HS; and the electrostatic 
interaction between the positive charge on allylamine and the negative charge 
inherent to HS.  
Chapter 4 describes the application of allylamine surface coated with HS and 
VN for the long-term culture of hESCs and the concomitant effects on VN surface 
density.  
Chapter 5 concludes with a summary of the findings of this study and 




CHAPTER 2 : CHARACTERIZATION 
OF VN SUBSTRATES  
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2.1. Introduction 
 
Human embryonic stem cells retain the ability to differentiate into all three 
germ layers and thus hold the promise of applications for tissue repair and drug 
development (Thomson et al. 1998). Early methods for culturing hESCs relied on co-
culture with inactivated mouse embryonic fibroblasts (Thomson et al. 1998). This 
method however is not suitable for the development of clinical-grade hESCs, partly 
due to the xenogenic risk it introduces.  
Other than cell-based feeder layers, MatrigelTM, a gelatinous basement 
membrane extract secreted by mouse Engelbreth-Holm-Swarm (EHS) tumour cells, is 
now routinely used as the substrate together with conditioned media (CM) from 
MEFs.  Hakala et al. compared the use of MatrigelTM with different feeder-free hESC 
culture substrates (biomaterials, human ECM proteins, human and animal sera 
matrices) and reported that MatrigelTM was superior in terms of the maximum passage 
number attained, as well as hESC morphology and pluripotent marker expression 
adopted (Hakala et al. 2009). Despite these advances in feeder-free systems, the use 
of MatrigelTM is limited by batch-to-batch variability, complex protein mixtures and 
the possibility of transferring non-human sialic acid, Neu5Gc, to the hESCs 
(Nasonkin & Koliatsos 2006). These discouraging results have led to the search for 
other defined systems suitable for the culturing of hESCs. 
Defined model surfaces, in the form of immobilized peptide arrays have been 
used as substrates for hESC adhesion and expansion (Derda et al. 2007, Orner et al. 
2004). However, the peptide densities in these studies were never quantified or 
otherwise measured. Furthermore, the analysis of hESC pluripotency was limited to 
detection of endogenous alkaline phosphatase and OCT-4 expression, without any 
examination of karyotypic stability or differentiation potential of the expanded 
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hESCs. In a study by Kolhar et al., immobilized cyclic RGD peptide sequences were 
shown to promote hESC attachment and propagation at an estimated peptide surface 
density of 10 - 30 fmol/cm2 (Kolhar et al. 2008). The density was calculated from 
such variable methods as fluorescence measurements and ELISA; unfortunately, no 
direct quantification of the peptide surface density or other surface characterization 
was attempted. 
A further development of a defined hESC-culture platform was described by 
Ludwig et al., who reported that a combination of human collagen IV, FN, and LN 
was able to support several passages of hESCs when combined with a xeno-free 
culture medium (TeSR1) (Ludwig et al. 2006b). However, those cells were found to 
be karyotypically abnormal, which may explain their adaptation to this platform. In 
other approaches, hESCs have been shown to propagate on separate matrices of FN, 
LN and VN (Amit & Itskovitz-Eldor 2006, Braam et al. 2008, Miyazaki et al. 2008), 
highlighting that a defined, scalable substrate on which to propagate hESCs may be a 
possibility. Also, induced pluripotent stem cells (IMR90) have been successfully 
propagated on plasma-purified VN (Rowland et al. 2010), suggesting that VN, of the 
various ECM proteins being investigated, may be universally applicable for the 
propagation of pluripotent stem cells. 
Vitronectin is an abundant ECM glycoprotein that promotes cell adhesion and 
spreading (Schvartz et al. 1999b). Braam et al. and Rowland et al. reported the 
successful culture of hESCs and iPSC on 5 g/ml of recombinant VN and 10 g/ml of 
plasma-purified VN respectively (Braam et al. 2008, Rowland et al. 2010). Braam et 
al. also identified V5 integrin as the VN receptor (Braam et al. 2008). Although 
studies by them employed VN as a substrate for the culture of hESCs, neither report 
determined the actual surface density of VN capable of supporting long-term cell 
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culture. As such, there is a need to better characterize and quantify VN substrates for 
hESC expansion so as to provide a defined platform for the scale-up of stem cell 
cultures (Oh & Choo 2008, Skottman et al. 2006, Unger et al. 2008). 
Thus, this chapter will present a more detailed examination of a reproducible 
and verifiable VN surface and the effect on adhesion, proliferation and long-term 
maintenance of hESCs compared to MatrigelTM. Two culture media, mTeSRTM1 and a 
control MEF conditioned media (CM) were assessed on their ability to support hESC 
culture. By utilizing Ponceau S staining, the Bradford protein assay and 125I-VN 
radiolabelling, threshold VN density was determined. A range of direct physical 
measurement methods, including X-ray photoemission spectroscopy (XPS) to analyze 
the atomic composition of the surface, and the physical roughness of the surface 
determined by atomic force microscopy (AFM), were also employed. Lastly the 
relative uniformity of VN coating was assessed by colloidal gold staining (Stochaj et 
al. 2006).  
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2.2. Materials and Methods  
 
2.2.1. Culturing of E-MEFs and generation of CM  
 In order to culture hESCs on MatrigelTM (Beckon Dickinson)-coated surfaces, 
conditioned media (CM) were generated from inactivated-mouse embryonic fibroblast 
(MEF) cells. MEF cells were first isolated from the foetuses of 139X1/SvJ mice at 
day 13.5 post coitum and then immortalized using the E6/E7 retrovirus as described 
by Choo et al. (Choo et al. 2006). Immortalized feeders (E-MEF) were cultured in 
MEF media (90 % Dulbecco’s Modified Eagle’s medium (DMEM) high glucose, 
10 % fetal bovine serum (FBS), 2mM L-glutamine, 25 units/ml penicillin and 
25 g/ml streptomycin). At 90% confluence, E-MEFs were incubated with 10 g/ml 
of mitomycin-C (Sigma Aldrich) for 150 min at 37 oC, after which cells were washed 
once with DMEM (Invitrogen), three times with PBS (Invitrogen), dissociated into 
single cells with trypsin-EDTA (Invitrogen) and counted with a haemocytometer. The 
mitomycin-C treated cells were seeded back into flasks at 4 x 105 cells/cm2 and used 
for the subsequent preparation of CM (85 % Knock-Out Dulbecco’s Modified Eagle’s 
medium (KO-DMEM), 15 % Knock-Out serum replacer supplemented with 1 mM L-
glutamine, 1 % nonessential amino acids, 0.1 mM 2-mercaptoethanol, 25 Units/ml 
penicillin, 25 g/ml streptomycin and 10 ng/ml FGF-2). 
 CM was prepared by overnight conditioning over E-MEFs, before collection 
and use for hESC culture. CM was then sterilized (0.22 m filtration) and 10 ng/ml of 
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2.2.2. Preparation of recombinant FGF-2 
 
Fresh recombinant FGF-2 (Invitrogen) was prepared in FGF buffer (10 mM 
Tris, 0.1 % BSA and stored at -20 oC) at 10 ng/ml. FGF-2 was added into CM, and 
media was refreshed daily.  
 
2.2.3. Coating of TCPS with VN, MatrigelTM. 
 
Routine culturing of hESC on TCPS coated with VN or MatrigelTM was 
performed. Stock plasma-purified VN solution (1 mg/ml) (Millipore) was diluted with 
PBS to a working solution of 5 µg/ml. From the working solution, 300 l was added 
into organ culture dishes (OCD) (Beckon Dickinson) and incubated overnight (18 h) 
at 4 ºC. The coated plates were then rinsed once with PBS and immediately used for 
cell seeding.  
As a positive control, OCDs were coated with 1:30 Knock-out DMEM (KO-
DMEM) diluted MatrigelTM (Beckon Dickinson). Diluted MatrigelTM (1 ml) was 
added onto the dishes and incubated overnight at 4 oC. Surfaces were then washed and 
cells seeded.   
 
2.2.4. Maintenance of hESCs 
 
 The human embryonic stem cell lines, HES-3 (46, XX, Female) from ES Cell 
International and H1 (46, XY, Male) from WiCell Research Institute were routinely 
cultured on TCPS plates with a VN substrate coating solution of 5 g/ml (VN5) at 
37 oC in 5 % CO2 (as described previously). Either CM or mTeSRTM1 (Stem Cell 
Technologies) were refreshed daily to maintain the cells in a pluripotent state. CM 
was used as a positive control as previously described by our laboratory (Choo et al. 
2006).  
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Confluent cell cultures were passaged at day 7 according to Choo et al. (Choo 
et al. 2008). Different passaging techniques were used for cells cultured on 
MatrigelTM and VN surfaces. Cells grown on MatrigelTM were enzymatically treated 
with collagenase IV (200 U/ml) (Invitrogen) for 5 min at 37 oC, washed with PBS and 
the differentiated cells removed by manual pipetting. Cultures were then separated 
into small pieces with a pipette and split into new MatrigelTM-coated plates at 1:4 
ratio.  
For cells that were cultured on VN surfaces, mechanical passaging was 
employed. Differentiated cells were similarly removed by pipette, and the 
undifferentiated cells scraped into small clumps and seeded onto freshly VN-coated 
surfaces at a 1:10 passage ratio. Cryopreservation was performed at - 80 oC in 90 % 
KO serum replacer (Invitrogen) and 10 % DMSO (Sigma Aldrich). 
 
2.2.5. Cell counting  
 
To determine the number of viable cells for plating, cells were counted with a 
NucleoCounter NC-100 (Chemometec, Copenhagen, Denmark). The cells were 
enzymatically lifted from the surface with TrypLETM express enzymatic dissociation 
buffer (Invitrogen) and sample (100 l) used for cell counting. Cells were first lysed 
with Nucleocounter reagent A (100 l), that perforates the cell membrane at low pH, 
and then 100 l of Nucleocounter reagent B to neutralize the pH of the mixture and 
allow efficient staining by propidium iodine as per the manufacturer’s 
recommendations. The solution was then mixed and loaded into the NucleoCassette 
for counting to achieve total cell number. For dead cell number, 100 l of reagent B 
was added into another cell sample (100 l) and counted. To determine viable cell 
number, the dead cell number was substratcted from the total cell number. Cell 
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numbers in the sample were then enumerated based on the manufacturer’s 
recommendations:  
x cell numbers * 3 * volume of sample = Actual cell numbers in the total volume  
 
2.2.6. Crystal violet adhesion assay  
 
To determine the efficiency of cell adhesion to the various experimental 
surfaces, the crystal violet adhesion assay was utilized. Crystal violet is a dye that 
stains DNA so that quantitative information about the relative density of cells can be 
determined. Surfaces were prepared with VN coating (100 l) at various 
concentrations (0, 2.5, 5, 10, 15, and 20 g/ml) onto 96-well flat bottom TCPS plates 
(NUNC) as previously described. Wells were then blocked with 200 l of 2 % BSA 
(Invitrogen) for 1 h at room temperature. Cells were dissociated with 200 l 
TrypLETM express and counted with the Nucleocounter NC-100 to determine total 
viable cell numbers (as described in section 2.2.5). Single cells at 3 x 105 densities 
were then seeded into each well with mTeSRTM1. The plates were incubated at 
37 oC, 5 % CO2 for 45 min to allow attachment. Uncoated wells incubated without 
cells were used as blanks.  
Non-adherent cells were removed with 200 l Iscove’s Modified Dulbecco’s 
Medium (IMDM) (Invitrogen) supplemented with 0.35 % BSA and then once with 
PBS. Attached cells were fixed in 100 % ethanol (Merck) and stained with 0.4 % 
crystal violet (Sigma Aldrich) solution in methanol for 5 min. Wells were washed 
three times with 200 l MilliQ water (Millipore) to remove the unbound dye, 
followed by the addition of  1 % sodium dodecyl sulphate (SDS) (Sigma Aldrich) 
(40 l) to solubilise the bound dye. The plates were left on an orbital shaker until a 
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uniform colour was observed in each well and cell adhesion determined at 570 nm. 
Data were normalized to the uncoated wells.   
 
2.2.7. In vitro differentiation assay (EB) and PCR analysis 
 
To assess the quality of the pluripotent cells, spontaneous differentiation of 
hESCs into the three germ layers using embryoid bodies (EBs) was conducted. 
Confluent hESCs grown on different substrates were removed with a cell scraper to 
form random-sized EBs. These cells were grown in suspension for 7 days and re-
plated on 0.1 % gelatinized plates for further 14 days, with a media change every 
2 days. Total ribonucleic acid (RNA) was extracted from EBs after differentiation 
using an RNA extraction kit (Qiagen). Quality and amount of RNA was quantified 
with a ND-1000 Spectrophotometer (Nanodrop Technologies, USA). The RNA was 
reverse transcribed with oligo dT primers (Invitrogen) and superscript II reverse 
transcriptase (Invitrogen) into complementary deoxyribonucleic acid (cDNA). 
Polymerase chain reaction (PCR) was carried out using cDNA with primers specific 
to the 3 germ layers. The endodermal lineage is detected with Alpha-feto protein 
(AFP); the mesodermal lineage with Msh homeobox 1 (MSH) and heart- and neural 
crest derivatives-expressed protein 1 (HAND1); and the ectoderm lineage with 
neurofilament heavy chain (NFH). Octamer-binding transcription factor 4 (OCT-4) 
served as the undifferentiated marker and Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as the internal control (Table A1). All primers 
were synthesized by Sigma Aldrich. In parallel, RNA from undifferentiated hESCs 
was extracted for comparison to differentiated cells. The amplified products were 
visualized in ethidium bromide-stained 1 % agarose gels.  
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2.2.8. In vivo differentiation assay (Teratoma analysis) 
 
 To confirm the pluripotentiality of hESCs cultured on the various 
substrates, intramuscular injections of cells were given to severe combined 
immunodeficiency (SCID) mice and the formation of tumours determined 10 weeks 
post injection (Choo et al. 2008). Cells cultured in various conditions for > 5 passages 
were dissociated by trypsin-EDTA digestion and an intramuscular injection 
(hamstring muscle) of 5 x 106 cells in 50 µl of sterile PBS was given to 4-week-old 
female SCID mice with a sterile 22G needle. After 10 weeks, mice were sacrificed, 
the tumours dissected, fixed in 10 % formalin, embedded in paraffin, then sectioned 
and stained with haematoxylin and eosin (H&E). The presence of the germ layers 
(ectoderm, mesoderm and endoderm) in the tumours was assessed by 
immunohistochemistry, using primary antibodies: polyclonal rabbit anti-cytokeratin 
(1:250), desmin Clone 33 (1:100) and rabbit anti-glial fibrillary acidic protein (GFAP) 
(1:250) with matching undiluted secondary antibodies: EnVision+ horse-radish 
peroxidase (HRP) anti-rabbit and EnVision+HRP anti-mouse. All antibodies were 
from DAKO. Sections were incubated with chromogen DAB and counter-stained with 
haematoxylin. Images were then taken under a light microscope (Olympus BX51).  
 
2.2.9. Karyotypic stability 
 
The chromosomal stability of hESCs cultured on VN for > 5 passages was 
analyzed by the Cytogenetic Laboratories at the Department of Obstetrics and 
Gynaecology, Kandang Kerbau Women’s and Children’s Hospital, Singapore. 
Karyotyping analysis was performed using BrdU/colcemid and 20 cells analyzed for 
each determination. Cells with more than 2 abnormal chromosomes were considered 
karyotypically unstable. 
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2.2.10. Flow cytometry analysis (FACS) 
 
To monitor the pluripotency during serial passaging of hESC on VN-coated 
surfaces, the cell surface marker, Tra1-60, and intracellular marker, OCT-4, were 
measured weekly by flow cytometry. Cells were first dissociated with 0.25 % trypsin-
EDTA at 37 oC / 5 % CO2 for 5 min, washed once with 1 % BSA, and fixed and 
permeabilised with the Fix and Perm kit (Invitrogen). Reagent A from the kit (100 l) 
was added to a washed cell pellet for 15 min, washed with 1 % BSA and spun down 
at 10,000 rpm for 30 sec. Then a 15 min permeabilization step was performed on the 
cells with reagent B (100 l) from the kit. During this step, OCT-4 (1:20) or Tra1-60 
(1:50) mouse monoclonal antibodies were incubated together. Cells were then washed 
with 1 % BSA, spun down and incubated in the dark (15 min) with FITC-conjugated 
goat anti-mouse antibody at 1:500 dilutions in 1 % BSA. Finally, cells were washed 
and resuspended in 1 % BSA for measurement on a FACS Calibur (Becton-
Dickinson). Data was analyzed using FlowJo software and cell gating (% expression) 
was done at the intersection between the isotype control and the marker expression 
(Yap et al. 2011). 
 
2.2.11. Ponceau S staining 
 
 Quantification of the amount of VN on the surfaces was made with Ponceau S 
staining assay. The dye binds to proteins and is easily desorbed with NaOH. The 
kinetics of VN on TCPS surfaces was also determined. This provided information on 
the rate of adsorption and desorption of VN.   
VN-coated OCDs (0 to 20 g/ml) were washed twice with MilliQ water and 
dried under nitrogen. Ponceau S staining solution (0.1 %) (Sigma Aldrich) at 500 l 
was added and incubated overnight to allow maximal binding of the stains to the 
CHARACTERIZATION OF VN SUBSTRATES                                                      67 
protein (Yap et al. 2011). The wells were then washed with water and air-dried, 
whereupon 400 l of 0.1 M NaOH (Sigma Aldrich) was added for 20 min with 
agitation to release bound Ponceau S stain from the surface. Desorbed stain (200 l) 
was neutralized with 10 l of 50 % acetic acid (Merck) and measured at 515 nm on an 
Infinite® 200 Multimode Microplate Reader (Tecan, Switzerland). Data were then 
compared to a standard curve using VN at 0 to 10 µg/ml concentration and final 
concentration of stain desorbed from the VN-coated TCPS was expressed in molarity.  
 
2.2.12. Adsorption and desorption kinetics 
 
 Understanding the kinetics of VN on TCPS is useful for the calculation of the 
rate of adsorption and desorption. The adsorption and desorption kinetics were 
similarly obtained from the coated OCDs using the Ponceau S staining assay 
(described previously). To quantitate the adsorption kinetics, OCDs were incubated 
with VN solution at 5 g/ml concentration (VN5) for varying times (0 to 32 h) and 
stained with Ponceau S. For VN desorption, OCDs were incubated with VN5 
overnight, washed, and air-dried. PBS (1 ml) was added into the wells and incubated 
at 37 ºC. At different time points (0 to 48 h), the wells were stained with Ponceau S 
and rate of desorption determined.     
 
 
2.2.13. Bradford assay  
 
A Bradford assay was performed to further quantify the amount of VN on 
surfaces. Final surface density was calculated by determining the amount of VN 
depleted from the depositing solution (Bradford 1976, Zor & Seliger 1996).  
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The OCDs were incubated overnight with different VN solutions, 100 l from 
each OCD combined, and 1.2 ml of Bradford dye (Sigma Aldrich) added into a 1.5 ml 
glass vial. To avoid inaccurate quantification, glass vials were used to prevent the 
absorption of VN onto the surface and all measurements done within 10 min. The 
solution was mixed for 5 min and 200 l sampled, and read in a microplate reader at 
both 590 nm and 450 nm. This was then normalized by subtracting the average 
A590 / A450 value for PBS (Zor & Seliger 1996). The reading was compared to a 
standard curve (A590 / A450 against different VN concentrations) to obtain the VN 
concentration. The difference between this concentration and the depositing 
concentration is the amount of VN adsorbed. The surface density (ng/cm2) was 
calculated by using the surface area of an OCD as 3.5 cm2, which includes the base 
and a rim extending 1.5 mm above it. 
 
2.2.14. 125I-VN quantification 
 
 Surface densities of VN were also assessed by a highly sensitive radiolabelling 
study. VN was labelled with the 125I isotope (Perkin Elmer) coupling (on tyrosine 
residues via lactoperoxidase reaction) using Thermo Scientific Pierce Iodination 
Beads as per the manufacturer’s recommendations. Prior to labelling, 2 iodination 
beads were washed with PBS and dried on filter paper. Beads were added to 100 l 
PBS solution containing 0.5 mCi of 125I isotope for 5 min; subsequently 50 g of VN 
was added into the reaction and incubated for another 10 min. The reaction was 
terminated by separating the solution from the beads with a pipette. The remaining 
free 125I in the solution was removed with PD Minitrap G-10 desalting columns (GE 
Healthcare). The 125I-VN was diluted with unlabelled VN (1:9 ratio) for each 
concentration (0 to 20 g/ml) and added into spatially removed white-walled 
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transparent bottom TCPS 96-well plates (Corning) to allow overnight binding of VN 
at 4 oC.  Following that, wells were washed 3 times with 200 l of PBS, 200 l of 
Ultima Gold scintillation cocktail (Perkin Elmer) added and the plates read in a 
MicroBeta liquid scintillation counter (Perkin Elmer) for 1 min. Surface density 
(ng/cm2) was calculated by comparing to reference concentrations of 125I-VN.  
 
2.2.15. XPS measurements 
 
To measure the surface elemental composition, a quantitative spectroscopic 
technique, X-ray photospectrometry (XPS) was employed. XPS spectra were obtained 
by irradiating the material with a beam of X-rays and simultaneously measuring the 
kinetic energy and number of electrons that escape from the top 1 to 10 nm of the 
material (Fally et al. 1995). The surface chemical composition of each VN coated-
TCPS was determined using a Theta Probe X-ray photoelectron spectrometer 
(Thermo Fisher Scientific), equipped with an aluminium anode (15 kV, 100 W) and a 
quartz monochromator. The monochromator was set to a 50 º take-off angle 
(measured from the normal to the plane of the sample surface), yielding a probe depth 
of ~ 5 nm. Detailed scans of the nitrogen (N1s), oxygen (O1s), and carbon (C1s) 
peaks were performed on each sample, taking data from a 400 µm2 spot and using 
pass energy of 40 eV. Detailed scans were repeated as follows: 20 x for C1s, 15 x for 
O1s, and 20 x for N1s. A wide scan (binding energy from 0 to 1300 eV) was then 
performed with pass energy of 200 eV. Peaks were fitted with a mixed Lorentz-
Gaussian function. Deconvolution of the C1s signal revealed 5 peaks: aromatic C 
(284.8 - 284.9 eV), C-C (285 eV), C-NH2 (285.5 – 286.0 eV), C-O (287.6 –
 288.4 eV), and C=O (287.6 – 288.4 eV). Results were analyzed with CasaXPS 
software.  
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2.2.16. AFM measurements 
 
Atomic force microscopy (AFM) profilometry was employed because of its 
high resolution to study the topographical features of different VN-coated TCPS. Air-
dried VN-coated and uncoated TCPS were measured using a Bioscope I microscope 
equipped with a NanoScope IIIa controller and a low noise scanner (Digital 
Instruments, Veeco Metrology Group, USA). PointProbe® Plus noncontact high 
resonance frequency (PPP-NCH) silicon cantilevers (Nanosensors, Switzerland) were 
used in intermittent-contact (also known as tapping) mode to obtain high-resolution 
images of the samples. Scan rates varied from 0.75 to 1 Hz and free amplitude (A0) 
setpoint values were ~ 1.6 V. Images of the TCPS surface morphology and the VN-
coated surfaces were taken at 85 - 90 % of the free amplitude. Roughness analysis 
was performed with Nanoscope software version v5.12rb. Briefly, two-dimensional 
AFM height maps were used to determine the arithmetic roughness (Ra) of the 
uncoated and VN-coated TCPS surfaces. The arithmetic roughness describes the 
absolute value of the surface height, measured relative to a two-dimensional plane, set 
at the average sample height. Ra was calculated from either the entire (4 µm x 4 m) 
image, or several smaller areas (2 m x 2 m) within the image. Phase data records 
the variations in the cantilever oscillation, reflecting changes in surface rigidity and 
viscoelasticity. This was used to improve the contrast between adsorbed VN 
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2.2.17. Colloidal gold staining 
 
 To assess the uniformity of VN adsorption onto TCPS, Colloidal Gold Total 
Protein Stain (Biorad) was employed. Colloidal Gold stain rapidly detects and stains 
proteins. VN coated-TCPS were washed and air-dried and then incubated with 
undiluted Colloidal Gold stain (500 l) overnight in room temperature. Surfaces were 
then rinsed with water, air-dried, and photomicrographs taken. 
 
2.2.18. Statistical analysis 
 
All data values are reported as the mean + standard error taken from three 
individual experiments with triplicate runs each. Where appropriate, one-way 
ANOVA was performed to compare differences across the groups, and P < 0.05 was 
considered as significant. Student's t-test (2-tailed) was done to determine the 
differences between two sample groups. Graphs were plotted and data transformed 
using Sigma plot software. 
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2.3. Results 
2.3.1. Stable expansion and analysis of hESCs cultured on VN5 
 
In order to assess the suitability of VN as a substrate for hESCs, HES-3 and 
H1 cells were cultured for > 10 passages on TCPS coated with a 5 g/ml VN solution 
(VN5) in either control CM or experimental mTeSRTM1 media. Both media were used 
to compare the cell responses to the various substrates. Photomicrographs of cells 
cultured at passage 15 revealed that both cells retained an undifferentiated 
morphology characterized by both the formation of compact colonies with distinct 
boundaries and a high nucleus to cytoplasmic ratio (Fig. 2.1). Weekly flow cytometry 
analysis was performed to measure the expression of the pluripotent marker, Tra1-60. 
The expression level during 12 weeks of passaging revealed that both cell lines had 
> 90 % positive expression (Table 2.1). Cells continued to express high levels of 
Tra1-60 over 30 passages. Representative FACS analysis on the various substrates is 
shown in Figure 2.2.  
 
 
Figure 2.1. Representative images of HES-3 and H1 cells. Cells retained the typical 
stem cells morphology of compact colonies with distinct boundaries (Yap et al. 2011). 
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Figure 2.2. FACS analysis of the pluripotent surface marker Tra1-60. HES-3 and 
H1 were > 90% positive for Tra1-60 suggesting the cells adapted well to VN5. (Yap 






Table 2.1. Tra1-60 expression in HES-3 and H1 cells over 12 passages in varying 








CHARACTERIZATION OF VN SUBSTRATES                                                      74 
To further determine the suitability of VN as a substrate for hESC expansion, 
an analysis of karyotype was performed on HES-3 (46, XX) at passage 9 and H1 
(46, XY) at passage 5. Data showed that the cells possessed a normal diploid 
karyotype (Fig. 2.3). This was again repeated at passage 30; with cells maintaining a 
normal karyotype. As both HES-3 and H1 cells are equally viable and remain 




Figure 2.3. Genomic stability of HES-3 and H1 cells on VN5. No chromosomal 
abnormality for HES-3 and H1 cells was observed at passage 9 and 5 respectively. 
They retained a normal diploid karyotype, 46, XY and 46, XX. Similar results were 
also obtained at passage 30 (Yap et al. 2011). 
 
A robust, tri-germ layer differentiation potential is a hallmark of pluripotent 
hESCs. Following propagation on VN5 for 25 passages, HES-3 cells were induced to 
differentiate in vitro through EB formation, and the presence of ectoderm, mesoderm 
and endoderm probed by PCR. After 21 days of differentiation, HES-3 cells expressed 
the mRNA transcripts for AFP (endoderm), MSX1 (mesoderm) and NFH (ectoderm) 
that are normally absent in undifferentiated cells (Fig. 2.4). As expected, the 
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expression of the pluripotent markers Nanog and OCT-4 were suppressed when the 
cells were induced to differentiate (Fig. 2.4).  
 
                      
Figure 2.4. mRNA transcript expression from the in vitro differentiation of HES-
3 cells through EB at passage 25.  The expression of AFP (endoderm), MSX1 
(mesoderm) and NFH (ectoderm) genes from the three germ layers were absent in the 
undifferentiated cells. OCT-4 marker diminished after 21 days of differentiation and 
GAPDH was used as a internal control (Yap et al. 2011). 
 
As a final test of pluripotency, the tumorgenicity of HES-3 was investigated 
in vivo. Cells at passage 18 were injected into SCID mice. Teratomas were present 
and contained structures from all 3 germ layers, as determined by H&E and 
immunohistochemical staining (Fig. 2.5). Clear evidence of ectoderm 
(neuroepithelium and pigmented epithelium), mesoderm (bone and cartilage) and 
endoderm (gut epithelium) was visible. Similarly, the presence of GFAP-positive 
intermediate filaments (ectoderm), desmin-positive muscle (mesoderm) and 
cytokeratin-positive epithelium (endoderm) was confirmed by immunohistochemistry.   
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Collectively, this data suggests that VN5 surfaces are able to support the long-term 
propagation of pluripotent hESCs in an undifferentiated state.  
 
 
Figure 2.5. Histological sections of teratomas from HES-3 cells (passage 18). A) 
Tissues representing the three germ layers were analyzed after H&E staining. 
Neuroepithelium and pigmented epithelium represented ectoderm lineage; bone and 
cartilage represented mesoderm lineage and gut epithelium represented endoderm 
lineage. B) Teratomas were also stained with antibodies for GFAP (ectoderm), 
desmin (mesoderm) and cytokeratin (endoderm). Scale bar = 100 m  (Yap et al. 
2011). 
 
2.3.2. Threshold concentration of VN that is required for the attachment and 
propagation of cells 
  
Having established a robust VN5 working condition for hESC culture, we next 
sought to assess the variation in bio-responses arising from systematic changes in the 
VN surface density. Cell attachment was compared across a range of VN densities 
after either 45 min or 1 day in culture (Fig. 2.6A).  Cell attachment increased in a VN 
density-dependent manner, with the greatest number of attached cells occurring at the 
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highest VN density. Surfaces with higher cell attachment reached confluence earlier 
but hESC do not exhibit contact-inhibition thus will continue to grow and stack onto 
each other. If they remain pluripotent with low cell death, cultures can be passage 
together. Notably, in CM the cell density plateaus at VN2.5, with ~ 2- to 4- fold more 
cells attached in the presence of mTeSRTM1 as compared to CM. Since no difference 
in cell adhesion at VN5 and VN10, therefore higher VN concentrations were not 
explored. No differences in cell number were also observed for either media 
treatments after 1 day (Fig. 2.6B). There was however a similar VN density-effect 
between 45 min and 1 day, with ~ 3-fold more attached cells detected in VN2.5 as 
compared to VN1.25.  
 
 
Figure 2.6. Short-term adhesion assay on different VN coatings. A) Crystal violet 
adhesion assay after 45 min in CM or mTeSRTM1 media. As VN concentration 
increase so did the number of HES-3 cells attached in mTeSRTM1 media than in CM. 
B) HES-3 were seeded and a count was performed at day 1. The number of cells 
attached to < VN1.25 was insignificant as compared to the rest of the conditions. Cell 
numbers plateau at VN2.5, regardless of the media used. * = P < 0.05 ** = P < 0.001 
(Yap et al. 2011). 
  
To fully assess hESC proliferation, changes in cell number after 1 week in 
culture were calculated on the various VN substrates. When cultured for 7 days, 
 VN2.5 was required for maximum proliferation, notwithstanding significant growth 
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differences were also observed between the CM and mTeSRTM1 media, with 
mTeSRTM1 significantly outperforming CM (~ 30 %) (Fig. 2.7A). A VN2.5 substrate 
capable of supporting hESC attachment and expansion was also evident from 
photomicrographs taken after 1 week in culture (Fig. 2.7B). Cells cultured on 
> VN2.5 had the typical “mosaic/cobblestone” appearance of confluent hESCs, as 




Figure 2.7. Cell counts and micrographs of HES-3 after 1 week in culture at 
various VN concentrations. A) Cell numbers were similar in VN2.5, VN5 and VN10 
but on VN1.25, numbers were significantly lower than the rest. Significant differences 
were observed in cells cultured on CM and mTeSRTM1 media. * = P < 0.05 
** = P < 0.001. Data are expressed as mean + standard deviation (n = 3). B) 
Representative day 7 images of HES-3; VN1.25 did not support robust cell expansion 
as well as the other concentrations, and cultures did not reach confluence by day 7 
(Yap et al. 2011). 
 
In order to more fully evaluate the threshold VN surface density suitable for 
the long-term maintenance of pluripotent hESCs, HES-3 cells were cultured for > 5 
passages in mTeSRTM1 media. Pluripotency was then assessed by FACS, EB 
differentiation and teratoma formation.  Initially, cells cultured on VN1.25, VN2.5 
and VN5 underwent a period of adaptation that was reflected by a decreased 
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expression of pluripotent markers at passage 1 (Table 2.2). Following subsequent 
passaging, cultures at passages 2 - 6 were > 90 % positive for Tra1-60 and OCT-4 
(Fig. 2.8 and Table 2.2).  These levels were similar to those observed for cells 
maintained on control MatrigelTM surfaces. 
Table 2.2. Expression of the pluripotent markers Tra1-60 and OCT-4 in HES-3 







Figure 2.8. Representative expression of Tra1-60 and OCT-4 as determined by 
FACS at passage 5.  HES-3 cells were grown on VN1.25, VN2.5 and VN5 with 
mTeSRTM1. Cells expressed > 90 % positive for these markers (Yap et al. 2011). 
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Next the genomic stability of hESC culture on VN1.25 and VN2.5 was 
assessed. As with VN5 coatings, HES-3 cultured on VN1.25 and VN2.5 maintained a 
normal karyotype over 5 passages (Fig. 2.9). Differentiation was then assessed by RT-
PCR for germline markers after EB formation. Cells cultured on VN1.25 failed to 
expand sufficiently for differentiation assays to be conducted, and so were not 
analyzed further. However, cells readily expanded on VN2.5, with differentiation 
assays showing the presence of mRNA transcripts for AFP (endoderm), Hand1 
(mesoderm) and NFH (ectoderm) and the absence of Nanog and OCT-4 (Fig. 2.10). 
Importantly, despite their in vitro differentiation potential, cells cultured on VN2.5 
failed to form teratomas when transplanted into SCID mice. As previously shown, 
cells cultured on VN5 maintained all the hESC characteristics of growth, 
differentiation and teratoma formation. Therefore, the VN threshold solution 
concentration needed to maintain hESC pluripotent during long-term expansion is 




Figure 2.9. Genomic stability of HES-3 cultured on VN1.25 and VN2.5 after 5 
passages. Karyotype analysis of HES-3 cells cultured mTeSRTM1. No chromosomal 
abnormalities were observed in either condition (Yap et al. 2011). 
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Figure 2.10. HES-3 (passage 5) in vitro differentiation assay (EB) when cultured 
on VN2.5. HES-3 was able to differentiate into the 3 germ layers. Expression of 
mRNA transcript for AFP (endoderm), Hand1 (mesoderm) and NFH (ectoderm) were 
present and the pluripotent markers Nanog and OCT-4 absent. GAPDH served as 




Table 2.3. Summary of the different pluripotency criteria for hESCs on VN1.25, 
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2.3.3. VN surface density determination 
 
 To determine the amount of surface-bound VN, Bradford protein assays and 
Ponceau S staining were performed so that the depletion of VN from the original 
solution concentration could be calculated. Results from both the Bradford protein 
assay (Fig. 2.11A) and Ponceau S staining (Fig. 2.11B) show matching trends for the 
adsorbed VN surface density: a steady increase in surface-adsorbed VN with 
increasing solution concentration that reaches a plateau for VN solution 
concentrations > 10 g/ml. These measurements estimated the surface density 
deposited from VN5 at 250 ng/cm2, increasing to a maximum of 500 ng/cm2 for 
deposition from  VN10. Previous analysis of the cell response indicated that hESCs 
did not attach, and long-term proliferation was not supported when < VN5 (Table 
2.3). Therefore the minimum surface density was set at 250 ng/cm2. 
 
 
Figure 2.11. Quantification of VN adsorbed to TCPS. A) VN density deduced from 
VN depletion in the depositing solution as measured by Bradford assay. B) Surface 
density of VN adsorbed to TCPS stained by Ponceau S dye. Both Bradford assay and 
Ponceau S staining showed that density plateaus at VN10 (Yap et al. 2011). 
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This threshold surface density was thus estimated at 250 ng/cm2 by assuming a 
linear dependence between adsorbed VN with solution concentration, as predicted by 
the Langmuir adsorption isotherm, and as corroborated by the Ponceau S staining and 
the Bradford protein assay. However, this assumption might not be strictly accurate; 
thus a more sensitive method for accurately determining the VN surface density by 
radiolabelling was performed. VN was iodinated with the 125I-isotope on tyrosine 
residues via the lactoperoxidase reaction to generate I125-VN, and this then used to 
coat TCPS overnight. Results showed the same adsorption trends on TCPS as with the 
Bradford and Ponceau S assays (Fig. 2.12). VN again adsorbed in a dose-dependent 
manner and saturated at VN10, thus confirming that the VN5 coating adsorbs 
250 ng/cm2 of VN.  
 
 
Figure 2.12. 125I-VN binding assay to TCPS. TCPS was coated with increasing 
concentrations of 125I-VN overnight. Radioactive counts were measured after washing 
with PBS the next day. Results confirmed that 5 g/ml of 125I-VN solution adsorbed 
250 ng/cm2 onto the culture surface.  
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2.3.4. Surface characterization 
 
XPS was used to quantitate the surface chemical composition of VN-coated 
TCPS, with the data revealing the presence of nitrogen, C-NH2, C-O, and C=O bonds 
(Fig. 2.13). The increasing signal from N and O atoms (from peptide bonds) with 
increasing depositing solution concentration confirmed a monotonic increase in VN 
surface density. This reached saturation at > VN10; thus this finding followed the 
same trend as observed with Bradford assay, Ponceau S surface staining and I125-VN 
quantification (Figs. 2.11 and 2.12). This independently confirms the dependence of 




Figure 2.13. XPS quantification of surface composition for VN-coated TCPS. 
Surface chemical bonds increase linearly and saturates at 10 g/ml, confirming the 
presence of VN on the surface by the presence of nitrogen (Yap et al. 2011).   
 
 
To directly observe VN aggregation on TCPS surfaces, AFM analysis was 
performed. AFM height images reveal the surface profilometry of the cell culture 
substrate and can be used to directly observe VN aggregates. Uncoated TCPS showed 
an intrinsic, structured surface roughness, consisting of random line features that were 
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presumably introduced during the TCPS manufacturing process. The substrate 
features were observed across all samples, from uncoated, to TCPS coated with 0, 2.5, 
5, 10 and 20 g/ml VN (Figs. 2.14 A to F). TCPS morphology remained unchanged 
after exposure to the PBS, implying that the features associated with VN aggregates, 
as observed on the coated TCPS, were not merely an artefact (Fig. 2.14B). The 
surface roughness (Ra) of the uncoated TCPS substrates was found to range from 2.7 
to 3.2 nm. Deposited VN aggregates, in the form of spot-like features, were visible on 
TCPS coated with VN solution concentrations from 2.5 to 10 µg/ml (Figs. 2.14 C to 
E). AFM phase images offered enhanced contrast, as seen on TCPS coated with the 
VN2.5 solution (Fig. 2.14H). A higher magnification of the nominated area in Figure 
2.14 H is shown in Figure 2.14 I. The absence of spot-like features, associated with 
VN aggregates, on the AFM phase image of uncoated TCPS (Fig. 2.14G) confirmed 
that these arise from the adsorbed VN. The adsorbed VN aggregates did not 
significantly increase the Ra value for coated samples beyond the range quoted above. 
Finally, the AFM profilometry of TCPS coated with VN20 showed a loss in 
resolution; the physical origins of this remain unexplained. Although AFM has 
previously been used to study VN adsorption on smooth mica surfaces (Zhang et al. 
2004), the present study will seek to examine VN when adsorbed to TCPS, a surface 
demonstrated to be successful for the long-term propagation of hESCs.  
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Figure 2.14. AFM height profilometry images. A) Uncoated TCPS, TCPS coated 
with (B) 0, (C) 2.5, (D) 5, (E) 10, and (F) 20 µg/ml VN solutions. (G to I) are phase 
images from the same samples (A) uncoated TCPS and (C) 2.5 g/ml. Image (I) 
shows a magnified view of the marked area on image H. The height range is 0 –
 25 nm, the phase range is 0 – 15 º. The scale bar is 1 µm on all images except image 
(I), where it is 200 nm (Yap et al. 2011). 
 
To observe the coating uniformity, total protein on the surfaces can be stained 
by colloidal gold. The staining, although not quantitative, may be used to discern the 
uniformity of the VN coated on the surface.  The staining confirmed that the amount 
of adsorbed VN increased with VN concentration (Figs. 2.15 A to F). The uncoated 
surface (Fig. 2.15A) demonstrated the absence of colloidal gold staining on TCPS. As 
the depositing VN solution concentration was increased, the samples shown in 
Figure 2.15 B did not show any staining, while in Figure 2.15 C, which depicts the 
coating of VN5, there is barely any discernible stain. Coating from the 10, 15, and 
20 µg/ml solutions (Figs. 2.15 D to F), respectively, reveals discernible, increasing 
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colloidal gold staining, whose uniformity indicates that the VN adsorbed to the 




Figure 2.15. Colloidal gold staining of TCPS.  VN concentrations of (K) 0, (L) 2.5, 
(M) 5, (N) 10, (O) 15, and (P) 20 µg/ml were used to coat TCPS. The diameter of 
each disk is 15 mm (Yap et al. 2011). 
 
2.3.5. Adsorption and desorption kinetics of VN on TCPS 
 
Adsorption and desorption kinetics (Fig. 2.16) were modelled assuming 
exponential time dependence. Modelling the data with an exponential as the square 
root of time, as proposed by several authors, did not improve the fit (Douglas et al. 
1993, Sukhishvili & Granick 1998, Sukhishvili & Granick 1999). The associated 
fitting parameters (Table 2.4) indicated an adsorption time constant of approximately 
1 h, and a desorption time constant of approximately 4 h. The desorption time 
constant may not be accurately represented under actual cell culture conditions, where 
it was influenced by competing adsorption from other proteins. The y0 parameter 
physically represents the VN protein that remains bound to TCPS following a 
desorption time of 2 days. Figure 2.16 B showed that only about 25 % of the adsorbed 
VN was desorbed from the TCPS substrate after a 48 h exposure to PBS. The 75 % of 
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VN adsorbed to TCPS after 2 days may, in small part, have arisen from VN re-
adsorbed from the PBS solution. However it can in large part are attributed to VN 
remaining durably bound to the TCPS substrate.  
 
 
Figure 2.16. Ponceau S staining to give VN adsorption and desorption kinetics 
onto TCPS. (A) Adsorption kinetics from VN5. (B) Desorption kinetics from TCPS, 




Table 2.4. Equations and fitting parameters for adsorption and desorption 
kinetics. “x” represents the ordinate and “y” the abscissa, with fitting parameters for 
adsorption and desorption kinetics of VN on TCPS (data and fitted curves shown in 
Fig. 2.16). For adsorption, A reflects the maximum surface density of VN and T is the 
time constant. For desorption, A reflects the initial surface density of VN, T is the 
time constant, and y0 reflects staining of non-desorbed VN (Yap et al. 2011). 
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2.4. Discussion 
 
The search for defined surfaces for pluripotent hESC culture has led to the 
development of several defined surfaces, including immobilized peptide arrays and 
cyclic RGD peptide (Derda et al. 2007, Kolhar et al. 2008, Liu et al. 2011, Orner et 
al. 2004) . Even though these surfaces demonstrated the ability to maintain hESCs, 
their peptide density was neither directly quantified nor characterized. Moreover, the 
analysis of pluripotency was limited to endogenous alkaline phosphatase and OCT-4 
expression. Other than peptide surfaces, Braam et al. and Rowland et al. demonstrated 
the ability of VN to support hESC propagation but they lack details concerning the 
characterization and quantification of VN on the culture surfaces. Here, I varied the 
concentration of VN in solution and determined the amount that adsorbed to TCPS 
with a view to developing a quantifiable platform on which to expand pluripotent 
hESC over multiple passages, and in a stable manner. TCPS was chosen because it is 
the most widely used surface for culturing cells, and also has demonstrated to be 
capable of the long-term propagation of hESCs. 
This study showed that a threshold VN surface density of at least 250 ng/cm2 
(VN5) is required for the long-term expansion (> 30 passages) of pluripotent hESCs 
in a serum-free defined medium (mTeSRTM1). Cells cultured at this VN threshold had 
sustained positive expression of Tra1-60 and OCT-4 (> 90 %), had a normal diploid 
karyotype and they maintained a compact morphology.  Importantly, the cells retained 
the potential to differentiate to the 3 germ layers through EBs and readily formed 
teratomas when transplanted into the muscle pouch of SCID mice. At VN surface 
densities < 250 ng/cm2 cell attachment and proliferation were compromised and the 
cells failed to differentiate in EBs and were unable to develop teratomas in vivo.  
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The absence of in vivo teratoma from the transplanted cells when cultured on 
VN2.5 showed that the cells cultured are not pluripotent, even though all in vitro 
studies confirm otherwise. Thus, in vivo teratoma formation is a necessary criterion to 
confirm the pluripotent state of cells. Without teratoma formation, this study would 
have erroneously suggested a threshold density of ~ 120 ng/cm2 from a depositing 
solution of 2.5 g/ml, an underestimate of the actual threshold.   
It was also observed that hESCs cultured in mTeSRTM1 media achieved higher 
cell numbers after 1 week as compared to cells grown in CM. This observation is 
supported by Chin et al., who reported that defined media such as mTeSRTM1 reduce 
the doubling time of hESCs to approximately 21 h, as compared to cells cultured in 
CM, that require 28 h (Chin et al. 2010).  
From the characterization studies we can conclude that the long-term, stable 
propagation of hESCs is possible with VN5, and that this defined surface is a viable 
alternative to MatrigelTM. The threshold surface density is estimated at 250 ng/cm2 of 
protein by assuming a linear dependence of adsorbed VN with solution concentration, 
as predicted by the Langmuir adsorption isotherm and corroborated by Ponceau S 
staining, Bradford protein assay and 125I-VN measurements. Thus, VN is an effective 
substrate for promoting cell adhesion and expansion of pluripotent stem cells at 
surface densities well below its saturation, which is estimated at 500 ng/cm2 as 
measured by Bradford assay (Fig. 2.11a) 
AFM image resolution was limited by the radius of the AFM probe tip, which 
is nominally 20 nm. This prevented the detection of individual VN molecules, which 
may be approximated by a cylinder of radius 3 nm and length 11 nm (Lynn et al. 
2005). Larger VN aggregates appeared as point-like asperities on the randomized line-
feature background of the TCPS substrate. Only the height of VN aggregates was 
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assessed, as dimensions in the plane of the surface are convoluted with the tip 
diameter. Their size is comparable to that reported by Zhang et al. for VN molecules 
adsorbing onto smooth mica surfaces (Zhang et al. 2004). Lynn et al. described the 
formation of VN aggregates in solution and Izumi et al. reported the presence of VN 
aggregates with a Stokes radius of 6.5 nm in human plasma (Izumi 1989, Lynn et al. 
2005). Thus, the observed VN aggregates may either have been adsorbed from 
solution, or may be formed as VN adsorbs to TCPS. Higher VN solution 
concentrations may lead to its adsorption in a different configuration, perhaps giving 
rise to the observed decrease in resolution when imaging TCPS coated with VN20.   
It must also be noted that mTeSRTM1 is not a completely defined media, as the 
BSA and VN used is from pooled human plasma and not recombinant sources. 
However, one would not expect this to significantly alter the viable VN platform 
described here. A further examination of the triggering thresholds could be performed 
in a completely chemical defined xeno-free medium such as X-VIVO10 from Lonza, 
TeSRTM-E8TM from Stem Cell Technologies, HEScGRO from Millipore or Nutristem 
hESC SF from Biological Industries. Although the use of recombinant proteins are 
clearly advantageous, such proteins are usually cloned and expressed in bacterial or 
animal cells, which are often sources of foreign antigen such as the highly 
immunogenic non-human forms of sialic acid (Neu5Gc). Furthermore, animal cells 
may possess inappropriate glycosylation patterns on their susceptible proteins, 
rendering them ineffective in the presence of highly glycosylated VN. Serum-derived 
proteins, despite being subject to lot-to-lot variability and the possibility of 
contamination from plasma, usually retain all their biological activity. Serum-derived 
proteins are useful in the studies of most applications. Future biotechnological 
innovation may provide the means to overcome these drawbacks in the future. 
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2.5. Summary 
 
 This chapter established a robust set of parameters for the coating of surfaces 
with VN for the long-term propagation of pluripotent hESCs, and summarizes the 
subsequent surface characteristics of VN-coated TCPS.   
 
Based on the experimental evidence, the following key findings were derived: 
(1) Vitronectin coatings are an alternative to MatrigelTM in culturing hESCs. It is a 
defined ECM protein, in contrast to the poorly characterized MatrigelTM. It 
thus reduces the risk of cell contamination. Cells remain pluripotent in the 
presence of a defined media (mTeSRTM1) without the use of CM. 
(2) The minimum threshold concentration of VN required for the successful long-
term culture of hESCs is 5 g/ml, which corresponds to 250 ng/cm2 as 
measured with Bradford assay and radioactivity.  
(3) In vivo differentiation as assessed by teratoma formation is critical for the 
establishment of the suitability of a substrate. I would strongly recommend 
doing a teratoma assay to confirm the continuing pluripotency of any cultured 
hESCs.  
 
Understanding the minimum VN surface density raises the issue of its 
efficiency and cost-effectiveness within the context of large-scale industrial 
manufacturing processes for generating clinical-grade stem cells more reliably (Oh & 
Choo 2008, Skottman et al. 2006, Unger et al. 2008). The reliable production of large 
quantities of stem cells may well benefit from optimized VN substrates. Optimized 
VN substrates can be engineered by extrapolating the relationship between cell 
surface HS and VN surface. The next chapter will therefore address the means of 
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CHAPTER 3 : ISOLATION, 
CHARACTERIZATION AND 
IMMOBILIZATION OF HS9 
VARIANT 
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3.1 Introduction 
 
 To better define hESC culture surfaces, and improve the cost-effectiveness of 
VN coating, a novel strategy is clearly called for. Glycosaminoglycans are complex, 
linear, highly charged carbohydrates that interact with a wide range of proteins to 
regulate their function and are usually synthesized attached to core protein. GAGs are 
classified into nonsulfated (HA) and sulfated (CS, DS, KS, heparin and HS) GAGs.  
Among the GAGs, the heparan sulfate (HS) family is of particular interest 
because of its ability to interact with targeted proteins based on specific sequences 
within its domains. The family (heparin and HS) consist of repeating uronic acid-
(14)-D-glucosamine disaccharide subunits with variable pattern of N-, and O-
sulfation. For example, the anti-coagulant activity of heparin requires 3O-sulfation in 
glucosamine residue with a unique pentasaccharide arrangement (Lindahl et al. 1979). 
A unique sulfation pattern is also apparent for ECM proteins; an avid heparin-binding 
variant for FN is particularly highly charged, with 7 to 8 N-sulfated disaccharides 
being required, and with a larger domain than normal (> 14 residues) (Falcone & 
Salisbury 1988, Mahalingam et al. 2007). However, HS differs from the sulfated 
heparin by having highly sulfated NS domains separated by the unsulfated NA 
domains, which provide a different unique arrangement for binding selective proteins 
especially without the side effects of heparin(Gandhi & Mancera 2008).  
Thus, elucidating the disaccharide composition of HS is essential to 
understanding its sulfation pattern, and eventually for the future generation of 
synthetic variants. The disaccharide composition of HS can be elucidated through a 
series of enzymatic cleavages (Desai et al. 1993b, Shriver et al. 2000, Venkataraman 
et al. 1999) using Flavobacterium heparinium enzymes heparinase I, II and III to 
cleave the glycosidic bonds. More than 90 % depolymerization of heparin or HS is 
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possible when all 3 heparinase are used in combination (Karamanos et al. 1997, 
Vynios et al. 2002). The disaccharides can be analyzed by PAGE (Hampson & 
Gallagher 1984), SAX-HPLC (Skidmore et al. 2009), or highly sensitive CE (Lamari 
et al. 2001) by comparing to known disaccharides standards. Several authors have 
described the separation of heparinase-digested disaccharides samples using CE at 
reverse polarities of  – 20 kV (Karamanos et al. 1996),  – 15 kV (Ruiz-Calero et al. 
1998) or – 30kV (Militsopoulou et al. 2002) at acidic pH. 
Numerous studies have also shown that HS is generally important for the 
maintenance and proliferation of stem cells (Bramono et al. 2011, Helledie et al. 
2012, Klim et al. 2010, Levenstein et al. 2008, Nurcombe & Cool 2007). Uygun et al. 
demonstrated that GAG-derivatized surfaces are able to promote 5-fold increase in 
mesenchymal stem cell growth compared to TCPS surfaces (Uygun et al. 2009). 
Therefore, to improve the effective VN density on TCPS, it may be possible to 
manipulate HS in such a way as to present VN more effectively. Immobilization 
strategies include coupling GAGs with BSA to allow adsorption onto surfaces (Feng 
et al. 2004, Nishioka et al. 2007); EDC chemistry to covalently immobilized 
disaccharide units (Plante et al. 2001); biotinylation of GAGs and coupling to 
streptavidin-coated surfaces (Foxall et al. 1995, Hasan et al. 1999, Parkar & Day 
1997) and positively charged plasma polymer films (Mahoney et al. 2004, Marson et 
al. 2005). As detailed previously, to analyze the elemental composition on plasma-
polymerized surfaces techniques such as XPS could be employed (Robinson et al. 
2012).   
This chapter describes the search for an HS variant with high VN-binding 
ability that can improve VN surface density for cell culture. The approach we adopted 
followed a path our Glycotherapeutics group (IMB, A*STAR) has pioneered over 
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several years. This chapter sets out to purify a novel VN-binding HS species from a 
raw HS starting material by affinity chromatography using the VN-HBD peptide as 
the capture ligand. A full range of biochemical assays to confirm the binding ability 
of this purified HS from the non-binding and starting material were employed. The 
length, sulfation pattern and composition requirements of HS were then analyzed by 
ELISA and CE. Three different strategies were then explored to immobilize the 
purified HS variants onto TCPS.  A method that utilized allylamine was shown to 
offer distinct advantages over the other methods tested.  
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3.2. Materials and Methods 
 
3.2.1. Preparation of VN-HBD peptide surfaces 
 
 After establishing the VN5 platform in earlier studies, this chapter seeks to 
assess the importance of cell surface HS for the binding of hESC to VN-HBD 
substrates. An N-terminal biotinylated VN-HBD peptide (Biotin-
PRPSLAKKQRFRHRNRRKGYRSQRGHSRGRNQNSRR) was synthesized by 
China Peptides Co. Ltd, Shanghai, China. This peptide, which lacks an RGD motif, 
was immobilized onto streptavidin-coated surfaces to assess the attachment 
efficiencies of the heparinase-treated hESCs and is described further on. The 
streptavidin (Genescipt) was first reconstituted in PBS to 1 mg/ml stock and 
subsequently prepared as a 20 g/ml working concentration. Bacterial grade 24-well 
plates (Beckon Dickinson) were coated with 625 l of the working streptavidin 
concentration and incubated overnight at 4 ºC. Wells were then washed twice with 
PBS and 10 M of VN-HBD peptide incubated for 2 h at room temperature, after 
which wells were washed again and 1 ml of mTeSRTM1 supplemented with 10 M 
Rock inhibitor (Y27632) (Calbiochem) according to the study by Klim et al. (Klim et 
al. 2010) . The use of Y27632 markedly increases the survival of dissociated-induced 
cell death as demonstrated by Watanabe et al. (Watanabe et al. 2007). Coated plates 
were used immediately for the crystal violet cell adhesion assay (Section 2.2.6). 
 
3.2.2. Heparinase digestion and heparin-inhibition of HES-3 cells  
 
 To efficiently remove cell surface HS for the study of cell attachment, 
heparinase I, II and III were employed. Heparinase I (E.C. 4.2.2.7), heparinase II (no 
E.C. number) and heparinase III (E.C. 4.2.2.8) were purchased from Sigma Aldrich, 
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resuspended in digestion buffer (20 mM Tris-HCL, 50 mM NaCl, 4 mM CaCl2 and 
0.01 % BSA, pH 7.5) and used within 1 freeze-thaw cycle.  HES-3 single cells at 
1 x 106 cells per well were resuspended in 100 l of DMEM/F12 media (Invitrogen) 
containing heparinase I (10 milli international units (mIU)), heparinase II (5 mIU) and 
heparinase III (10 mIU). The cell suspensions were incubated at 37 oC for 1 h, with 
mixing every 10 min. The cells were then spun at 12,000 rpm and surface HS 
expression analyzed by FACS.   
 Soluble heparin (Sigma Aldrich) was preincubated with cells and served as a 
competitor to the surface-bound HS with the peptide surface. Similarly, cells (1 x 106) 
were resuspended in 100 l DMEM/F12 media (Invitrogen), incubated with soluble 
heparin at 500 g/ml concentrations for 1 h, with mixing after every 10 min. Cells 
were then analysed for binding to VN-HBD surfaces with the crystal violet assay 
(Section 2.2.6). 
   Both the heparinase-digested cells and cells incubated with soluble heparin 
were seeded onto the prepared 10 M of VN-HBD peptide surface (as described 
above) or positive control VN5 in 96-well plates (as described in Chapter 2). Plates 
were left to incubate for 45 min to allow attachment, and crystal violet cell adhesion 
assays performed as described in Section 2.2.6. Streptavidin-coated surfaces served as 
a negative control and data was normalized to the absorbance of VN5. 
 
3.2.3. FACS analysis of heparinase-digested cells 
 
To ensure enzymatic digestion effectively removed exogenous HS chains from 
HES-3 cells, FACS analysis using both the 10E4 and 3G10 antibody was performed. 
The 10E4 antibody recognizes common N-sulfated and N-acetylated glucosamine 
sugar units in native HS sugar chains on cell surfaces (van den Born et al. 2005) and 
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the 3G10 antibody specifically binds to de-saturated uronic acid residues that remain 
after digestion of HS with heparinase (David et al. 1992). Live staining was done on 
ice to prevent cell death. Digested cells at a density of 2.5 x 105 were washed with 
1 % BSA and 200 l of either 10E4 or the 3G10 (1:100) antibodies (Seikagaku) added 
for 1 h. Respective isotype controls (10 g/ml) (DAKO) for the primary antibodies 
were used to stain cells to account for non-specific antibody binding. Cells were then 
washed and stained with FITC-conjugated goat anti-mouse secondary antibody 
(DAKO) (1:500) for 30 min. Exogenous HS expression was then determined using a 
FACS Calibur (Becton Dickinson) and the results analyzed with FlowJo software. 
Gating was done at the point of intersection between the isotype control and 
10E4/3G10 expression.  
 
 
3.2.4. Peptide binding assay with 3H-heparin  
 
To confirm the binding ability of the synthesized VN-HBD peptide to heparin, 
the 3H-heparin binding assay was employed in the manner of Baird et al. (Baird et al. 
1988). Biotinylated VN-HBD peptide (Biotin-
PRPSLAKKQRFRHRNRRKGYRSQRGHSRGRNQNSRR) was serially diluted in 
PBS (0, 12.5, 25, 50 and 100 g peptide) and individually spotted onto 0.2 M 
nitrocellulose membranes (Biorad). Peptide was left to dry on the membrane for 1 h at 
room temperature and heated to 80 oC for 30 min. The membrane was then washed 
three times with PBS, where upon 1 ml of 0.1 Ci of 3H-heparin (Perkin Elmer) in 
4 % BSA (Sigma Aldrich) was added, and the membrane incubated overnight at room 
temperature with agitation. Next day, the membrane was washed three times with 
PBS and 1 ml of Ultima Gold scintillation cocktail (Perkin Elmer) was added in a 
20 ml glass scintillation vial (Perkin Elmer). The vial was analyzed in a liquid 
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scintillation Tri-carb 2800TR counter (Perkin Elmer, Massachusetts, USA) for 1 min, 
three times. The counts-per-minute readings were averaged and plotted.  
 
3.2.5. Affinity chromatography 
 
 To isolate the VN binding variants from starting porcine intestinal mucosal HS 
(HSpm) material, affinity chromatography using biotinylated VN-HBD peptide as the 
capture ligand was performed. Saturating amounts of biotinylated VN-HBD peptide 
(3 mg) were coupled to a 1 ml streptavidin column (GE Healthcare) as assessed by the 
detection of unbound peptide at 280 nm in the flowthrough. To ensure peptide is 
firmly bound to the column, a 1.5 M high salt buffer wash was performed. When no 
traces at 280 nm were detected, the column was equilibrated with low salt buffer and 
was ready for HS loading.  
Crude HS (HSpm) (Celsus Laboratories) was dissolved in low salt buffer 
(20 mM phosphate buffer, 150 mM NaCl, pH 7.2) at a concentration of 1 mg/ml. A 
total of 100 mg HSpm solution was loaded in a total of 30 separate injections in low-
salt buffer (Biologic-Duoflow chromatography system; Bio-Rad) at a flow rate of 
0.2 ml/min, and the column washed with the same buffer until the baseline reached 
zero. The bound HS was eluted with a one step gradient of 1.5 M high salt (20 mM 
phosphate buffer, 1.5 M NaCl), the bound and unbound variants collected (monitored 
at A232 nm), and the column re-equilibrated with low-salt buffer. The eluent (HS9+ve) 
and flow-through (HS9–ve) peak samples were collected separately, freeze-dried, and 
stored at -20 oC. Both the HS9+ve and the HS9–ve variants were then separately 
dissolved in 10 ml of HPLC grade water (Sigma Aldrich) and desalted once on a 
HiPrep 26/10 desalting column (Amersham Biosciences) at a flow rate of 10 ml/min. 
The different HS variants were then collected, freeze-dried, and stored at – 20 oC.  
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3.2.6. Dot Blotting 
 
To analyze the different HS variants for binding affinity to VN, dot blotting 
was conducted. Nitrocellulose membranes were rinsed with TBST and assembled into 
the Biorad dot blot apparatus according to manufacturer’s instructions. The edges of 
the membrane were marked to help in reassembling the membrane sandwich after 
blocking. VN (1 g) was added into the wells and the assembly put under vacuum. 
The membrane was removed and blocked with 5 % BSA for 1 h. After blocking the 
membrane was assembled back into the dot blot apparatus in the same configuration.  
The GAGs (2 mg) were initially biotinylated using biotin-LC-hydrazide (60 l 
of a 2 mg/ml solution) (Thermo Scientific) dissolved in 1 ml of 0.1 M MES buffer, 
pH 5.5. Briefly, EDC (1.5 mg) was added to the mixture and incubated for 2 h before 
the addition of another 1.5 mg of EDC after which unincorporated biotin was 
removed with a Fast Desalting (PD 10) Column (GE Healthcare). These biotinylated 
GAGs (1 g) were added into the wells of the dot blot apparatus, left for 10 min and 
then aspirated off with a pipette. After incubation, the membrane was then washed 
with TBST. Streptavidin-HRP (2 ml) was added onto the membrane for 10 min, and 
washed again with TBST. Finally, the membrane was exposed to the LumiGLO 
chemiluminescent substrate (Kirkegaard & Perry Laboratories) and exposed to X-ray 
film (Amersham) in the dark.   
 
3.2.7. Heparin-Sepharose bead competition assay 
 
 Heparin-Sepharose bead competition assays were performed to investigate the 
binding affinity of each desalted HS variant (Heparin, HSpm, HS9+ve and HS9-ve) to 
VN and other ECM proteins according to Ono et al. (Ono et al. 1999). The assay was 
done at room temperature and a “master mix” of bead slurry was prepared to reduce 
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error. For each reaction, 20 l of heparin-Sepharose beads (Sigma Aldrich) were 
mixed with 20 l of Biogel P10 (Biorad). The total volumes of beads and Biogel for 
the required reactions were calculated and brought together to form a master mix. The 
height of the suspension was marked for later resuspension. The bead suspension was 
washed 3 times with 1 ml of 1% BSA, and the beads allowed to settle to the bottom of 
the tube between washes. After the last wash, beads were left to settle and 
resuspended back to the original height using the initial marked height. From the 
master mix, aliquots (40 l) of bead slurry were separated into individual 1.5 ml 
Eppendorf tubes for binding experiments. Excess liquid was removed by pipette, 
leaving the beads at the bottom of the tube.  
Optimization of the amount of protein needed to achieve sub-optimal binding 
to beads was first conducted. Varying concentrations of ECM proteins (VN, LN, and 
FN) were added to the beads in 100 l volume. The suspension was incubated for 
30 min under constant rotation, after which the beads were spun down at 2000 rpm for 
1 min, and washed twice with 1 ml of 1% BSA and with 1 ml of 0.02 % Tween20 
(Sigma Aldrich) in PBS. Excess wash buffer was removed from the last wash. The 
corresponding anti-ECM antibody (100 l) (Millipore) prepared in PBS (250 ng/ml 
anti-VN, 5 g/ml anti-LN, 2 g/ml anti-FN), was added and, the mixture incubated 
for another 30 min with constant rotation. The beads were washed again as previously 
described and 100 l of the HRP-conjugated goat anti-mouse antibodies (1:10,000) in 
PBS was added to each reaction, under rotation for 30 min. Finally, the beads were 
washed, 100 l of TMB substrate (Thermo Scientific) added and colour allowed to 
develop. The reaction was stopped at 30 min by adding 50 l of 2 M H2SO4. Beads 
were centrifuged at 2000 rpm and 100 l of the supernatant removed and added into a 
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96-well plate (NUNC) to be read at 450 nm. Results were plotted and sub-optimal 
concentrations of each ECM protein used for the subsequent competition assay. 
The binding affinities of the GAGs to ECM proteins were next investigated 
using the competition assay. Different concentrations (0, 5, 50 and 100 g) of GAGs 
were pre-incubated with the individual ECM protein in 100 l for 30 min with 
rotation. The reaction was then added into the washed 40 l of bead slurry as 
previously prepared. Results were expressed as “percentage bound” by normalizing to 
readings from control, uncompeted beads. 
To confirm the results from the competition assay, immunoblotting was 
performed. After the competition, the beads were washed and boiled at 95 oC with 
30 l of Laemmli buffer (Sigma Aldrich). The beads were spun and the supernatant 
loaded into SDS-PAGE gels (Invitrogen) at 180 V for 40 min and transferred to 
nitrocellulose membranes at 100 V for 90 min. The membrane was then probed with the 
corresponding primary antibody in 5 % BSA at 4 oC overnight. Membranes were washed 
with TBST 3 times for 5 min each. Then, HRP-conjugated goat anti-mouse secondary 
antibody (Jackson Immunoresearch) (1:10000) in 5 % BSA was incubated for 1 h at room 
temperature. Membranes were finally washed and exposed to LumiGLO ReserveTM 
chemiluminescent substrate (Kirkegaard & Perry Laboratories) to visualise the bands on 
X-ray films.             
 
3.2.8. Glycosaminoglycan ELISA  
 
 To further examine the VN binding affinities of each HS variant, GAG ELISA 
was performed. This assay was based on the immobilization of HS variants onto the 
glycosaminoglycan-binding 96-well plates (Iduron) by electrostatic interactions and 
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the VN binding ability assessed by antibodies as per manufacturer’s 
recommendations.  
Wells were incubated overnight at room temperature with 200 l of 5 g/ml 
GAGs (Heparin, HSpm, HS9+ve and HS9-ve), heparin disaccharides standards (dp2 to 
dp12) or selectively desulfated heparin standards prepared in standard assay buffer 
(SAB).  SAB was prepared with 100 mM NaCl, 50 mM NaAc, (v/v) 0.2 % Tween 20, 
pH 7.2. Wells were then washed with 200 l of SAB three times and blocked (0.4 % 
(w/v) fish gelatin in SAB), for 1 h at 37 oC. Wells were washed with SAB three times 
and VN at different concentrations (0 - 1 g/ml, 200 l each) was added into the wells 
and incubated at 37 oC for 2 h. Wells were again washed (3 times) and 200 l of anti-
VN antibodies (250 ng/ml) (Millipore) added into the wells and incubated at 37 oC for 
1 h. Wells were washed (3 times) to remove unbound antibody and 200 l of 
250 ng/ml goat anti-mouse biotinylated antibody (Sigma Aldrich) added for 1 h at 
37 oC. After incubation, wells were washed again (3 times) and ExtrAvidin (200 l of 
220 ng/ml) (Sigma Aldrich) added for 30 min for 37 oC. Wells were finally washed 
(3 times)  and 200 l of SIGMAFAST™ p-Nitrophenyl phosphate (Sigma Aldrich) 
added into the wells with incubation at room temperature for 40 min. Colourimetric 
absorbance was read at 405 nm with a Victor multiplate reader (Perkin Elmer, 
Massachusetts, USA). 
 
3.2.9. Capillary electrophoresis 
 
 To investigate the different molar percentages of each disaccharide present in 
the heparinase-polymerized HS variants, capillary electrophoresis (CE) was 
performed. CE is a sensitive technique to separate the samples based on charge and 
molecular weight. Heparin, HSpm, HS9+ve and HS9-ve variants (200 g) were all 
HS9 VARIANTS                                                                                                      106 
digested with heparinase I, II and III (Iduron) in digestion buffer (100 l) to give 
2 mg/ml stock. Digestion buffer consisted of 50 mM NaAc, 1 mM calcium acetate 
and 100 g/ml BSA, pH 7. Heparin was first digested with 4 mIU of heparinase I and 
II each for 3 h at 30 oC, and later 1 mIU of heparinase II for another 60 min to 
complete the digestion. HS samples were digested with 4 mIU heparinase I for 30 min 
and later 4 mIU heparinase II and III each for another 3.5 h at 30 oC. Absorbances at 
232 nm were measured throughout the digestion process to ensure complete digestion; 
this was recognized by the lack of further increases in absorbance. Absorbance was 
performed at 232 nm because of the C=C bonds created in the uronic acid after 
digestion can be detected at this wavelength. Reactions were terminated by denaturing 
the enzymes at 95 oC for 1 min. Solutions were centrifuged at 10,000 rpm and 
supernatants used for the CE analysis.  
The quantification of each disaccharide in the depolymerized samples were 
completed by diluting the stock (2 mg/ml) to 1 mg/ml with MilliQ water and 25 l of 
a 1 mg/ml internal standard (4UA-2S ® GlcNCOEt-6S) (Iduron) Δ-disaccharide 
added. This internal standard was added because it had a migration time distinct from 
the Δ-disaccharide standards and could thus be utilized for the determination of each 
disaccharide unit from its relative migrational shift. The depolymerized sample was 
then injected into the CE system to generate the electropherogram. The area-under-
the-peak was then measured and compared to a standard curve to derive the 
concentrations. Molar percentages of each sample were then calculated from the 
molecular weight of each standard and compared in a table.  
To generate the standard migration profile for comparison, commercially 
available, digested heparin disaccharide (Δ-disaccharide) standards (Iduron) as shown 
in Figure 1.12 were separated at 250 g/ml, with the exception of IVA. These 
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standards were used for the generation of the electropherogram to identify the 
migration time; from these the quantification of each disaccharide unit in the digested 
GAGs samples became possible. By using 7 different concentrations (undiluted 
(1 mg/ml), 1x, 2x, 4x, 8x, 12x and 16x dilution) of each standard to generate a 
calibration curve based on its area-under-the-peak, the standard curve of area against 
concentration was plotted.  
CE was performed on a P/ACE MDQ instrument equipped with a diode array 
detector (Beckman instrument) at 25 oC.  Membrane-filtered (0.22 m) 60 mM formic 
acid solution (pH 3.4) (Sigma Aldrich) was used as the running buffer. Separations 
were carried out in uncoated fused-silica capillaries, with a length of 60 cm and a 
75 m internal diameter (Beckman instrument). Capillaries were first pre-treated with 
1 M NaOH for 30 min and rinsed with MilliQ water for another 20 min. The capillary 
was than conditioned with formic acid buffer for 60 min in readiness for sample 
injection. The cycles were programmed for 5 min water rinses, 3 min 1M NaOH, 
5 min buffer washes and 5 sec sample injection (0.5 pound force per square inch 
(p.s.i.) and reverse polarity of -15 kV), so that disaccharides would migrate from 
cathode to anode due to their electrophoretic mobility (EM) against the electro-
osmotic flow (EOF) of the buffer. Disaccharides were separated for 40 min and 
individual peaks were detected at 232 nm. This cycle was repeated for the next 
injection.  
To ensure reproducibility of migration times and peak areas (expressed as 
relative standard deviation, R.S.D.), 5 replicates of the heparin standards were 
performed daily. Digestion buffer was also run through the system to ensure no 
interference to the sample peaks.  
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3.2.10. Sodium hydroxide etching of polystyrene surface 
 The first strategy was to immobilize HS with a chemical method to covalently 
anchor it onto surfaces. The generation of a positively charged surface is first needed 
for such an immobilization reaction. Habardzumyan et al. reported the successful 
oxidation of polystyrene substrates using NaOH (Hambardzumyan et al. 2002). 
Therefore NaOH was employed for the etching of polystyrene surfaces to expose the 
maximal number of carboxyl groups.  
White-wall transparent bottomed 96-well TCPS plates (Corning) were used 
for NaOH etching. Following Habardzumyan et al., a solution of 4: 1 (v/v) NaOH 
(4 N): methanol was prepared and 250 l added into each well at the nominated time 
points (day 0 to day 7) at 37 oC. After 7 days, the wells were washed with 10 % citric 
acid (Sigma Aldrich) for 1 h and used for subsequent 3H-GAG grafting assays. 
 
3.2.11. Fluorescamine Assay 
 
 To compare the amount of primary amines in various GAGs (heparin, HSpm, 
HS9+ve and HS9-ve), a fluorescamine protein dye assay was conducted. The dye reacts 
rapidly with primary amines and, when activated at 365 nm, emits at 470 nm; thus it 
is particularly suitable for the quantification of minute amounts of GAG. Fresh stocks 
of fluorescamine (Sigma Aldrich) (3 mg/ml) were prepared with dimethyl sulfoxide 
(DMSO) in an amber tube with vigorous mixing. Two GAG concentrations (0.5 and 
1 mg/ml) were utilized. GAG solutions (90 l) were added to 30 l of the stock 
fluorescamine solution and mixed by pipeting. The reaction was allowed to proceed at 
room temperature for 15 min, after which the reaction was thoroughly mixed and read 
using an Infinite® 200 Multimode Microplate Reader (Tecan, Switzerland).  
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 Standard curves were generated from the two-fold dilutions of BSA (from 
500 g/ml) standards. The 90 l standards were mixed with 30 l of dye at room 
temperature for 15 min and read. Concentrations of primary amines were quantified 
by comparison to the standard curve. 
 
3.2.12. Covalent binding of GAG to TCPS with EDC 
 To physically link HS onto NaOH-etched PS and TCPS surfaces, covalent 
immobilization using EDC was explored. The carboxyl groups on the plates were 
utilised to form stable amide bonds with the free amine groups on the GAGs. The 1-
ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) (Sigma Aldrich) 
is a soluble, zero-length carbodiimide crosslinker that activates carboxyl groups into a 
reactive ester for the spontaneous reaction with primary amines. Preliminary 
experiments aimed at optimizing the concentration of EDC required to crosslink 
amine of 3H-lysine (Perkin Elmer) yielded a working concentration of 50 mg/ml. This 
EDC concentration was dissolved in 0.1 M MES buffer, pH 6, and 200 l of this 
solution was added into a well of the white-wall transparent bottomed 96-well TCPS 
plates to react for 1 h at room temperature with agitation. EDC reacts with the 
carboxyl group on the plate to form an amine-reactive O-acylisourea ester 
intermediate. This intermediate forms an amide bond when it encounters a primary 
amine; if not, it hydrolyzes and regenerates the carboxyl group. After 60 min, the 
plate was first washed with 0.1 M MES buffer and then with water, twice each. This 
removes the excess reagents and cross-linking by-products. Different concentrations 
of 3H-heparin and 3H-HS (0 to 100 mg/ml) in PBS (100 l) were added into triplicate 
wells and incubated at room temperature for 2 h with agitation. Finally, the wells were 
washed twice with 10 x PBS (10 min each), once with water (10 min) and three more 
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times with water (5 min each). This excessive washing removes any unbound reagent. 
Scintillation liquid (200 l) was added into each well and radioactive counts (1 min) 
monitored on a MicroBeta counter (Perkin Elmer, Massachusetts, USA). 
 
3.2.13. Poly-L-lysine coating 
 
 A simpler method of creating a positively charged surface is by the coating of 
poly-L-lysine on TCPS. This allowed electrostatic binding between the positively 
charged surface and the negatively charged HS. The 0.01 % PLL solution (Sigma 
Aldrich) (50 l) was added into each well of the white-wall transparent bottomed 96-
well TCPS plates or 300 l into each well of 24-well plate for 5 min at room 
temperature with agitation. Excess unbound PLL solution was removed and the 
surface washed twice with PBS. The plate was air-dried for 3 h. The poly-L-lysine 
coated positive charged surfaces were then utilized for the immobilization of GAGs 
(5 g/ml) and subsequent cell culture. 
 
 
3.2.14. Screening of PLL surface with HES-3 cells 
 
To ensure the suitability of PLL surfaces for stem cell culture, a cell 
attachment assay was performed with HES-3. PLL-pre-coated 24-well plates were 
coated with 400 l of GAG (heparin, HSpm, HS9+ve, HS9-ve) (5 g/ml) in PBS for 2 h 
at room temperature. Wells were washed with PBS and subsequently coated with 
VN2.5 or VN5 (300 l per well) in PBS overnight at 4 oC. Wells were named 
according to which GAG and what VN concentration was used i.e.; PLL+GAG+VN.  
 HES-3 cells were routinely maintained on TCPS coated with VN5 in 
mTeSRTM1 media (Stem Cell Technologies). Differentiated cells were removed by 
manual pipetting and the rest were dissociated mechanically. Cells (3 x 105) were 
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3.2.15. Allylamine plasma polymerization and analysis  
 
To robustly generate positively charge TCPS surfaces for electrostatic 
immobilization of negative charged GAGs, plasma polymerization using allylamine 
monomer (Sigma Aldrich) was employed. The plasma reactor is made up of a 
cylindrical stainless steel vacuum vessel (~ 100 L volume) with an internal electrode 
at one end. Polystyrene plates (96-well or 24-well) (SARSTEDT) and an aluminium 
foil were placed in the chamber under vacuum overnight to remove any air prior to 
the next day’s plasma coating. The reactor was evacuated to a base pressure of less 
than 5 x 10-4 mbar, using a two-stage rotary pump coupled to a liquid nitrogen cold 
trap. The flow of the monomer into the chamber was controlled with a needle valve.   
Allylamine monomer was degassed over several freeze-thaw cycles to remove 
dissolved gases before use. A monomer flow rate of ~ 5 standard cubic centimetres 
per minute (sccm) (Mahoney et al. 2004) was tuned with the needle valve and 
allowed to stabilise before deposition. To achieve the different percentages of the AA-
coated plates, the flow was mixed with different ratios of allylamine and octa-1, 7-
diene. The monomer ratios used were 100% allylamine, 90% allylamine: 10% octa-1, 
7-diene, 80% allylamine: 20% octa-1, 7-diene, 50% allylamine: 50% octa-1, 7-diene 
and 100% octa-1, 7-diene. The flow rate was calculated using this formula based on 
Robinson et al. (Robinson et al. 2008): 
 
(Pressure after isolating the chamber at the end of 30 sec – pressure before isolating 
the chamber)/ 30 *1251 
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 Plasma was then ignited with a radio frequency generator (Coaxial Power 
System Ltd, UK) at 13.56 MHz and 5 Watts of power. The plasma was turned on for 
40 min after which the chamber was pumped back to base pressure. The plates were 
removed and lids were replaced to maintain sterility. These sterile plates were then 
used for the experiments involving immobilization of GAGs for cell culture. The 
aluminium foil in the chamber was read by a XPS equipped with an aluminium anode 
and wide-scan analysis to confirm the density of amines deposited onto the plates 
(Mawson Institute, University of South Australia).  Results were analyzed with 
CasaXPS software. The nitrogen: carbon (N: C) ratios were calculated from the area 
underneath the N and C peaks to obtained the relative amount of AA on the surface. 
Immobilized GAGs on the various percentages of AA coated 96-well plates were 
analysed for its binding ability to VN using the GAG ELISA assay method as 
described in Section 3.2.8.  
      
3.2.16. Quantification of 3H-heparin and 3H-HSpm  
 
 To determine the amount of GAG bound to the 100 % AA-polymerized 96-
well plate, binding assays using 3H-heparin (Perkin Elmer) and 3H-HSpm 
(radiolabelled by RC TRITEC, Switzerland) were employed. Ascending 
concentrations (0, 1.25, 2.5 and 5 g/ml) of mixtures of 90 % un-labelled heparin or 
HSpm : 10% of 3H-heparin and 3H-HSpm radioactive solution were prepared in PBS. 
Each GAG solution (200 l) was incubated on the surfaces to be tested (TCPS, PLL, 
AA) overnight at room temperature. The next day, wells were washed with PBS three 
times, 200 l of scintillation cocktail added, and the plates read three times in a 
MicroBeta liquid scintillation counter for 1 min each. A standard curve was generated 
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with known amounts of 3H-GAG and surface densities of heparin and HSpm were 
determined. 
 
3.2.17. 125I-VN quantification on surfaces 
 
 To quantify the amount of VN bound to the different 96-well plates (TCPS, 
PLL+HS9+ve and 100 % AA polymerized surfaces coated with HS9+ve (AA+HS9+ve)), 
a highly sensitive radiolabelling study using radioactive-labelled VN was employed. 
Surfaces were previously coated with 5 g/ml of HS9+ve at 300 l per well. VN was 
labelled with 125I isotope (Perkin Elmer) using Thermo Scientific Pierce Iodination 
Beads and quantification was conducted as described in section 2.2.14.   
 
3.2.18. Statistical analysis 
 
All data values are reported as the mean + standard error taken from three 
individual experiments with triplicate runs each. One-way ANOVA was performed to 
compare differences across the groups, and P < 0.05 was considered as significant. A 
two-tailed student's t-test was performed to determine the differences between two 
sample groups. Graphs were plotted and data transformed using Sigma plot software. 
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3.3. Results 
3.3.1. Surface heparan sulfate is important for attachment to VN-HBD substrate 
 
 As endogenous GAGs could be part of the attachment apparatus to VN (Klim 
et al. 2010), I first sought to investigate the role of surface HS in cell attachment. 
Braam et al. have previously shown that V5 integrin is required for hESCs to 
adhere to full-length VN (Braam et al. 2008). Another study by Klim et al. 
demonstrated that surface GAG is important for hESCs to bind VN-HBD, which lack 
RGD motif, after digestion with chrondroitinase ABC. Together both studies reported 
the involvement of integrins and endogenous CS in attachment.  
However, chrondroitinase ABC digests primarily chondroitin sulfate (CS), 
rather than the most abundant GAG on stem cell surfaces, HS. Therefore, to 
investigate the functional role of surface HS on cell attachment to VN-coated TCPS, 
the enzymes heparinase I, II and III were first used to specifically digest cell surface 
HS. When used in combination, the enzymes can remove > 90 % of endogenous HS 
(Manton et al. 2007). After digestion, the cells were analyzed by FACS to confirm the 
absence of surface HS with both the 10E4 and 3G10 antibodies (Fig. 3.1). The 10E4 
antibody binds to intact HS and 3G10 antibody binds to depolymerized HS chains. 
Before digestion, the cells expressed high levels (> 90 %) of intact 10E4-reactive HS 
and low levels (< 2 %) of digested 3G10-reactive HS. After heparinase digestion, 
intact HS chains were removed, so revealing > 95 % 3G10-reactive de-saturated 
uronic acid residues on the cell surface (Fig. 3.1). This confirmed the absence of 
endogenous HS after heparinase digestion.  
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Figure 3.1. FACS analysis of HES-3 cells before and after heparinase I, II and III 
digestion. (A) 10E4 (B) 3G10 antibody staining of cells before enzyme digestion. 
Cells expressed high levels of intact HS chains, and low levels of digested HS chains. 
(C) 10E4 and (D) 3G10 antibody staining of cells after enzyme digestion. Cells 
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The digested cells were then seeded onto VN or VN-HBD surfaces and their 
attachment was measured. Data clearly showed that the binding ability to this peptide 
surface was reduced for digested cells but not affected for untreated cells (Fig. 3.2). 
Pre-incubation of cells with soluble heparin also reduce its binding (~ 40 %) implying 
that heparin was able to compete with endogenous HS in binding to peptide. Taken 
together, this showed that the cells bind to VN-HBD peptide via endogenous HS. In 
contrast, cells in either treatment did not have their binding reduced on the VN5 
surface, which is similar to untreated cells. Therefore, this suggested that surface HS 
was not critical for the binding to full length VN, a binding for which cells mainly use 
V5 integrin.   
 
 
Figure 3.2. Heparinase I, II and III-digested HES-3 cell adhesion assay. Intact 
cells, cells pre-incubated with heparin, and heparinase-digested cells were analyzed 
by the crystal violet cell adhesion assay. Cells were seeded onto streptavidin control 
surfaces, VN-HBD peptide surfaces or VN5 surfaces. The adhesion to VN-HBD 
peptide was reduced by ~ 40 % after heparin and heparinase treatment, while the 
cells’ ability to bind VN5 was not affected. Thus cell surface HS is important for the 
binding of hESCs to the VN-HBD.   
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3.3.2. Isolation of HS9+ve variant 
 
 Following the findings that endogenous HS participated in cell binding, we 
next explored the possibility of isolating an HS variant with high VN binding affinity. 
To confirm the heparin binding ability of the synthesized biotinylated VN-HBD 
peptide, a 3H-heparin radioactivity binding assay was first performed. It was adapted 
from a publication by Baird et al. who enzymatically digested FGF-2 into peptides 
and investigated its binding to 3H-heparin (Baird et al. 1988). The assay was 
performed on nitrocellulose membranes and the data showed that the peptides were 
able to bind to 3H-heparin in a concentration-dependent manner (Fig. 3.3), suggesting 




Figure 3.3. Binding ability of VN-HBD to 3H-heparin. VN-HBD peptides were 
spotted onto nitrocellulose membranes, air dried and incubated with 3H-heparin. 
Bound 3H-heparin was determined by liquid scintillation.   
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 As the peptide was able to bind heparin, it was then used to derivatise 
streptavidin columns for affinity chromatography. The column was first saturated 
with biotin-peptide until excess peptide (green trace) was observed in the flowthrough 
at 280 nm (Fig.3.4). To assess the binding affinity between streptavidin and biotin-
peptide, the column was washed with 1.5 M high salt buffer (red trace). No peptide 
was eluted off the column, indicating that the column is saturated with strongly bound 
peptides that will not dissociate during the later elution of HS variants. The column 
was equilibrated with low salt buffer in readiness for the loading of the commercial 
preparation of HSpm (Fig. 3.5). Collected variants that did not bind to the peptide (blue 
trace) were designated as the HS9-ve variant. Bound variants were eluted from the 
column using a one-step 1.5 M NaCl elution (red trace) and collected as the HS9+ve 
variant (blue trace). The NaCl was removed by a desalting step using HiPrep 26/10 
desalting columns (Fig. 3.6). From the 100 mg of starting HSpm, 19.6 mg (19.6 %) of 
HS9+ve and 43.4 mg (43.4 %) of HS9-ve were isolated; the rest of the weight was 
constituted by NaCl. An interesting observation was the presence of a lag time to 
reach maximum elution in HS9+ve during the high salt washes. This suggested that 
there is a heterogeneous population of high- to low-binding affinity species in HS9+ve 
variant. A modification to the elution buffer, involving a step-wise elution with a 
different molarity buffer to separate the different species in HS9+ve is a future 
possibility. The binding ability of the HS9+ve and HS9-ve fractions to VN were 
determined prior to further characterization. 
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Figure 3.4. Chromatogram of biotinylated VN-HBD peptide loading. Peptide was 
loaded into the column and excess peptide that flows out of the column was 
monitored at 280 nm. Column was washed with 1.5 M high salt buffer to ensure 
peptide is tightly bound to the column.  
 
 
Figure 3.5. Chromatogram depicting HS9+ve isolation. HS9+ve variant were isolated 
from the starting HSpm mixture using streptavidin column pre-bound with VN-HBD 
peptide. A high salt wash (1.5 M) (red trace) released the HS9+ve variant (blue trace) 
and was collected. 
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Figure 3.6. Elution profile of desalted HS variants. The high molecular weight HS 
eluted first, while the smaller NaCl eluted last. (A) Elution profile of HS9+ve variant 
(B) Elution profile of the HS9-ve variant.  
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3.3.3. HS variants characterization 
 
To further investigate the binding affinity of heparin, starting material (HSpm), 
bound variant (HS9+ve) and unbound variant (HS9-ve), dot blotting, heparin-Sepharose 
bead assays and GAG microtiter plate assays were conducted. These assays used 
different strategies to assess their VN binding affinity, either by immobilizing VN or 
GAG, or a competition for VN binding to heparin beads. 
 
3.3.3.1. Dot blotting 
 
 An immunoblot using nitrocellulose-immobilized VN, followed by 
biotinylated GAG, was used to verify the binding ability of each HS variant. No non-
specific binding of the GAGs was detected as shown by the absence of spots in 
negative control (Fig. 3.7). In the positive control, heparin was found to bind strongly 
to VN, producing an intense spot on the film. As for the rest of the variants, HS9+ve 
bound to VN better than HS9-ve variants, and HSpm was found to have an intermediate 
binding ability. This was expected, as we surmised HSpm contained mixtures of HS, 
and thus highly variable degrees of binding ability.   
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Figure 3.7. Dot blots binding profile of the different HS variants. VN was spotted 
onto the membrane and incubated with different GAGs (HS9+ve, HS9-ve, HSpm and 
heparin). HS9+ve variants have a higher binding capacity for heparin than the HS9-ve 
variants; HSpm has only intermediate binding ability. Heparin serves as a positive 
control. 
 
3.3.3.2. Heparin-Sepharose bead competition assay 
 
 To more fully explore the relative affinity of each of the HS variants to VN, a 
heparin-Sepharose bead assay was employed. This assay measures the ability of the 
HS variants to inhibit the binding of VN to heparin beads. Heparin, having a net 
negative charge, will bind to VN with the highest affinity. Therefore, the binding 
ability of heparin for VN was challenged with the different HS variants. A successful 
challenge would result in lower VN binding to the beads, suggesting that the HS 
variant binds to VN with higher affinity, as measured by ELISA.   
To show that VN did bind to the heparin beads, and to determine a good 
working concentration for VN, various amounts of VN were utilized (0 – 80 ng) and 
detected using this ELISA method. A good working concentration of VN will require 
suboptimal VN levels to prevent any false positive results arising from the excess VN 
binding to the beads. The VN saturation curve revealed that VN bound in a 
concentration-dependent manner, with maximal binding occurring at 40 ng of VN. 
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The sub-optimal VN amount identified from the curve was 20 ng (Fig. 3.8). The 
inserts in Figure 3.8 depict the immunoblot bands, which visualize the amount of VN 
on the beads. As a control, absorbance from the VN (20 ng) was used as the 100 % 
VN bound to the beads. The subsequent competition was done with the same amount 




Figure 3.8. VN binding profile on heparin beads. Beads were incubated with 
different amounts of VN, and visualized with HRP. To prevent non-specific binding, 
sub-optimal amounts of VN were used as probes. The small insert shows the 
immunoblot images of the respective amounts of VN.  
 
After establishing the sub-optimal VN concentration, competition with heparin 
beads was performed. The assay was done with pre-incubation of VN with soluble 
heparin (as a positive control), HSpm, HS9+ve or HS9-ve variants, each at 5, 50 and 
100 g. Results were normalized to the absorbance of 100 % VN-bound beads as 
measured previously, and plotted as % bound to beads (Fig. 3.9A). In this procedure, 
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the HS variants that specifically bind to VN would competitively inhibit the binding 
of the VN to the heparin beads. Soluble heparin (100 g) could almost completely 
inhibit VN binding (< 10 % binding) to the heparin beads as confirmed by the lack of 
detection of bound VN. The HS9-ve variant had the weakest binding affinity for VN as 
shown by the high absorbances detected.  Increasing amounts of HS9-ve even to 
100 g could not inhibit the interactions between VN and the heparin beads, thus a 
higher amount (~ 50 %) remained bound on the beads. In contrast, with the increasing 
amount of HS9+ve variant, a concentration-dependent inhibition of VN binding to the 
beads was observed. The HS9+ve variant had a much greater binding affinity for VN 
than HS9-ve, because it can strongly inhibit VN from binding to the beads as indicated 
by the lesser amount of VN detected (~ 10 % bound at 100 g VN). An intermediate 
binding affinity was detected from HSpm as suggested by the intermediary inhibition 
(~ 30 % bound at 100 g VN) to the VN-bead interaction. Together, these findings 
suggested that the binding affinity of the HS9+ve variant is higher than the HS9-ve 
variant, and that HSpm has an intermediate affinity.  
To further understand the requirements of HS-VN binding, the ionic strength 
of the binding buffer was also systemically varied. Immunoblotting results revealed 
that desalted HSpm could inhibit VN-bead binding, as indicated by the decrease in 
band intensity. However, NaCl-containing HSpm could not bind to VN, as confirmed 
by the strong band intensity (Fig. 3.9B). This was expected because the cations in the 
NaCl-containing buffer will bind to the negative charges on HS and mask its VN 
binding domains. Therefore only physiological buffers such as PBS were used for 
subsequent binding experiments.  
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Figure 3.9. Inhibitory effects of various HS variants on the binding of VN to 
heparin beads. (A) The competition assay was performed with soluble heparin (as a 
positive control), or the HS variants. Soluble heparin binds to most avidly to VN, 
followed by HS9+ve, HSpm and HS9-ve. (B) Immunoblot images of the VN left on the 
beads after competition. Note that desalted HSpm binds to VN better than NaCl 
containing HSpm. ** = P < 0.05 
 
 In order to confirm the relative specificity of HS9+ve for VN, the affinity of 
HS9+ve for other ECM proteins (FN and LN) was also investigated.  Similarly, the 
suboptimal working amount of each ECM protein was predetermined, before the 
competition assays were performed. The saturating binding profiles of FN and LN 
showed that the sub-optimal amounts were 200 ng and 1 g respectively (Fig. 3.10). 
These determined amounts were utilized for the subsequent competition assays and 
for the normalization of competition data to achieve % bound on beads.   
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Figure 3.10. Binding profiles of FN and LN to heparin beads. Binding profile of 
each protein (A) FN and (b) LN on heparin beads. Beads bound to increasing amount 
of protein and reached saturation at 200 ng for FN and 1 g for LN. 
 
Increasing concentrations of soluble the HS9+ve variant were used to 
competitively inhibit the binding of the different ECM proteins to the heparin beads, 
and the amount of protein left on the beads measured with their respective antibody 
(Fig. 3.11A). The HS9+ve variant dose-dependently inhibited the binding of VN to 
heparin beads, leading to a lower level of VN detected, but did not inhibit the binding 
of FN and LN to heparin beads. This was indicated by the lack of dose-dependent 
decrease in protein bound even at 100 g of HS9+ve, suggesting that HS9+ve have 
specificity for VN. Concurrently, the HS9-ve variant was also used to inhibit VN 
binding to heparin beads (Fig. 3.11B). The data showed that HS9-ve variant was able 
to inhibit FN binding to the beads better than VN or LN. This suggested that that the 
HS9-ve variant was enriched for FN-binding sequences. Further isolation of an FN-
binding HS is thus justifiable.      
In order to ensure that this competitive inhibition procedure is reliable, soluble 
heparin was used as the competitor (Fig. 3.11C). Heparin inhibited all three ECM 
proteins to varying degrees, with VN inhibition better than FN and LN in binding to 
heparin beads (Fig. 3.11C). Collectively these findings in heparin-Sepharose bead 
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assays clearly show that HS9 variants have a graded binding affinity to VN: heparin > 
HS9+ve > HSpm > HS9-ve. Also, the HS9+ve variant avidly bind more VN than the HS9-
ve variant. This highlighted the practical use of affinity chromatography to separate 
better VN-binding HS variants from a mixture HSpm. 
 
   
 
Figure 3.11. Inhibitory effect of HS variants on the binding of VN, FN and LN to 
heparin beads. (A) Different concentrations of HS9+ve were used to compete with 
heparin beads for binding to VN, FN and LN. HS9+ve variants inhibited VN rather 
than to FN and LN in binding to heparin beads. (B) HS9-ve had higher affinity to FN 
than VN and LN. (C) Heparin was used as positive control. Heparin was able to bind 
VN, FN and LN in a concentration-dependent manner with varying affinities.   
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3.3.3.3. Glycosaminoglycan ELISA  
 
 To provide another independent validation of HS9 variant binding affinity, an 
ELISA based on GAG binding to VN was investigated. The initial experiments were 
designed to optimize the concentrations of GAGs (heparin, HSpm, HS9+ve and HS9-ve) 
needed to completely saturate the plate surface. Wells were coated with 1, 5 and 
10 g/ml of each GAG and the binding affinity for VN explored (Fig. 3.12). At the 
various heparin concentrations, a dose-dependent increase in VN binding was 
observed (Fig. 3.12A). For HSpm coatings, a marked difference was observed from 
1 g/ml and 5 g/ml, while the increase in VN binding was less compared to the 
5 g/ml and 10 g/ml HSpm solutions (Fig. 3.12B). Similar trends were also observed 
with the HS9+ve and HS9-ve variants (Fig. 3.12 C and D). As significant differences 
were observed between the 1 and 5 g/ml of GAGs, no further increase in VN 
binding was seen between 5 and 10 g/ml. This suggested that 5 g/ml of a GAG 
solution was sufficient to completely saturate the wells; this saturating concentration 
was therefore used for the rest of the experiments. 
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Figure 3.12. Determination of saturating amounts of GAGs with GAG ELISA. 
Differing concentrations of (A) heparin, (B) HSpm, (C) HS9+ve and (D) HS9-ve were 
coated onto the wells and their ability to bind VN analyzed. No significant difference 
was observed in either 5 or 10 g/ml; therefore 5 g/ml was the saturating 
concentration. Uncoated wells served as the negative control. 
 
 After determining the saturating GAG concentration (5 g/ml), GAGs were 
coated overnight and investigated for their binding affinity to VN (Fig. 3.13). The 
binding curve showed that, irrespective of GAGs, there was a dose-dependent 
increase in VN binding. HS9+ve had a significantly higher affinity for VN than starting 
material HSpm and flowthrough HS9-ve variants. Heparin, being the most negatively 
charged variant, was bound to VN at significantly higher levels than the rest. This 
reinforced the results of the heparin beads competition assay, showing that the HS9+ve 
variants have a higher affinity for VN. 
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Figure 3.13. Binding profile of various GAGs to VN by GAG-ELISA. Heparin, 
HSpm, HS9+ve and HS9-ve variants were coated onto wells and different concentrations 
of VN used to determine the binding ability of each GAG variant. HS9+ve variants had 
a significantly higher affinity for VN than the HSpm and HS9-ve variants. Heparin 
served as a positive control. ** = P < 0.05 
 
 Because HS binding is in part the result of negatively charged sulfate residues 
along the disaccharide chain, understanding the structural composition of HS that is 
likely to interact with VN was next explored. To understand the necessary sulfation 
motifs for VN binding, selectively desulfated heparin standards were immobilized 
onto the ELISA surfaces (Fig. 3.14). Heparin that had been selectively de-N-sulfated 
or de-6-O-sulfated was found to have significantly reduced levels of binding to VN. 
In contrast, chains lacking 2-O sulfation were unaffected, and strongly bound to VN 
in a manner comparable to that of the intact heparin chains. In analogous experiments, 
heparin standards of varying length, from 2 disaccharides (degree of polymerization 
(dp2)) to 12 disaccharides (dp12), were used to look for the minimum size needed for 
VN binding (Fig. 3.15). There was a significant lack of binding from the dp2 and dp4 
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chains. For chains with more than 3 repeating units, there was similar binding affinity 
for VN. These results strongly suggest therefore that N- and 6-O-sulfation on chains 
of at least 3 repeating disaccharide units are necessary for VN binding to heparin. As 
heparin and HS share roughly similar disaccharide composition, this conclusion may 
also be valid for HS. A detailed CE analysis of the composition of HS9+ve and HS9-ve 
variants will be used to further quantitate such differences.              
 
 
Figure 3.14. Binding profile of various de-sulfated heparin to VN by GAG-
ELISA. Desulfated 2-O, 6-O and N- standards were coated onto the wells and 
investigated for their binding affinity to VN. Variants without 6-O and N sulfation 
had significantly reduced binding, and variants without 2-O sulfation had no effect on 
VN binding. Heparin served as a positive control. ** = P < 0.05 
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Figure 3.15. Binding profile of various length of heparin to VN by GAG-ELISA. 
Lengths of heparin varying from dp2 to dp12 were coated onto the wells. GAGs of 
dp2 and dp4 were not able to bind VN, but dp6 units and longer were able to bind to 
VN. ** = P < 0.05 
 
3.3.3.4. Capillary electrophoresis 
 
 Capillary electrophoresis is a sensitive and powerful technique for the 
separation of individual heparin disaccharides based on size and charge. This method 
was employed for the further analysis of each of the generated HS variants. Ruiz-
Calero et al. demonstrated that this could be attained with the separation and 
quantification of 8 heparin disaccharide species using a formic acid buffer, 15 kV 
reverse polarity and pH 3 (Ruiz-Calero et al. 1998). Using this protocol, the 
separation of 7 heparin disaccharide standards was completed, and is depicted in 
Figure 3.16. Δ-disaccharide standard IS designation represents Δ UA2S(14)-D-
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GlcNS6S containing 2O-, 6O- and N-sulfation; IIS represents Δ UA(14)-D-
GlcNS6S containing 6O- and N-sulfation; IIIS represents Δ UA2S(14)-D-GlcNS 
containing 2O- and N-sulfation; IVS represents Δ UA(14)-D-GlcNS containing 
only N-sulfation; IA represents Δ UA2S(14)-D-GlcNAc6S containing 2O- and 6O- 
sulfation; IIA represents Δ UA(14)-D-GlcNAc6S containing only 6O-sulfation and 
IIIA represents Δ UA2S(14)-D-GlcNAc containing only 2O-sulfation. All these 
structures are shown in Figure 1.12.  
 
 
Figure 3.16. Electropherogram of Δ-disaccharide standards. Standards were 
individually separated with distinct peaks.  
 
The electropherogram generated from this study has a similar profile to the 
one presented by Ruiz-Calero et al. (Fig. 1.13). The last peak (IVA) could not be 
detected even when the recommended 0.5 per square inch (p.s.i.) pressure gradient 
was applied for a further 30 min after the completion of the run. Thus IVA is omitted 
from this study. The observed differences in the detection times from Ruiz-Calero et 
al. might be due to the different equipment used, or the inability to achieve 0.5 p.s.i.; 
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nevertheless the peaks were well separated from each other. An internal standard was 
added to assist in the identification of the various peaks in the digested samples.   
 To achieve reproducible results and account for the variations in the samples, 
5 replicates of the Δ-disaccharide standards were separated. The migration time and 
peak areas were expressed as relative standard deviation (R.S.D.) (Table 3.1). R.S.D. 
was considered reliable when area standard deviations were < 5 %, and migration 
time standard deviations of < 1 % were achieved.  The R.S.D. was calculated and 
confirmed the reproducible results.  
 
Table 3.1. Relative standard deviation (R.S.D.) of ∆-disaccharide standards. RT 




The measurement standard (R.S.D.) allowed for the generation of calibration 
curves for each Δ-disaccharide standard. These curves were constructed by using 
different dilutions of the stock (1 mg/ml), from undiluted control to 1, 2, 4, 8, 12 and 
16 times dilution. The individual peak areas were determined, plotted and regression 
lines generated; the working linear concentrations have a goodness-of-fit (R2) > 0.99 
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(Fig. A1). These calibration curves were then used for the quantification of the molar 
concentration (mol %) of each disaccharide.  
 Following the generation of a standard curve, the electropherogram profiles of 
depolymerized heparin, HSpm, HS9+ve or HS9-ve variants were generated.  Before CE 
analysis, the depolymerization of each HS variant was monitored at 232 nm. The 
undigested samples had an absorbance of 0.01 and increased to ~ 1.1, and when no 
further increase was seen the depolymerization was be deemed to be complete.  The 
samples were injected into the system for 5 sec, and peaks detected at 232 nm.  
Electropherograms showing each sample profile are shown in Figure 3.17. Three 
replicates were run and average areas-under-the-peak calculated and compared to the 
standard curve. The identity of each peak was determined from the relative shift from 
the internal standard added into the mixture. Moreover, the migration time of each 
peak was also consistent with the standards’ migration time. Due to the almost 
undetectable peak for IIIA, its identity was confirmed by adding IIIA Δ-disaccharide 
standard into the depolymerized HS sample. The increase in the height of that peak 
from the original sample confirmed it to be the IIIA variant.  
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Figure 3.17. Electropherograms of the depolymerized samples.  (a) Heparin, (b) 
HSpm, (c) HS9+ve and (d) HS9-ve. IS: ∆UA2S(14)-D-GlcNS6S (2S, NS, 6S); IIIS: 
∆UA2S(14)-D-GlcNS (2S, NS); IIS: ∆UA(14)-D-GlcNS6S (NS, 6S); IA: 
∆UA2S(14)-D-GlcNAc6S (2S, 6S); IVS: ∆UA(14)-D-GlcNS (NS); IIIA: 
∆UA2S(14)-D-GlcNAc (2S); IIA: ∆UA(14)-D-GlcNAc6S (6S)  Internal standard 
helped in identifying each peak. 
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 A comparison of the disaccharide composition of each digested HS variant is 
shown in Table 3.2. The results revealed that the major units in heparin are the 
trisulfated (2S, 6S and NS) IS and disulfated (6S and NS) IIS at 66.1% and 20.8 % 
respectively. In contrast, the major units in HSpm are the monosulfated (NS) IVS and 
disulfated (6S and NS) IIS (36.8 % and 23.7 % respectively). The large decrease in 
trisulfated (2S, 6S and NS) IS observed in HSpm is likely because of the lower 
sulfation in HS. It was also observed that after the affinity chromatography step, the 
HS9+ve variant was enriched for trisulfated (2S, 6S and NS) IS and disulfated (6S and 
NS) IIS (26.0 % and 30.6 % each), and whereas the HS9-ve variant most prominently 
possessed monosulfated (NS) IVS (33.3 %) as its major disaccharide unit.  
 
Table 3.2. Comparison of the different composition of depolymerized GAG 
samples.   
 
 
 Clearly the most notable point is the presence of the higher proportions of the 
trisulfated (2S, 6S and NS) IS and disulfated (6S and NS) IIS ∆-motifs in HS9+ve than 
in HS9-ve variants. This clearly suggests that a combination of 6O- and N-sulfation is 
very important for HS binding to VN, a result also supported by the GAG-ELISA in 
Figure 3.14. Lack of enrichment of monosulfated (NS) IVS and monosulfated (6S) 
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IIA in HS9+ve variants as compared to starting HSpm material suggests that neither 
domain alone are sufficient for VN binding. Instead, a combination of 6O- and N-
sulfation seems to be critical for VN binding. In contrast, 2O-sulfation is clearly not 
essential for the binding of HS to VN, as evidenced by the lack of enrichment of the 
monosulfated (2S) IIIA, disulfated (2S, 6S) IA and disulfated (2S and NS) IIIS ∆-
disaccharide units in HS9+ve. Also, in GAG ELISA assay, removal of 2O-sulfation did 
not reduce VN binding. The other disaccharide units appear to be of less importance 
for the HS9+ve and HS9-ve variants.  
 Collectively, the results in this section demonstrate that the highly 6O- and N-
sulfated HS9+ve variant isolated by VN affinity chromatography has a higher capacity 
for VN than either the HSpm starting material or the HS9-ve flow-through. It also has a 
greater capacity to bind VN than either LN or FN, suggesting that the specificity of 
the HS9+ve has increased. This clearly demonstrated that affinity chromatography is a 
powerful technique for isolating VN-binding HS forms from a heterogeneous HS 
mixture. Following this characterization study, and with the aim of using HS9 as a 
substrate to capture and present sufficient VN for hESC culture, the following section 
will delineate the different methods for immobilizing the HS9+ve variant for cell 
culture. 
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3.3.4. Immobilization of HS9 variants 
 
As HS9+ve demonstrated high binding affinity to VN as compared to the rest of 
the HS variants, strategies to immobilize it efficiently onto surfaces for the 
presentation of unmodified VN for cell culture using covalent and electrostatic 
methods were explored. The first was to use the covalent EDC method to chemically 
link the amine groups on HS to the carboxyl groups on surfaces. The second was to 
create a net positively charged surface with poly-L-lysine and lastly to use plasma 
polymerization to create high net positive charges for electrostatic interactions 
between surfaces and HS.  
 
3.3.4.1. Covalent EDC chemistry 
 
 In order to provide an optimal substrate to immobilize HS variants, NaOH was 
utilized to etch surfaces to create free carboxyl groups on low carboxylated 
polystyrene (PS) surfaces. The coupling of the primary amine groups in HS and 
carboxyl groups on etched PS surfaces was accomplished with EDC chemistry. It was 
previously shown by Plante et al. that EDC chemistry could be used to tether 
disaccharide units through their free amine ends to surface carboxyl groups (Plante et 
al. 2001). Therefore, NaOH-treated PS, together with TCPS surfaces, was both 
analyzed for their ability to be derivatized with HS variants (Fig. 3.18).  
An optimization of EDC concentrations (10, 50 and 100 mg/ml) was first 
required. 3H-lysine was used, because every molecule contains 2 primary amines for 
coupling so that the amine will not be the limiting factor. The results demonstrated 
that 24 h of NaOH treatment was sufficient to etch the maximum levels of the 
carboxyl groups on PS surfaces. However, TCPS yielded better grafting than NaOH-
treated PS; thus TCPS was used for the subsequent reactions. A concentration-
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dependent increase in grafting of 3H-lysine was observed with 10 and 50 mg/ml. 
However, no significant increase from 50 to 100 mg/ml of EDC was observed, 
suggesting that the grafting concentration saturated at 50 mg/ml. Therefore the EDC 
concentration was settled at 50 mg/ml. 
 
 
Figure 3.18. Optimizations of surface and EDC concentration for covalent 
grafting. 3H-lysine was used as a read-out for the EDC grafting ability on the 
different surfaces. NaOH was used to etch the PS surface for 6 days to produce 
different densities of carboxyl groups. TCPS gives the highest grafting ability as 
compared to NaOH-treated surfaces, regardless of how many days etching was carried 
out. The optimized EDC concentration was 50 mg/ml. ** = P < 0.05 
  
 Another parameter that required consideration was the amount of primary 
amines in heparin and HSpm. To confirm these levels, a fluorescamine protein assay 
was employed (Fig. 3.19). The dye binds to primary amines and has an excitation 
wavelength at 365 nm and an emission wavelength at 470 nm. The relative levels of 
primary amines can then be deduced using a BSA standard curve. Using two 
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concentrations of each GAG (0.5 and 1 mg/ml); the results confirmed as expected that 
there are more (> 60 %) primary amines present in HSpm than in heparin. By 
comparing 1 mg/ml heparin and the HSpm variants, it was shown that there are 
~ 3 x 1016 amines present in heparin and ~ 5 x 1014 amines present in HSpm, a 
difference of > 60 %. This difference was less (~ 40 %) in heparin compared to HS9 
variants (~ 2 x 1016 amines), suggesting some compositional differences in both of 
them after affinity chromatography, confirming the data obtained previously with CE. 




Figure 3.19. Number of primary amines in GAGs by fluorescamine protein 
assay. Increase in number of amines from 0.5 mg/ml to 1 mg/ml GAGs. A > 60 % 
difference in the number of primary amines at 1 mg/ml of HS and heparin.  
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 Having established the suitable surface, optimal EDC concentration and 
number of amines in GAGs, 3H-heparin and 3H-HSpm were grafted onto TCPS 
surfaces (Fig. 3.20). Concentration-dependent increases in 3H-GAG binding were 
observed, with the surface densities of 3H-GAGs measured by comparison to standard 
curves (Fig. A2). The surface density of 3H-HSpm was notably higher than 3H-heparin 
at all concentrations tested. This was expected, because heparin has > 80 % N-sulfates 




Figure 3.20. Surface density of heparin and HSpm on EDC grafted surfaces. 
Concentration-dependent increase in 3H-GAG grafting onto surfaces. The percentages 
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 Although this method does immobilize GAGs onto surfaces, the overall 
grafting is inefficient. For example, by using 30 mg/ml of 3H-GAG at 3mg per well 
(0.32 cm2), only ~ 1.5 g of 3H-heparin and ~ 6 g of 3H-HSpm were detectable on the 
surfaces, which equates to a 0.05 % and 0.2 % grafting efficiency respectively. At 
such low efficiencies, these methods are not suitable for further applications. 
Moreover, a study by Roy et al. has shown that covalently binding GAGs to surfaces 
carries significant disadvantages. In particular, utilizing the N-domains for coupling 
compromises the biological activities of GAGs (Roy et al. 2011). Therefore, better 
and more efficient strategies need to be uncovered. 
 
3.3.4.2. Poly-L-lysine coatings 
 
 As covalent immobilization is not efficient, strategies exploiting the 
electrostatic interactions between the negatively charged HS and positively charged 
surfaces were employed. Poly-L-lysine (PLL) has been used successfully as a 
substrate for many types of stem cells, but not for hESCs on TCPS (Cai et al. 2012a, 
Cai et al. 2012b, Galli et al. 2011). Therefore to test such surfaces, PLL-coated TCPS 
plates were subjected to overnight coating with different concentrations of 3H-heparin 
and 3H-HSpm (Fig. 3.21). The surface density of each GAG was then determined: 1 g 
of 3H-GAG solution yielded a surface density of ~ 200 ng/cm2, with density 
increasing to ~ 800 ng/cm2 and 400 ng/cm2 respectively at 2 g of 3H-heparin and 3H-
HSpm. The higher density of 3H-heparin observed was due to its higher overall 
negative charge. Interestingly, differences in surface density were observed in heparin 
and HSpm only at 2 g, suggesting an inferior binding of GAGs onto PLL surfaces at 
lower GAG concentrations. Therefore, 2 g was subsequently used for the 
immobilization of GAGs on PLL surfaces.   
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Figure 3.21. Surface density of heparin and HSpm on PLL surfaces. Different 
GAG concentrations were used for overnight coating of PLL surfaces. Increasing 
surface density was observed with increasing solution concentrations. The surface 
density of 3H-heparin and 3H-HSpm after exposure to 2 g of coating solution was ~ 
800 ng/cm2 and 400 ng/cm2 respectively.    
 
To further analyze the utility of the PLL surface for cell culture, hESCs (HES-
3) were screened for cell proliferation on PLL-coated GAG (PLL+GAG) surfaces 
(Fig. 3.22). VN2.5 and VN5 was coated onto PLL+GAG surfaces, and HES-3 cells 
seeded and allowed to grow for 7 days. Photomicrographs at the end of one week 
revealed that the cells had not spread well on these surfaces, with the exception of 
those on PLL+heparin+VN5. This suggested that PLL-coated surfaces are not optimal 
for hESC culture. Therefore a third strategy that of exploiting plasma polymerization 
was next explored. 
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Figure 3.22. HES-3 cell images after 7 days of culture on PLL+GAG+VN 
surfaces. Cells did not spread, or reach confluence, suggesting that PLL surfaces are 
not suitable. Scale bar = 0.3 mm. 
 
 
3.3.4.3. Allylamine polymerization 
 
As the previous two methods (EDC covalent grafting, PLL coating) failed to 
address the key characteristics (cost, simplicity, safety and efficacy) required of an 
engineered substrate; another surface is clearly needed to immobilize GAGs for long-
term cell propagation. Professor Short’s laboratory at the University of South 
Australia has developed a method for immobilizing GAG via the plasma 
polymerization of allylamine (AA) monomers onto plastic surfaces. The AA 
monomer is positively charged, and, when polymerized onto surfaces, gives the 
surface a net positive charge that persists over time (Whittle et al. 2000).  
To assess the optimal AA density for immobilizing HS on surfaces, different 
percentages of AA surfaces were generated to determine which density has the 
highest functional binding ability for GAGs as assessed by ELISA. Surface densities 
were controlled with a neutral octa-1, 7-diene monomer. Density varied from 0% AA: 
100% octa-1, 7-diene, 50% AA: 50% octa-1, 7-diene, 80% AA: 20% octa-1, 7-diene, 
90% AA: 10% octa-1, 7-diene to 100% AA: 0% octa-1, 7-diene. The results revealed 
that the 100% AA surfaces bound the highest amount of functional GAG, followed by 
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the 90% AA surface (Fig. 3.23). It was interesting to note that the GAGs bound to 
80 % AA surface no longer retained their capability to bind VN, instead having a 
negative effect. This was almost certainly due to the high background observed in the 
blank wells, which may have been because of the ineffective blocking of the fish 
gelatin. The 50% AA surface could not trigger any VN binding, suggesting that 
insufficient GAG was immobilized by it onto the surface. Thus, the 100% AA 




Figure 3.23. GAG binding profile on the different allylamine surface by ELISA. 
GAG (5 g/ml) was coated onto the different AA density surfaces (0, 50, 80, 90 and 
100%) followed by binding of 500 ng/ml of VN. The AA surface at 100 % density 
binds the highest amount of VN while densities < 100 % no longer bind the optimal 
amount of GAG.  
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In order to confirm the presence of AA polymer on the surface, an XPS 
analysis was performed to determine the oxygen (O), nitrogen (N) and carbon (C) 
content of the AA polymerized aluminium foil surfaces placed together in the plasma 
reactor chamber. The readings on the foil reflected the amount of each atom on the 
plate surface (Robinson et al. 2012). The 50% AA surface gave readings of C 
(92.5%), N (4.56 %) and O (2.93 %); the 80% AA surface produced C (85.2 %), N 
(12.14 %) and O (2.7 %); the 90 % AA surface produced C (80.7 %), N (15.3 %) and 
O (4 %); the 100% AA surface had C (79.2 %), N (16.4 %) and O (4.34 %) 
(Fig. 3.24). A consistent nitrogen: carbon (N: C) ratio of 0.18 to 0.22 was observed 
for several batches of the 100% AA plates (Table 3.3). It is summarized to show the 
various N: C ratios of the AA surfaces in Table 3.3. This all demonstrated the 
reproducibility of the plasma polymerization reaction, which was also consistent with 
the study done in Professor Short’s laboratory (Mahoney et al. 2004, Robinson et al. 
2012). Thus an N: C ratio of 0.18 to 0.22 was optimal for functional HS9 binding and 
was used subsequently for immobilization of unmodified VN. 
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Figure 3.24. Representative XPS binding energy profile of 0-100% AA plates. 
The amount of O, N and C atoms on the surfaces of plates were read from the 
aluminium foil placed in the reaction chamber. Results were analyzed with CasaXPS 
software to determine the area of the peaks and N: C ratio was calculated. (A) 50% 
AA: 50% octa-1, 7-diene (B) 80% AA: 20% octa-1, 7-diene (C) 90% AA: 10% octa-
1, 7-diene (D) 100% AA: 0% octa-1, 7-diene. The 100% AA surface has C (79.2 %), 
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Following the success of HS immobilization, the ability of each GAG variant 
to bind VN was assessed by ELISA (Fig.3.25). Irrespective of the GAG, there was a 
concentration-dependent increase in absorbance. Wells without GAG served as the 
negative control, indicating no non-specific interactions. Binding data revealed that 
the heparin and HS9+ve variants had the highest affinity for VN, and that the 
flowthrough HS9-ve variant and starting HSpm had the weakest. Moreover, the HS9+ve 
variant produced a higher absorbance than the HS9-ve variant, indicating a significant 
higher affinity for VN. This result is similar to that which employed the GAG-ELISA 
(Fig. 3.13), suggesting the higher binding affinity in the HS9+ve. 
 
 
Figure 3.25. VN binding profile on the 100% AA surface. GAGs were coated onto 
the AA surface and the binding profiles of different concentrations of VN analyzed by 
ELISA. The HS9+ve variants bind VN significantly better than the HS9-ve variants. 
Uncoated wells and heparin-coated wells served as the negative and positive control 
respectively. ** = P < 0.05 
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To confirm the presence of GAGs on the AA surfaces, the surface density of 
3H-heparin and 3H-HSpm was determined. 3H-GAG was immobilized onto the surface 
overnight, washed and read in a scintillation counter. Counts were compared to the 
standard curve, and a surface density determined (Fig. 3.26). There was a 
concentration-dependent increase in surface density, with a higher density seen for 
heparin than for HSpm. When 1 g of GAG was used for coating, the 3H-heparin 
yielded a surface density of ~ 250 ng/cm2; 3H-HSpm yielded only ~ 100 ng/cm2. This 
corresponds to immobilization efficiencies of ~ 8 % and ~ 3.2 % respectively, which 
was a significant increase over the use of covalent EDC immobilization chemistry 
depicted in Figure 3.19. It was expected that heparin would bind better to the surfaces 
because of its higher density of negative charge per unit length. Thus, this simple and 
robust AA+GAG surface was used for all further immobilization of VN.  
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Figure 3.26. Surface densities of heparin and HSpm on the 100% AA surface. 
GAG binds to AA surface in a concentration-dependent manner with the heparin 
density higher than HSpm. 3H-GAG (1 g) was used for coating; the final surface 
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3.3.5. 125I-VN surface density  
  
 Chapter 2 demonstrated that the threshold density for successful maintenance 
of hESCs on VN-adsorbed TCPS surfaces is 250 ng/cm2. The question now became 
whether an HS with tuned affinity for VN can be used as a substrate to capture and 
present VN in an efficient way. The surface densities of VN on TCPS, AA+HS9+ve 
and PLL+HS9+ve substrates were measured and compared. Increasing concentrations 
(0, 1.25, 2.5 and 5 g/ml) of 125I-VN were incubated on the different surfaces, and the 
amounts measured by scintillation and compared to a standard curve (Fig. 3.27). All 
surfaces showed a concentration-dependent increase in binding of the 125I-VN, with 
the lowest VN surface density recorded on the PLL+HS9+ve surface and the highest on 
TCPS surface. There was insufficient VN on the surface for cells to attach and 
proliferate on the PLL+HS9+ve surface, presumably explaining the HES-3 cell 
response seen in Figure 3.22. Thus, establishing this surface density profile on the 
various substrates was useful for the determination of the density most suitable for 
hESC culture in the next chapter. 
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Figure 3.27. 125I-VN surface density on TCPS-, AA+HS9+ve- and PLL+HS9+ve- 
coated surfaces. The highest VN density was measured on TCPS, followed by the 
AA+HS9+ve surface, with the lowest density on PLL+ HS9+ve across all the VN 
concentrations used. ** = P < 0.05 
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3.4. Discussion 
 
Glycosaminoglycans are an important structural and functional component of 
the ECM (Gandhi & Mancera 2008). Previously studies have shown that cell surface 
HSPGs are crucial for cell adhesion to a FN heparin-binding peptide, as shown after 
soluble heparin and heparinase treatment (Drake et al. 1992, Mahalingam et al. 2007). 
A study by Klim et al. showed that digesting hESCs with chrondroitinase ABC 
impaired the binding ability of cells to VN-HBD surfaces, suggesting that surface 
GAGs were important for cell binding (Klim et al. 2010). One of most abundant 
GAGs on stem cell surfaces is HS, with CS predominant in the ECM of mature bone, 
cartilage and heart valve (Gandhi & Mancera 2008). Thus, to extend these findings, 
heparinase digestion of surface HS was employed to determine its importance for cell 
binding to VN-HBD. The results showed that cells could bind to VN-HBD peptide via 
surface HS, but that they are not critical if the RGD motif is present. Several studies 
have also shown that heparin and HS are able to support hESC self-renewal and 
growth (Furue et al. 2008, Sasaki et al. 2008). Following this, we aimed to isolate a 
high affinity VN binding HS variant from a mixture, to present VN efficiently.  
The isolation of a VN-binding HS variant via VN-HBD peptide affinity 
chromatography has allowed us to engineer a novel hESC culture platform. The 
binding ability of the different variants was compared using a combination of dot blot, 
ELISA and heparin bead competition assays. To check the apparent specificity of the 
HS9+ve variant for VN binding, it was compared to the binding of LN and FN. 
Together these results confirmed that the HS9+ve variant binds VN with relative 
specificity and certainly better than the HSpm and HS9-ve variants. This result suggests 
the possibility of isolating a library of HS variants tuned to other ECM proteins for 
generating a range of specific substrates.  
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Affinity-separated heparin variants have been isolated before, but by 
employing whole native protein during the affinity step. Thus, heparin variants  with 
high affinity to fibronectin (Falcone & Salisbury 1988), heparin co-factor II (Kim & 
Linhardt 1989), tissue plasminogen activator (Andradegordon & Strickland 1986), 
FGF-1 (Barzu et al. 1989, Sudhalter et al. 1989) and anti-thrombin III (Hook et al. 
1976, Scully et al. 1988) have been isolated. However, the use of whole protein is 
both impractical and costly, especially at this scale. McCaffrey and colleagues 
subsequently demonstrated that two variants, with high and low TGF- binding 
affinity, could be isolated from heparin mixtures with a synthetic peptide that 
mimicked the TGF- HBD (McCaffrey et al. 1992). Their study used heparin as the 
starting material, a molecule not suitable for clinical applications.  
Understanding the compositional make-up of the variants is clearly important 
for the future design of a synthetic HS9. As evidenced by the low R.S.D. values with 
all the depolymerized samples, the compositional analysis of heparin and HS can be 
considered reliable. The percentages of disaccharides in heparin were consistent with 
those published by other groups (Ampofo et al. 1991, Desai et al. 1993a, Jandik et al. 
1994, Karamanos et al. 1996, Ruiz-Calero et al. 1998, Scapol et al. 1996). The molar 
percentages of the major disaccharides in porcine intestinal mucosa heparin, are IS 
and IIS, which range from 50 % to 68 % and from 10 % to 20 % respectively. No 
compositional studies have been done with the porcine mucosa HS; however, a 
previous comparison between HS from other sources such as bovine kidney revealed 
a similar trend, with the monosulfated IVS disaccharide unit having a higher molar 
percent ratio compared to the other units (Ampofo et al. 1991, Militsopoulou et al. 
2002). 
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The elucidation of the anti-coagulant pentasaccharide sequence in heparin 
revealed that 3O-sulfation is essential for its anti-coagulant effects (Lindahl et al. 
1980); in a similar manner, FGF-2 binding to HS requires 2O-sulfation (Faham et al. 
1996, Maccarana et al. 1993) whereas 6O- and N- sulfation impair binding (Ernst et 
al. 1995); FGF-1 interaction with HS in contrast requires the 6O-sulfate group 
(Fromm et al. 1997). FGF-4 requires both 2O- and 6O-sulfation for binding and 
signalling (Ashikari-Hada et al. 2009, Guimond et al. 1993) and hepatocyte growth 
factor requires 6O-sulfation (Lyon et al. 1994). Falcone et al. and Mahalingam et al. 
demonstrated that an avid heparin-binding variant for FN appeared particularly highly 
charged, with 7 to 8 N-sulfated disaccharides being required, and a larger domain (> 
14 residues) than unfractionated heparin (Falcone & Salisbury 1988, Mahalingam et 
al. 2007). Ling et al. also showed that N-sulfation in heparin contributes to the 
binding and activity of Wnt3a ligands for its osteogenic activity (Ling et al. 2010). 
These studies support the idea that differentially modified HS motifs confer distinct 
protein recognition properties on HS. The GAG ELISA and CE analysis both directly 
and indirectly revealed that the 6O- and N-sulfation of the glucosamine residue, and 
that at least 3 disaccharide units, are required for VN binding to HS. Removal of N-
sulfation from the heparin standards also reduced the level of binding to VN, 
indicating that N-sulfation together with 6O-sulfation is crucial. This is the first report 
of an essential sulfation motif within HS important for VN binding.  
In the search for an effective and efficient way to immobilize HS9+ve variants 
onto TCPS, the results demonstrated that the low proportion of primary amines in HS 
renders the EDC coupling method inefficient. This also accounts for the lack of 
proliferation on VN-coated PLL surfaces revealed in the 125I-VN binding assay. The 
low VN surface density on PLL surfaces was also not sufficient to support robust 
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culture of hESCs. As shown in Chapter 2, the minimum VN surface density required 
on TCPS is at least 250 ng/cm2 (Yap et al. 2011).  Therefore, of the various 
approaches, AA plasma polymerization was the most efficient and effective method. 
AA polymerized cell culture surfaces have been studied by Punzon-Quijorna et al. 
and Schroder et al. to culture mesenchymal stem cells on both polycaprolactone 
(PCL) (Punzon-Quijorna et al. 2011) and titanium surfaces (Schroder et al. 2010). 
Although AA surfaces have been used for cell culture, this thesis is particularly 
interested in the culture of hESCs, which are known to be very demanding in their 
choice of substrate.    
An interesting observation about the surface density of VN was that the 
amount of VN was in the order: TCPS > AA > PLL. VN (P04004) contains a similar 
number of negatively (66) and positively (56) charged residues (calculated from data 
on the ExPASy website, www.expasy.com), which might explain VN binding to both 
of the negative and positive charged surfaces. Thus I posit that the hydrophilic, net 
negatively charged TCPS surface is favourable for VN binding, while the highly 
positively charged AA surface supports more VN binding than PLL. PLL might not 
uniformly coat the surface, so that less positive charge is deposited, explaining the 
lower VN density. Such patchy coating might also translate into an inability of stem 




 The aim of this chapter was to develop a substrate capable of binding 
unmodified VN based on its affinity for heparan glycosaminoglycans. An avid VN-
binding variant (HS9+ve) derived from HSpm was isolated using affinity 
chromatography. Comparison of the HS9+ve, HS9-ve and HSpm variants revealed that 
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the HS9+ve variant had a higher binding propensity for VN, suggesting that affinity 
chromatography is a powerful technique for the separation of active GAG variants 
tuned to specific adhesive proteins. The HS9+ve specificity for VN rather than FN and 
LN proteins was confirmed using ELISA.   
 Compositional analysis with CE confirmed an enrichment of trisulfated (2S, 
6S and NS) IS and disulfated (6S and NS) IIS disaccharides in the HS9+ve variant. 
Together with the GAG-ELISA results, it can thus be concluded that 6O-sulfation 
together with  N-sulfation on glucosamine residue and at least 3 disaccharide units are 
critical for HS9+ve binding to VN. 
 A consistent 100 % AA polymerized surface was generated by plasma. This 
surface was able to bind to functional GAG, which in turn was able to bind sufficient 
amounts of VN for successful cell culture as depicted in Figure 3.28. This layer-by-
layer approach was used for the subsequent long-term culture of hESCs. The surface 
density of the various layers, from HS to VN, was determined and subsequently used 
for later quantification. This chapter thus demonstrated the process development of a 




Figure 3.28. Summary of novel substrate for hESC culture. TCPS surfaces were 
first polymerized with positively-charged AA, than coated with negatively-charged 















CHAPTER 4 : CELL CULTURE 
STUDIES ON HS9 SUBSTRATES
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4.1 Introduction 
 
Previous chapter described a successful method for culturing hESCs on 
different concentrations of VN, and established a threshold surface density of 
250 ng/cm2 as being necessary. However, the method of immobilizing VN was based 
on passive adsorption onto TCPS surface, and as such was inefficient and non-
specific. There is thus a major opportunity to replace this poorly defined method by 
using a tuned VN-binding HS variant (HS9+ve) isolated by utilizing the affinity 
chromatography platform. To immobilize the HS9+ve variant, an allylamine (AA) 
polymerized surface was utilized. In order to assess this surface for the capture of 
sufficient unmodified VN and provide for the long-term culture of hESC, this chapter 
will describe several biological assays. 
The most widely used microenvironment to cultivate hESCs unfortunately still 
relies on MatrigelTM of mouse origin. To achieve such defined substrates, other 
“defined” contituents including ECM proteins (LN, VN, FN, and collagen), peptides 
(biotinylated VN-HBD) and synthetic compounds (PMEDSAH, APMAAm, PMVE-
alt-MA) (Table 1.1) have been studied. However, the exact surface density of these 
coatings for the successful long-term culture of hESC remains unknown.  
To evaluate a surface as suitable for hESC expansion, criteria encompassing 
cell attachment, cell proliferation, pluripotent marker expression, chromosomal 
stability and differentiation capability need to be assessed (Yap et al. 2011). Two 
different hESC cells (HES-3 and H7) were used here to ensure the robustness of these 
assays. From the cell responses, a minimal functional VN surface density was 
deduced as being optimal for the successful long-term stem cell culture.  
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4.2. Materials and Methods 
4.2.1. Preparation of AA cell culture surfaces 
 
Based on the earlier findings that AA-polymerized TCPS surfaces 
demonstrated superior HS binding, these were utilized for the investigation of hESC 
bio-responses. AA-polymerized 24-well plates were coated with 5 g/ml of GAG 
(heparin, HSpm, HS9+ve, HS9-ve) (400 l, 2 g per well) overnight at room 
temperature. Wells were washed twice with PBS, and 300 l of the various VN 
solutions (from 0 to 10 g/ml) added, with a further incubation at 4 oC overnight. The 
coated substrate are referred to as AA+GAG+VN, depending on which GAG 
(heparin, HSpm, HS9+ve, HS9-ve) and which VN concentration was used to coat the 
surface. The coated substrate was then named accordingly: for example, surfaces pre-
coated with AA and HS9+ve variants for the capture of 5 g/ml VN solution 
concentration are named AA+HS9+ve+VN5.  
 
4.2.2. Cell culture on AA surface 
 
HES-3 (ES Cell International) or H7 (WiCell Research Institute) cells were 
maintained on AA surfaces for > 8 weeks in mTeSRTM1 media. Routine maintenance 
of cells by weekly mechanical passaging using a 1:10 passage ratio was performed on 
cells cultured on control TCPS surfaces coated with VN5.  
 
4.2.3. Adhesion, differentiation and FACS assays 
 
To assess cell responses on the AA surfaces, various assays were performed. 
For the study of cell attachment efficiency, a crystal violet adhesion assay was utilized 
as described in Section 2.2.6. The in vitro (EB differentiation) and in vivo (teratoma 
formation) differentiation potential of both cells at week 5 was analyzed according to 
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the techniques introduced in Sections 2.2.7 and 2.2.8 respectively. For the study of 
pluripotent marker (OCT-4 and Tra1-60) expression, weekly staining of cells and 
analysis with FACS was performed as described in Section 2.2.10. 
 
4.2.4. Cell growth analysis 
 
 To determine the doubling time of cells, a 7 day growth curve was generated 
with daily cell counts. Cultured cells were dissociated mechanically, counted with the 
nucleocounter NC-3000 and seeded (3 x 105 cells) into AA-polymerized 24-well 
surfaces in mTeSRTM1 medium. Cells were left to proliferate for 7 days and counted 
daily by dissociation with TrypLETM express (Invitrogen). Total viable cell numbers 
were plotted against time, and the specific growth rate determined from the calculated 
gradients during exponential phases of growth. The doubling time was calculated in 
the manner of the study by Ding et al. (Ding et al. 2010): 




 In order to assess changes in pluripotency during culture, antibodies were 
utilized to stain the target pluripotent proteins OCT-4 and Tra1-60. Staining was 
performed at room temperature with agitation. After approximately 24 – 48 h, cells 
were fixed with 4 % paraformaldehyde (Sigma Aldrich) for 1 h, washed 3 times with 
0.1 % Triton-X100 (Biorad) in PBS for 5 min and blocked with 5% BSA for 1 h. 
Cells were then reacted with either anti-OCT-4 (1:30) or anti-Tra1-60 (1:150) each 
diluted in 1 % BSA for 1 h. Cells were then washed, and probed with Alexa (647)-
tagged anti-mouse IgG2b (1:500) for OCT-4 or Alexa (633)-tagged anti-mouse IgM 
(1:500) for Tra1-60 for 30 min. Secondary antibodies were all from Invitrogen. Cells 
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were then washed with PBS to remove unbound antibodies and counterstained with 
SlowFade Gold anti-fade reagent with DAPI (Invitrogen) to visualise nuclei.  
 
4.2.6. Quantitative real time PCR 
 
Real time PCR (qRT-PCR) was employed to quantitate mRNA transcript 
levels for cells cultured on AA+HS9+ve substrates. Total RNA was extracted and 1 g 
reversed transcribed to cDNA. SYBR® green-based (Applied Biosystems) PCR was 
then performed using 5 M of both forward and reverse primers for the three germ 
lineages (endo-, meso- and ectoderm). To detect the endoderm lineage, AFP and 
GATA binding factor 6 (GATA6) primers were used. For the mesoderm lineage, 
HAND1 and Nkx2.5 primers were used and for the ectoderm lineage, paired box 
protein 6 (PAX6) and microtubule-associated protein 2 (MAP2) primers were utilised. 
Nanog and OCT-4 primers were used as the pluripotent markers, with GAPDH as the 
internal control. Primer sequences are shown in Table A1. Total RNA was extracted 
in a similar manner from undifferentiated cells for comparative purposes. Reactions 
were measured in an ABI PRISM® 7500 PCR machine, which analyzed the optical 
absorption from each well. Cycling conditions were: 10 min at 95 oC, 45 cycles of a 
three-step amplification including 20 sec at 95 oC, 10 sec at 55 oC and 30 sec at 60 oC, 
followed by a final extension for 40 sec at 72 oC. Fold induction was calculated 
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4.2.7. Karyotype stability 
 
Genetic stability is an important factor to ensure that the cells are not 
adversely affected by the culturing on various substrates. The stability of hESCs 
cultured on AA surfaces for > 5 passages was analyzed by the Cytogenetic 
Laboratories at the Department of Obstetrics and Gynaecology, Kandang Kerbau 
Women’s and Children’s Hospital, Singapore. Karyotyping analysis was performed 
using BrdU/colcemid with 20 cells being analyzed per condition. Cells with more 
than 2 abnormal chromosomes were considered karyotypically unstable. 
 
4.2.8. Statistical analysis 
 
All data values are reported as the mean + standard error taken from three 
individual experiments with triplicate runs each. When appropriate, one-way ANOVA 
was performed to compare differences across the groups, and P < 0.05 was considered 
as significant. The two-tailed student's t-test was performed to determine the 
differences between two sample groups. Graphs were plotted and data transformed 
using Sigma plot software. 
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4.3. Results 
4.3.1. Cell adhesion on AA substrates 
 
 To determine the suitability of the substrate coating that consisted of 
AA+GAG+VN for serial culturing, hESC growth was assessed over a 7 day period. 
Surfaces that were pre-coated with AA and GAGs (heparin, HSpm, HS9+ve and HS9-ve) 
were used to immobilize different concentrations (0, 2, 2.5 and 5 g/ml) of VN. 
Surfaces were screened for HES-3 attachment. Photomicrographs taken after 7 days 
revealed that, irrespective of the surface, cells attached to an overlay of VN5 
(Fig. 4.1). However, cell attachment and proliferation on VN2 and VN2.5 was only 
supported with the heparin and HS9+ve pre-coatings. In many ways this finding was to 
be expected, given the previously identified VN surface density in Section 3.3.5. 
Clearly, higher amounts of VN were adsorbed on the heparin and HS9+ve substrates as 
compared to the HSpm and HS9-ve substrates (Fig. 3.27) at these concentrations. This 
confirmed that the affinity chromatography was able to separate ‘tuned’ HS with a 
higher VN-binding affinity from low binding HS9-ve and medium binding HSpm. 
According to the VN surface densities previously identified with 125I-VN (Fig. 3.27), 
the densities on AA+HS9+ve+VN2.5 and AA+HS9+ve+VN5 were 80 ng/cm2 and 
150 ng/cm2 respectively. Notably, after 2 weeks of continuous passaging, HES-3 cells 
were unable to maintain their growth on AA+HS9+ve+VN2. This VN concentration 
was therefore deemed as not suitable, and was excluded from further study.  
 As heparin binds strongly to a wide range of ECM proteins, it was utilized as a 
positive control for the experiments. Although heparin can support HES-3 cells at low 
VN concentration (VN2), it is not a suitable pre-coating for future therapy because of 
its adverse clinical side effects (Gandhi & Mancera 2008).  
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Figure 4.1. Photomicrographs of HES-3 cells on AA surfaces. Cells attached to 
VN5 regardless of the underlying GAG substrate, but selectively attached to heparin 
and HS9+ve surfaces coated with VN2.5 and VN2. Therefore AA+HSpm and AA+HS9-
ve substrates were not viable for further cell culture. Cells detached from HS9+ve+VN2 
after 2 passages and this coating was also excluded from the study. Scale bar = 1 mm 
 
 
4.3.2. Characterization of HES-3 cells on AA+HS9+ve+VN substrates 
 
 After screening AA+GAG, it was concluded that VN concentrations of 
> 2.5 g/ml would be suitable for all subsequent long-term pluripotent cell-based 
assays. Thus, HES-3 cells cultured on either AA+HS9 substrates coated with either 
VN5 or VN2.5, or control TCPS surfaces coated with VN at 5 g/ml (VN5), were 
subjected to adhesion assays, cell growth analysis, pluripotent marker expression and 
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4.3.2.1. Crystal violet adhesion and cell growth assay  
 
 To assess the attachment efficiency of HES-3 cells on surfaces (AA+HS9+ve 
and AA+HS9-ve) coated with VN2.5 or VN5, a crystal violet cell adhesion assay was 
performed (Fig. 4.2A). An AA+HS9-ve-coated surface was included in this attachment 
assay as a comparison. Irrespective of the surface, cells attached in a concentration-
dependent manner, reaching saturation at VN5. Cells preferentially bound to 
AA+HS9+ve rather than the AA+HS9-ve substrate, which was consistent with the 
previous data. Results were normalized to the absorbance from cells attached to VN5. 
Even though the % bound to AA surface was less than VN5, the cell growth curve 
and doubling times were similar (Fig. 4.2B). A 7 day cell growth curve was then 
constructed for TCPS coated with 2.5 g/ml VN solution (VN2.5), VN5, 
AA+HS9+ve+VN2.5 and AA+HS9+ve+VN5. Cells attached and proliferated on all 
substrates, although initially having a lag phase (day 0 to day 2) for cell adaptation 
followed by an exponential growth phase from day 2 to day 5, with saturation reached 
after day 5. Similar cell numbers were seen at the end of 7 days for all the cultures, 
and the doubling times calculated from the exponential phase of the growth curve 
were similar at ~ 32 h (Table 4.1). These results thus suggested that AA+HS9+ve 
surfaces were at least comparable to TCPS surfaces.  
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Figure 4.2. HES-3 adhesion and cell growth assay. (A) Adhesion assay on 
AA+HS9+ve and AA+HS9-ve surfaces with 0, 1.25, 2.5 and 5 g/ml VN solution. 
Results were normalized to the absorbance of VN5. Cells bind preferentially to 
AA+HS9+ve rather than AA+HS9-ve substrates. Thus the former surface was better for 
cell culture. (B) Cell growth analysis on VN2.5, VN5, AA+HS9+ve+VN2.5 and 
AA+HS9+ve+VN5 substrates. Similar cell numbers were achieved at the end of 




Table 4.1. Doubling time of HES-3 and H7 cells. Cells cultured on VN5, VN2.5, 
AA+HS9+ve+VN2.5 and AA+HS9+ve+VN5 substrates had a similar doubling time of 
~ 33 h on all surfaces. 
 
  
To determine the pluripotency marker expression levels of HES-3 cells, FACS 
was applied to cells cultured AA+HS9+ve+VN2.5 and AA+HS9+ve+VN5 substrates for 
8 passages. Cells were > 95 % positive for the Tra1-60 and OCT-4 markers of 
pluripotency (Fig. 4.3A). The FACS analysis across the 8 passages is summarized in 
Table A2. Immunostaining of colonies also revealed that all colonies stained positive 
for Tra1-60 and OCT-4 (Figs. 4.3 B and C). Thus, the similar pluripotency marker 
expression levels on the cells cultured on control VN5 substrates suggest that they are 
at the very least an equally viable surface for cell culture.   
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Figure 4.3. FACS analysis and immunostaining of HES-3 cells. Cells were 
cultured on VN5, AA+HS9+ve+VN2.5 and AA+HS9+ve+VN5 substrates. (A) Tra1-60 
and OCT-4 FACS analysis at passage 6. Cells express high levels of the pluripotency 
markers (> 95%). Merged cell images of the DAPI and (B) OCT-4 or (C) Tra1-60 
markers. The OCT-4 and Tra1-60 antigens appear red and nuclei appear blue. 
Colonies expressed comparable levels of pluripotency markers to cells cultured on 
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4.3.2.2. Karyotyping 
 
 To assess whether cells underwent culture-adaptation, chromosomal stability 
was determined with karyotyping. Long-term (passage 5) cells cultured on VN5 or 
AA+HS9+ve+VN2.5 and AA+HS9+ve+VN5 substrates were analyzed and shown to 
retain normal diploid chromosomes when cultured on AA+HS9+ve+VN5 (Fig. 4.4A). 
However, 3 out of 20 of the cells cultured on AA+HS9+ve+VN2.5 substrates were 
abnormal. These 3 cells were found to have a terminal deletion of the long arm of 
chromosome 7 at band 7q32 (Fig. 4.4B). This is of interest because the changes 
observed here are different from the changes seen in the large scale study with 125 
hESC and 11 iPSC lines analyzed by the International Stem Cell Initiative (Amps et 
al. 2011). They reported changes in chromosomes 1, 12, 17 and 20, rather than 
chromosome 7, with > 20 % of the abnormal cells having amplifications in 
chromosome 20q11.21. A strong candidate for driving culture-adaptation in ESC is 
the BCL2L1 gene located in chromosome 20. To confirm this, another independent 
study with HES-3 cells cultured on the same surface (AA+HS9+ve+VN2.5) for 5 
passages showed normal karyotype. This suggests that this particular change could be 
spontaneous and random. Although cells cultured on AA+HS9+ve+VN2.5 have higher 
propensity for slight variations in their chromosome structure, further downstream 
characterization was still done.  
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Figure 4.4. Karyogram of HES-3 cells. (A) Cells cultured on the AA+HS9+ve+VN5 
surface for 5 passages were analyzed for genetic instability. Results showed that the 
cells remained normal, with diploid chromosomes. (B) Cells cultured on 
AA+HS9+ve+VN2.5 surfaces showed at a rate of 3 out of 20 a deletion on 
chromosome 7; the other 17 of the cells have normal diploid chromosomes.  
 
4.3.2.3. In vitro and in vivo differentiation  
 
 Other than pluripotent marker expression, the key “trademark” of pluripotent 
cells is the ability of cells to differentiate into the 3 germ layers (endo-, meso- and 
ectoderm). Cells cultured on AA+HS9+ve+VN2.5 or AA+HS9+ve+VN5 substrates 
were thus triggered into in vitro and in vivo differentiation. When pluripotent hESCs 
were lifted from the culture surface and allowed to form embryoid bodies (EB), they 
randomly differentiated into all 3 germ layers. Thus, in vitro EB differentiation was 
induced here in HES-3 cells at passage 6, with the various germ layer gene expression 
patterns analyzed by quantitative real-time PCR (Fig. 4.5). Endoderm (AFP and 
GATA6), mesoderm (Hand1 and Nkx2.5) and ectoderm (Pax6 and MAP2) genes 
were upregulated and pluripotent genes (Nanog and OCT-4) were downregulated after 
differentiation. 
Finally, HES-3 cells were tested for in vivo teratoma differentiation by 
injecting the treated cells into SCID mice. If the cells remained pluripotent, they 
should form tumours consisting of cells from all 3 germ layers. Teratomas formed by 
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7 weeks, and all possess the characteristic structures of all 3 germ layers (Fig. 4.6). 
Cells differentiated along the ectoderm lineage formed neural rosettes, those along the 
mesoderm lineages formed cartilage and bone and those along the endoderm lineages 
formed gut epithelium structures. Collectively, these differentiation assays confirmed 
the continuing pluripotency status of the cells cultured on the AA+HS9+ve+VN2.5 and 




Figure 4.5. mRNA transcripts expression in HES-3 cells after EB differentiation. 
Complementary DNA was generated from HES-3 cells before and after EB 
differentiation and then probed by qRT-PCR for the genes from the 3 germ layers. 
AFP and GATA6 represented the endoderm markers; Hand1 and Nkx2.5 represented 
the mesoderm markers and PAX6 and MAP2 represented the ectoderm markers. Ct 
values were normalized to those before EB differentiation and expressed as fold 
difference. Cells upregulate genes from all the 3 germ layers and downregulate 
pluripotent genes (Nanog and OCT4). 
 




Figure 4.6. Representative structures in teratomas from HES-3 cells stained with 
haematoxylin and eosin. Teratomas formed from HES-3 cells cultured on 
AA+HS9+ve+VN2.5 surfaces show (A) neural rosettes, (C) cartilage and (E) gut 
epithelium, which corresponds to the endo-, meso- and ectoderm lineages. Similarly, 
cells cultured on AA+HS9+ve+VN5 surfaces show (B) neural rosettes, (D) bone and 
(F) gut epithelium, indicating that cells differentiated along the endo-, meso- and 
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From the earlier 3H-HSpm and 125I-VN surface measurements made on 
AA+HS9 surfaces (Fig. 3.26 and 3.27), it was determined that 2 g HS coating 
solution gives rise to a 300 ng/cm2 HS density. The AA+HS9+ve+VN2.5 and 
AA+HS9+ve+VN5 substrates captured 80 ng/cm2 and 150 ng/cm2 of VN respectively. 
These VN densities were much lower than the ones measured with VN5 (250 ng/cm2). 
This indicates that AA+HS9+ve surfaces can successfully modulate the function of VN 
at much lower threshold densities. Although there is more VN adsorbed onto TCPS, it 
appears that this extra VN is not functional. It can be thus surmised that protein needs 
to be immobilized in the correct conformation to maintain its function, because 
simply having more VN on TCPS does not translate into higher biological activity. 
Marson et al. showed that protein immobilized on surfaces can lose function by steric 
hindrance or conformational perturbation (Marson et al. 2005). These data strongly 
suggested that the appropriate immobilized GAGs were contributing positively to the 
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4.3.3. Characterization of H7 cells cultured on AA+HS9+ve+VN substrate  
 
To ensure the robustness of these results for the general culture of pluripotent 
hESCs on AA+HS9+ve+VN substrates, another hESC (H7) line was tested. The initial 
photomicrographs at day 7 of AA+GAG substrates were taken. As seen previously, 
heparin and HS9+ve surfaces (AA+HS9+ve+VN2.5 and AA+HS9+ve+VN5) were the 
only ones able to support H7 cell attachment (Fig. 4.7).  
 
 
Figure 4.7. H7 cell attachment on various AA surfaces. Irrespective of underlying 
coating, wells coated with 5 g/ml of VN (VN5) could support cell attachment and 
proliferation to confluence. However, cells preferentially bind and proliferate on 




 Similarly, H7 cells have a similar growth curve and doubling time (~ 33 h) 
(Table 4.1) on VN5 (Fig. 4.8A). FACS analysis of cells also revealed high levels of 
Tra1-60 and OCT-4 marker expression (Table A2). It is worth noting that the 
karyotype of H7 cells on both surfaces remained normal. This confirms the idea that 
there are wide variations between hESC lines.   
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 Differentiation potential was also determined, by both EB and teratoma 
formation. Together these results revealed that AA+HS9+ve+VN2.5 and 
AA+HS9+ve+VN5 surfaces are able to support the robust, long-term pluripotent status 
of hESCs in culture. As HES-3 cells have higher propensity for chromosomal changes 
at AA+HS9+ve+VN2.5, the AA+HS9+ve+VN5 surface was selected as the most viable 
surface. Therefore, I conclude that the potential minimum threshold indentified for the 
successful long-term culture of hESCs is at least 150 ng/cm2 VN coated over 
300 ng/cm2 HS9+ve. 
 
 
Figure 4.8. Growth curve and FACS analysis of H7 cells. (A) The 7 day cell 
growth analysis on the various surfaces showed similar growth kinetics, with a 
doubling time of ~ 33 h. (B) High expression levels of Tra1-60 and OCT-4 
pluripotent markers revealed by FACS analysis.   
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Figure 4.9. Differentiation potential of H7 cells. (A) qRT-PCR analysis of cells 
after EB differentiation. mRNA transcripts from the 3 germ layers were upregulated 
and pluripotency genes (Nanog and OCT-4) were downregulated. Teratomas formed 
from cells cultured on (B) AA+HS9+ve+VN2.5 and (C) AA+HS9+ve+VN5 substrates 
contained structures from all the 3 germ layers. Ectoderm lineage is represented by 
pigmented epithelium; mesoderm lineage is represented by the formation of cartilage 




It has become clear that to fulfill the potential that hESC have for clinical 
application, defined culture surfaces will need to be rigorously specified to allow for 
the maximum propagation with minimal differentiation. I believe that VN is a 
promising candidate, and that understanding the surface threshold requirements that 
stem cells have for it will help to reduce the cost of culturing them in large-scale 
bioreactors. However, hESCs, unlike other stem cells, are particularly demanding. 
They do not attach and grow on bare TCPS, and are in fact extremely sensitive to the 
ECM components they will tolerate.  
Here I employed a novel attachment strategy: using plasma-polymerized AA 
substrates to immobilize a VN-tuned HS variant, on the premise that the optimized 
presentation of VN will prove a great advantage for the culture of hESCs. The 
platform affinity chromatography technology is well suited for a scale-up of the 
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isolation of a avid VN binding variant (HS9+ve) as shown from the preferential 
binding of hESCs for it as compared to the flowthrough (HS9-ve) or starting HS 
(HSpm) (Fig. 4.1 and 4.7). These data suggests that this compound substrate could 
sufficiently mimic the essential features of stem cell ECM, where GAGs and proteins 
are known to combine to support cell attachment and growth in vivo.  
Chromosomal stability was used to check the quality of the cultured cells on 
the substrate variations. Karyotypic instability was found in HES-3 cells, but not in 
H7 cells, when they were cultured on AA+HS9+ve+VN2.5 substrates. This confirms 
the intrinsic differences between stem cell lines. Indeed, differences in growth rate, 
genetic and epigenetic changes between different hESC lines in culture have long 
been reported (Carpenter et al. 2003, Carpenter et al. 2004, Hoffman & Carpenter 
2005b). As the H7 cells remained karyotypically normal on the AA+HS9+ve+VN2.5 
surface, they appear better adapted to it than HES-3 cells. We therefore chose to 
continue with the apparently safer VN density of 150 ng/cm2.  
The VN density differences seen between the AA+HS9+ve+VN2.5 
combination and the AA+HS9+ve+VN5 are very significant, from 80 ng/cm2 to 150 
ng/cm2. The actual threshold must lie between these two densities, and further fine-
tuning might reveal an even lower VN threshold. This surface density is at least 30 % 
lower than the one initially identified for VN5 (250 ng/cm2). This significant 
reduction in surface requirement is a potentially important cost saving for any cell 
culture scale-up using VN as a regimen. 
What is most interesting was the comparison of surface densities from VN 
absorbed onto TCPS at VN2.5 and AA+HS9+ve+VN5 surfaces. Both surfaces have a 
similar density of ~ 150 ng/cm2. However, cells cultured on VN2.5 did not form 
teratomas after their injection into mice (Chapter 2), unlike cells cultured on the 
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AA+HS9+ve+VN5 surface. This suggested that the absorbed VN on TCPS is not as 
biological active. Indeed, it is possible that the immobilized HS plays a role in the 
multimerization of plasma VN, transforming the inactive monomer into active 
heparin-binding multimers. Izumi et al. and Seiffert et al. both demonstrated that 
plasma VN exists in these two structurally and functionally distinct forms (Izumi 
1989, Seiffert & Schleef 1996). Upon VN binding to HS, via its HBD, the complex 
becomes allosterically stabilized (Francois et al. 1999). These structural changes 
within VN expose additional binding sites within it, enabling the binding of additional 
proteins (Morris et al. 1994, Seiffert & Smith 1997). Thus the binding of VN to 
GAGs presumably anchors it onto the culture surface, and opens up new complexing 
opportunities. VN’s RGD sequences are located at its N-terminal, whereas the HBD is 
located at its C-terminal. In the first proposed model of VN-HBD engagement 
(Fig. 1.4), the structural changes induced in VN upon HS binding causes cryptic sites 
at N-terminal to be revealed, exposing loci for other ligands. Seiffert et al. 
demonstrated that these cryptic sites contained extra RGD cell adhesion motifs, so 
promoting integrin-mediated cell binding (Seiffert & Smith 1997). It was also 
demonstrated by Noble et al. that breast cancer cell migration is enhanced when 
insulin growth factor-II is bound to surface-adsorbed VN, rather than when it is left in 
solution, again suggesting a complex conformational activation. As is the case for LN 
and FN, both proteins which require conformational activation by pre-binding to 
heparin,  it is clear that VN belongs to the same class of large, multi-domain ECM 
proteins that are designed to cross-link collagens, proteoglycans, adhesive 
glycoproteins and cell surface integrins into large informational networks. Thus it is 
hardly surprising that VN requires similar HS binding to reach the zenith of its 
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potential activity. Thus, we conclude that the HS-functionalized surface permits VN 
to adopt a more optimal configuration for hESC attachment.   
In attempts to further delineate the lower VN density required on HS-
functionalized surfaces as compared to TCPS surfaces, the inherent properties of the 
VN protein need to be considered. Plasma-derived VN exists mainly in an inactive 
monomeric form, with only a small proportion existing in the active, RGD-exposed 
multimeric form (Francois et al. 1999, Gibson & Peterson 2001, Izumi 1989, Schvartz 
et al. 1999b). As plasma-derived VN was used here, it was to be expected that more 
inactive VN was absorbed onto the TCPS surfaces. The VN adsorption itself might 
add to this intrinsic steric hindrance, thus further compounding the loss of activity. 
Mei et al. has also shown that adsorbed VN protein needs to interact with an 
appropriate surface to be able to adopt a conformation that can promote colony 
formation (Mei et al. 2010).  
The successful attachment of cells to a substrate via integrin receptors leads to 
the formation of focal adhesion contacts; these surface complexes conduct cues from 
ECM into the cells (Askari et al. 2009, Hynes 2009, Zou et al. 2007). Integrin 
signalling is critical for cell survival and proliferation. It has been observed that 
optimal cell stimulation with various growth factors is itself dependent on integrin-
mediated cell attachment to an appropriate ECM (Giancotti & Ruoslahti 1999). 
Integrin clustering triggered by sufficient binding becomes associated with the 
cytoskeleton through talin-vinculin binding, which in turn mostly through FAK (focal 
adhesion kinase) leads to the formation of integrin-growth factor receptor complexes 
(Askari et al. 2010, Calderwood et al. 1999, Hynes 2009, Mostafavi-Pour et al. 2003). 
Such an example of molecular cooperation is the activation of the EGF receptor by 
integrin-mediated pancreatic cancer cell migration and chemoresistance (Danilov et 
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al. 2011). Such integrin activation by ECM binding in turn lowers the threshold for 
growth factor receptor signalling. The stable bioresponses of hESCs to the substrate 
combinations tested here implies that just such stable FAK interactions are themselves 
promoting long term stem cell survival and pluripotency. This remains to be proven.  
Vitronectin is known to synergize with several growth factors in such a way as 
to maintain both embryonic and adult stem cells in an undifferentiated state. Parker et 
al. reported that VN, together with IGF-1 and transforming growth factor 1 (TGF-1), 
could modulate human mesenchymal stem cell activity (Parker et al. 2009). Studies 
by Upton and colleagues demonstrated the ability of VN and IGF-1, together with 
IGF binding protein (IGFBP) or a chimeric VN: IGF-1 protein, as adjuvant to the 
serum-free cell culture medium could support the successful culture of hESCs 
(Manton et al. 2010, Richards et al. 2008). Mutagenic studies have shown that the 
HBDs in IGFBP-3 and IGFBP-5 are also involved in the enhancement of IGF-1 
binding to VN (Firth et al. 1998, Nam et al. 1997), which is necessary for the growth 
factor’s activities (Clemmons et al. 1999, Grulich-Henn et al. 2002, Rees & 
Clemmons 1998). These growth factors can induce markedly different mitotic rates in 
embryonic and adult stem cells (Ghule et al. 2008). The mTeSRTM1 medium used in 
this study contains FGF-2, TGF-1 and BSA, markedly different growth factors that 
all require HS. Moreover Levenstein et al. have shown that MEFs secrete HSPGs 
which help to stabilize and extend the half-life of FGF-2, a key growth factor for cells 
to remain pluripotent (Levenstein et al. 2008). Thus, the HS-VN substrate is generally 
beneficial for the activities of these important growth factors.  
A study by Doran et al. reported a method of creating substrates with high 
ECM-derived protein content on a layer-by-layer, self-assembled surface of HA and 
chitosan (Doran et al. 2010). Both the ability of the hESCs to initially attach to such 
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surfaces and the ability of mesenchymal stem cells to differentiate down the 
osteogenic lineage were studied. They employed NHS/EDC chemistry to covalently 
link 3 layers of the ECM protein to the 5 pre-coated bilayers of the HA/chitosan 
surface, resulting in > 50 % of the protein becoming bound, a very high proportion 
under such circumstances. The technique resulted in ~ 3 g/cm2 recombinant VN and 
~ 5 g/cm2 recombinant FN being coupled for cell culture. However, the method 
employed to quantify the protein was only indirect, being a measurement from the 
difference between the concentration of the input solution and the output unbound 
solution and based on the relatively insensitive Bio-rad Protein assay. The high VN 
density reported is above the threshold density (150  ng/cm2) measured in this study 
with the much more accurate 125I-VN binding assay. In terms of using VN in systems 
for large-scale cell culturing, their technique is neither cost-effective, nor scalable.  
Using EDC to tightly and covalently link ECM proteins clearly poses the risk 
of altering their protein structure, and thus affecting their function. The high density 
of measured protein might not translate to full activity on such immobilized surfaces. 
I believe that the most economical and effective way to immobilize a protein, without 
affecting its conformation or function, is through non-covalent methods. Even though 
a culture surface is constantly modified by proteins from both the cell culture media 
and secreted by the cells, this merely reflects the extraordinarily dynamic environment 
to which cells become exposed. Embryonic stem cells naturally exist within the 
complex 3-D environment within blastocysts; shifting them suddenly onto a 2-D 
surface is a particularly harsh change. Therefore, it can be posited that a dynamic 
surface, with conformationally better presented adhesive factors, will better mimic the 
natural environment for such cells.   
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A recent study by Peng et al. showed that decellularized human fibroblast 
matrix was able to propagate hPSC (Peng et al. 2012). The surface was generated 
using dextran sulfate as a macromolecular crowder to increase the ECM deposition 
from fibroblasts. However, not all every fibroblast cell lines are suitable and this 
highly complex substrate is not defined. Specific staining of the matrix showed the 
presence of HS, collagens and FN. It is interesting to note that VN is not present in 
this decellularized substrate and MatrigelTM, which indicates that in the presence of a 
combination of different ECM components, VN is not essential (Hughes et al. 2011). 
However without the complex matrix, a single component VN is sufficient to 
propagate hPSCs. These results supported our hypothesis that by using HS and VN 
can recapitulate the function of the natural ECM.  
Development in hPSC culture surfaces has increase expoenentially leading to 
various commercial products. Study by Melkoumian et al. led to the development of 
synthemax® by Corning® that require high RGD peptide density and the peptide 
conjugation reaction is limited by EDC/NHS efficiency. Study by Nagaoka et al. led 
to the development of StemAdhereTM by StemcellTM Technologies that used 
colorimetric measurement to determine E-cadherin surface density which is not a 
specific methodology. Human recombinant laminin-511 surfaces demonstrated by 
Rodin et al. led to the development of recombinant coating by BioLamina. The 
surface was made active by passive adsorption of peptide onto culture surfaces. 
PuraMatrixTM substrate by BD Biosciences, PuraMatrixTM is a hydrogel that require 
optimization with additional ECM protein or growth factor to be functional, thus 
utilizing it for hPSC culture is cumbersome. Therefore, the substrate developed in this 
thesis contributes to the field by establishing a defined surface density of HS and VN 
without any modification or optimization for the long-term propagation of hPSCs.      
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4.5. Summary 
 
The previous chapter demonstrated that HS9+ve variants have significantly 
higher affinity to VN than HS9-ve variants, and that the novel engineered HS9+ve-
functionalized AA surfaces could serve as an effective ECM replacement for the long-
term culture of hESCs. Among all the HS9 variant-AA surfaces, only 
AA+HS9+ve+VN2.5 and AA+HS9+ve+VN5 could support cell growth. Thus, a full 
characterization of pluripotency of HES-3 and H7 cells with the combination of 
FACS, EB differentiation potential and teratoma formation was conducted for 
AA+HS9+ve+VN2.5 and AA+HS9+ve+VN5 surfaces. Cells cultured on 
AA+HS9+ve+VN2.5 were found to be relatively karyotypically unstable, even though 
they were able to form teratomas in vivo. Thus this surface was not considered 
suitable for further development. 
   Such results allowed me to conclude that an HS surface density of 
300 ng/cm2 and VN surface density of 150 ng/cm2 on HS-derviatised AA surfaces are 
the threshold levels for successful long-term hESC culture. This study distinguishes 
itself from earlier attempts in that a real unmodified functional VN surface density 
was defined. A significant, cost-saving density reduction of at least 30 % was 
achieved with the tuned HS9 variant as compared to mere passive adsorption onto 












CHAPTER 5 : CONCLUSIONS AND 
RECOMMENDATIONS  
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5.1. Conclusions 
 
The aim of this thesis is to engineer an effective substrate capable of binding 
and presenting unmodified VN, without compromising its biological utility, for the 
culture of pluripotent hESCs. Such a defined set of components should allow for the 
identification of appropriate threshold surface densities suitable for the long-term 
propagation of clinically relevant cells such as hPSCs. Such mixtures would allow for 
faster rates of progress in the improvement of industrial stem cell culture. The basis of 
the novel surface was the “tuned” HS9+ve variant, purified from HS starting mixture, 
through an inexpensive and quick affinity chromatography step, on its ability to bind 
to the heparin-binding domain of vitronectin. The minimum HS-supplemented VN 
threshold surface density was identified, and compared for its efficacy against the 
standard passive adsorption of VN onto TCPS. Based on this study, the following 
conclusions were derived: 
 
(1) The relatively specific VN-tuned HS variant can be isolated from crude 
HS material with reproducible confidence. This HS9+ve variant bind VN 
with significantly higher affinity than the other HS variants; furthermore, 
the 6O- and N-sulfation motifs and a length of at least 6 disaccharide units 
on HS appear to be crucial for this association.  
(2) Plasma-polymerized AA films are a particularly suitable substrate for the 
immobilization of HS. The hESCs are able to attach and thrive on 
AA+HS9+ve+VN substrates for > 8 passages, and remain pluripotent.  
(3) Defined surface densities need to be carefully identified, as in this study. 
An N: C ratio of 1.8 to 2.2 is optimal for HS binding. When 300 ng/cm2 of 
CONCLUSIONS AND RECOMMENDATIONS                                                     188 
HS is combined with 150 ng/cm2 of VN on the engineered substrate, it 
allows for the successful long-term culture of hESCs in a pristine state.  
(4) Even at this early stage of optimization, a significant cost savings (~ 30 %) 
can be achieved with this novel engineered substrate, as compared to the 
widely practiced, standard passive adsorption of VN onto TCPS. This 
novel technique can easily be scaled-up for even greater cost savings.  
 
This thesis thus propose that the data presented here concerning this defined 
platform more than justifies a proper trailing for the large scale culturing of 
pluripotent stem cells to meet the unmet clinical demand. Higher densities of hESCs 
and their differentiated progenies are required for those future applications that cannot 
be achieved with conventional 2D culture systems. It has long been known that 3-D 
suspension culture systems are more effective for the generation of high cell densities 
because of the larger surface growth areas per volume offered by bioreactors (Oh et 
al. 2009). Several groups have addressed this issue by culturing cells in suspension 
culture as pluripotent aggregates, or by using microcarriers (MCs) (Amit et al. 2011, 
Chen et al. 2011, Heng et al. 2012, Larijani et al. 2011, Oh et al. 2009, Steiner et al. 
2010, Zweigerdt et al. 2011). As this thesis reports only on the successful culture of 
hESCs in a 2D system, it will be very interesting to see whether the technology can be 
up-scaled onto bioreactor MCs.  
Bioreactors present a viable and industrially scalable means to generate large 
quantities of such cells. Due to its capacity for automation of the large scale batch 
processing of cell culture in a controlled and reliable manner, bioreactor MC 
technology  has stimulated much interest recently (Chen et al. 2011, Heng et al. 2012, 
Storm et al. 2010). MC culture is a well established technology in the pharmaceutical 
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industry, which employs it extensively for the culture of mammalian cells which 
synthesize commercially important vaccines and enzymes (Braeckmans et al. 2002). 
Chen et al. demonstrated that conventional MCs that had proven successful for 
mammalian cells were not suitable for hESCs, and reported that either MatrigelTM or 
laminin coating seemed necessary for the latter’s culture on beads (Chen et al. 2011). 
Recently, Heng et al. showed that VN-coated MCs allowed for the 3-D culture of 
hESCs at a VN surface density of 450 ng/cm2 (Heng et al. 2012). The MC coating 
method was the usual overnight passive absorption of protein, which presumably 
explains the high concentration of VN required. Obviously I surmise that AA+HS9+ve 
MCs would coincidentally reduce the surface density of VN needed for cell culture by 
a significant amount, and improve the quality and numbers of cells.  
Few studies have addressed the cost-benefits of improved cell adhesion 
technology for the large scale manufacturing of stem cells. The overall costs involve 
many factors. If it is assumed that 1 mg of recombinant human VN costs USD1400 
(from Millipore), then, according to Chen et al., a 1 litre bioreactor contains 1 -
 4 mg/ml of polystyrene MCs with a total surface area of approximately  4000 -
7000 cm2. Based on a minimum VN threshold identified on TCPS for hESC culture of 
250 ng/cm2  (described in Chapter 2), this translates to ~ 1 - 1.75 mg of effective 
surface VN after passive adsorption, costing between USD1400 - 2450 (Chen et al. 
2011).  
On the basis of the results reported here for the AA+HS substrate, I believe a 
savings of at least USD 420 to 735 per litre, a 30 % reduction. This is even before a 
thorough optimization at scale, where even greater efficiencies can be expected. The 
cost of building a plasma reactor to polymerize surfaces with AA is relatively low, 
and affinity chromatography purification is well established commercially as one of 
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the cheapest and easiest purification technologies now available. In large scale 
manufacturing plants, where bioreactors with capacities of hundreds of litres are used, 
significant efficiencies can be envisaged. 
In conclusion, the process development reported in this thesis from isolating a 
high VN binding affinity HS variant and immobilizing it onto surfaces to capture 
functional VN for hESC culture is novel. Moreover, the generation of the 
AA+HS9+ve+VN substrate fulfilled the key features include cost, simplicity, safety 
and efficacy. Finally, the technology of obtaining a ‘tuned’ HS variant, isolated from 
a heterogeneous population of HS by affinity binding to a HBD-VN peptide, clearly 
demonstrated the applicability for the isolation of other ‘tuned’ HS variants aimed at 
specific ECM components 
 
5.2 Recommendations for future research 
5.2.1. Physical characteristics of AA+GAG+VN surface 
 
A detailed physical characterization of TCPS coated with VN was completed 
by employing XPS, AFM, colloidal gold staining and VN adsorption/desorption 
kinetics. To further analyze the AA+GAG+VN surface, a physical characterization 
could also be attempted. Material properties such as surface topology can be 
measured by AFM, XPS and water contact angle. Water contact angle analysis would 
provide wetability details, which would help define the hydrophobicity-hydrophilicity 
of the surface. Li et al. have shown that a substrate water contact angle of 65o is 
optimal for HES-3 culture (Li et al. 2010). High-throughput methods such as AFM 
and XPS would reveal the surface morphology and its elemental composition. These 
would be useful as they would better define the structure-function relationship 
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between the material properties of the surface and its subsequent biological 
performance. 
5.2.2 The 3-dimensional (3-D) culturing of hPSCs on synthetic polymers 
 
 Translating the use of hPSCs from the bench into the clinic is a multi-faceted 
problem. Reliance on the culturing of cells on 2-D TCPS is inefficient; thus other 
scalable methods need to be explored. As the AA plasma polymerization method can 
be applied to most surfaces, carriers made of any cell culture-friendly material, 
including cellulose and polystyrene, can be so derivatized, and thus further coated 
with the HS9+ve variant and VN, or any other HS-ECM protein combination. I 
envisage an AA-coated material that can be produced commercially and made 
available off-the-shelf, so that the end-user has merely to coat surfaces with the 
appropriate ECM protein tuned-HS. This again should translate to major cost savings 
and a more effective manufacturing process.  
 
5.2.3 Further fine-tuning of HS9+ve variants 
 
 I also envisage a “second generation” HS9+ve variant with an increased 
binding avidity for VN. This idea was generated from the observation that a delay in 
HS9+ve variant elution in high salt buffer suggested that a mixture of binding HSs 
could be present (Fig.3.4).The affinity chromatography method can be fine-tuned to 
include either a slow gradient, or a more gradual step-wise NaCl series of washes, 
instead of the single 1.5 M NaCl wash described here. A more gradual increase in 
ionic strength would more effectively remove the weaker binding HS9+ve variants, and 
leave the stronger binding (more avid) HS bound to the peptide. The stronger-binding 
HS9+ve variant would be eluted at the highest ionic strength buffer. Presumably this 
more specific variant would allow even better VN activity at less concentration.  
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 The results from the GAG-binding ELISA indicated that 6 disaccharide units 
was the minimum length that the HS must possess for effective VN binding. Thus a 
third generation HS9+ve variant could also be separated based on the basis of its 
minimum size; that is, it should be possible to remove HS of less than 6 repeats. Such 
procedures will generate an even more potent VN-binding variant. Such advanced 
purification procedures should simplify the job of sequencing the disaccharides that 
make up the VN-binding domain. This is turn would bring us a step closer to 
generating fully synthetic HS molecules for stem cell application.       
    
5.2.4 Extension of HS isolating technology to other ECM proteins 
 
 Regarding the isolation of other ECM-specific HS variants, such as those 
against FN or LN, the affinity chromatography technique is also clearly applicable. A 
library of different ECM-binding HS species could be generated with relative ease, 
and used for the culturing of many other clinically relevant cell types, including 
mesenchymal or endothelial stem cells.  Heydarkhan-Hagvall et al. recently showed 
that 3D scaffolds coated with either LN or VN support murine ESC differentiation 
into cardiac progenitor cells (Heydarkhan-Hagvall et al. 2012). Thus, isolating ECM-
binding HS species could potentially improve the function of many different varieties 
of tissue-specific ECM protein, thereby promoting the specific differentiation 
capacities needed in such specialized areas as cardiovascular or connective tissue 
engineering.  
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Figure A1. ∆-disaccharide standard curve. Different dilutions of each standard 
were separated by CE, area-under-the curve determined and standard curve plotted. 
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Table A2. FACS analysis of Tra1-60 and OCT-4 pluripotent marker expression 
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APPENDIX B: SUPPLEMENTARY INFORMATION FOR MATERIAL AND 
METHODS 
 
General chemicals and reagents 
0.01% poly-l-lysine (Cat No. P4707, Sigma Aldrich, MO, USA) 
1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) powder (Cat. 
No. N2770, Sigma Aldrich, MO, USA)   
2-(N-Morpholino)ethanesulfonic acid (MES) powder (Cat. No. M3670, Sigma 
Aldrich, MO, USA) 
3,3′,5,5′-Tetramethylbenzidine (TMB) substrate (Cat No. 34021, Thermo Fisher 
Scientific Inc, IL, USA)  
Acetic acid (Cat. No.1.00063.2500, Merck Millipore, Darmstadt, Germany) 
Agarose powder (Cat. No. 10975-035, Invitrogen, Life Technologies Corporation, 
CA, USA)  
Allyamine monomer (Cat. No. 14,583-1, Sigma Aldrich, MO, USA) 
Bio-Gel® P-10 Gel (Cat No. 150-4144, Biorad Laboratories, Hercules, USA) 
Biotin-LC-hydrazide (Cat No. 21340, Thermo Fisher Scientific Inc, IL, USA) 
Bovine serum albumin (BSA) (Cat No. A7906, Sigma Aldrich, MO, USA)  
Bradford reagent (Cat. No. B6916, Sigma Aldrich, MO, USA) 
Calcium acetate (Ca(OAc)2) (Cat. No.C-1000, Sigma Aldrich, MO, USA) 
Calcium chloride (CaCl2) (Cat No. C5670, Sigma Aldrich, MO, USA) 
Colloidal Gold Total Protein Stain (Cat. No. 170-6527, Biorad Laboratories, 
Hercules, USA) 
Crystal violet powder (Cat. No. C3886, Sigma Aldrich, MO, USA) 
Dimethyl sulfoxide (DMSO) (Cat.No. D2438 , Sigma Aldrich, MO, USA) 
Ethanol (Cat. No. 1.00983.2500, Merck Millipore, Darmstadt, Germany) 
Ethidium bromide (Cat No. 161-0433, Biorad Laboratories, Hercules, USA) 
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ExtrAvidin® - Alkaline phosphatase (Cat No. E2636, Sigma Aldrich, MO, USA) 
Fish gelatin powder (Cat. No. G7041, Sigma Aldrich, MO, USA) 
Fluorescamne protein dye (Cat. No. F9015, Sigma Aldrich, MO, USA) 
Formic acid (Cat. No.06450, Sigma Aldrich, MO, USA) 
Gelatin from porcine skin Type A (Cat No. G1890, Sigma Aldrich, MO, USA) 
Glycine (Cat. No. 161-0718, Biorad Laboratories, Hercules, USA) 
Heparan sulfate sodium salt from porcine intestinal mucosa (HSpm) (Cat No. HO-
03103, Celsus Laboratories Inc, Ohio, USA)  
Heparin Sepharose beads (Cat. No. H6508, Sigma Aldrich, MO, USA) 
Heparin sodium salt from porcine intestinal mucosa (Cat. No. H3149, Sigma Aldrich, 
MO, USA) 
HPLC grade water (Cat. No. 95304, Sigma Aldrich, MO, USA) 
Laemmli buffer (Cat. No. S3401, Sigma Aldrich, MO, USA) 
LumiGLO chemiluminescent substrate (Cat. No. 54-61-01, Kirkegaard & Perry 
Laboratories, Gaithersburg, USA)  
LumiGlo ReserveTM chemiluminescent substrate (Cat. No. 54-71-01, Kirkegaard & 
Perry Laboratories, Gaithersburg, USA) 
Methanol (Cat. No. 1.06009.2500, Merck Millipore, Darmstadt, Germany) 
MilliQ water (MilliQ Integral water purification system, Merck Millipore, Darmstadt, 
Germany) 
Mitomycin-C (Cat. No. M4287, Sigma Aldrich, MO, USA) 
MOPS SDS running buffer (20 X) (Cat No. NP 0001-02, Invitrogen) 
Octa-1,7-diene monomer  (Cat. No. 02501, Sigma Aldrich, MO, USA) 
Paraformaldehyde (Cat. No. P6148, Sigma Aldrich, MO, USA) 
Ponceau S staining solution (Cat. No. P7170, Sigma Aldrich, MO, USA) 
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Precision Plus protein standards (Cat No. 161-0373, Biorad Laboratories, Hercules, 
USA) 
SIGMAFASTTM p-Nitrophenyl phosphate tablets (Cat. No. N2770, Sigma Aldrich, 
MO, USA) 
Sodium acetate (NaAc) (Cat No. 71185, Sigma Aldrich, MO, USA) 
Sodium chloride (NaCl) (Cat No. 73575, Sigma Aldrich, MO, USA) 
Sodium dodecyl sulfate (SDS) powder (Cat. No. 1.13760.1000, Merck Millipore, 
Darmstadt, Germany) 
Sodium hydroxide (NaOH) (Cat. No. S8045, Sigma Aldrich, MO, USA) 
Streptavidin-HRP (Cat No. 21324, Thermo Fisher Scientific Inc, IL, USA) 
Sulfuric acid (H2SO4) (Cat No. 87003 – 234, VWR, USA) 
Triton X100 (Cat No. 161-0407, Biorad Laboratories, Hercules, USA) 
Triza® base minimum 99.9 % (Cat No. T1503, Sigma Aldrich, MO, USA) 
Tween 20 (Cat. No. P1379, Sigma Aldrich, MO, USA) 





0.2 M nitroceullose membrane (Cat No. 162-0112, Biorad Laboratories, Hercules, 
USA) 
20 ml glass scintillation vials (Cat No. 6000128, Perkin Elmer, Massachusetts, USA.)  
GE PD MinitrapTM G-10 (Cat No. 28-9180-0, GE Healthcare) 
GE PD MinitrapTM PD-10 (Cat No. 17-0851-01, GE Healthcare) 
Glycosaminoglycan 96-well binding plates (Cat No. H/G Plates, Iduron Ltd, 
Manchester, UK) 
APPENDIX B                                                                                                            219 
Iodination beads (Cat. No. 28665, Thermo Fisher Scientific Inc, IL, USA) 
NUPAGE® 4-12% Bis-Tris gel SDS-PAGE gel (Cat No. NP0335PK2, Invitrogen, 
Life Technologies Corporation, CA, USA)  




125I isotope (17.4 Ci/mg) (Cat. No. NEZ 033A, Perkin Elmer, Massachusetts, USA.) 
3H-heparin (0.35 mCi/mg) (Cat. No. NET476, Perkin Elmer, Massachusetts, USA.) 
 3H-lysine (105.4 Ci/mmol) (Cat. No. NET376, Perkin Elmer, Massachusetts, USA.) 




Heparin disaccharide standards (∆UA,2S – GlcNS,6S; ∆UA,2S – GlcNS, ∆UA,2S – 
GlcNAc,6S, ∆UA – GlcNS,6S, ∆UA – GlcNS, ∆UA – GlcNAc, ∆UA,2S – GlcNAc, 
∆UA – GlcNAc,6S, ∆UA-2S ® GlcNCOEt-6S, ∆UA,2S – GlcN, ∆UA,2S – GlcN,6S, 
∆UA – GlcN,6S, ∆UA – GlcN) (Cat No. HD001  to HD013, , Iduron Ltd, 
Manchester, UK) 
Heparin Oligosaccharides (dp4, dp6, dp8, dp10, dp12) (Cat. No. HO04, HO06, HO08, 
HO10, HO12) 
Selectively desulfated heparin standards (2-O, 6-O and N- desulfated heparin) (Cat 




Heparinase I (Cat No. H2519, Sigma Aldrich, MO, USA) 
Heparinase I (Cat. No. HEP-ENZ I, Iduron Ltd, Manchester, UK) 
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Heparinase II (Cat No. H6512, Sigma Aldrich, MO, USA) 
Heparinase II (Cat. No. HEP-ENZ II, Iduron Ltd, Manchester, UK) 
Heparinase III (Cat No. H8891, Sigma Aldrich, MO, USA) 
Heparinase III (Cat. No. HEP-ENZ III, Iduron Ltd, Manchester, UK) 
Superscript II reverse transcriptase (Cat No. 18064-014, Invitrogen, Life 




Fix and Perm kit (Cat No. GAS003, Invitrogen, Life Technologies Corporation, CA, 
USA) 




Oligo dT primers (Cat No. 18418-020, Invitrogen, Life Technologies Corporation, 
CA, USA)  
Primers for PCR and qRT-PCR synthesized by Sigma Aldrich, MO, USA, sequences 
in Table A1 




Alexa(633) anti-mouse IgM (Cat No. A-21046, Invitrogen, Life Technologies 
Corporation, CA, USA) 
Alexa(647) goat anti-mouse IgG2b (Cat No. A-21242, Invitrogen, Life Technologies 
Corporation, CA, USA) 
Anti- ΔHS 3G10 antibody (Cat No. 37026, Seikagaku corporation, Tokyo, Japan) 
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Anti-fibronectin (Cat No. MAB 1932, Merck Millipore, Darmstadt, Germany) 
Anti-heparan sulfate 10E4 antibody (Cat No.370255, Seikagaku Corporation, Tokyo, 
Japan) 
Anti-laminin  (Cat No. MAB 88918, Merck Millipore, Darmstadt, Germany)  
Anti-OCT-4 (Cat No. sc5279, Santa Cruz, USA)  
Anti-Tra1-60 (Cat No.MAB4360, Merck Millipore, Darmstadt, Germany)  
Anti-vitronectin (Cat No. MAB1945, Merck Millipore, Darmstadt, Germany) 
Chromogen DAB (Cat No. K400711, DAKO, Denmark) 
Desmin clone 33 (Cat. No. M076001, DAKO, Denmark) 
EnVision+ horse-radish peroxidase (HRP) anti-rabbit (Cat No. K4002, DAKO, 
Denmark)  
EnVision+HRP anti-mouse (Cat No. K4000, DAKO, Denmark)  
FITC-conjugated goat anti-mouse secondary antibody (Cat No. F0479, DAKO, 
Denmark) 
Goat anti-mouse biotinylated antibody (Cat No. ab 6788, Abcam, Cambridge, UK) 
HRP-conjugated goat anti-mouse Ig G (H+L) antibody (Cat No. 115-035-062, 
Jackson Immunoresearch laboratories Inc, PA, USA) 
Mouse IgG2 isotype control (Cat No. X0943, DAKO, Denmark) 
Mouse IgM isotype control (Cat No. X0942, DAKO, Denmark) 
Polyclonal rabbit anti-cytokeratin (Cat No. Z0622, DAKO, Denmark)  
Rabbit anti-Glial fibrillary acidic protein (GFAP) (Cat. No. Z033401, DAKO, 
Denmark) 
SlowFade Gold anti-fade reagent with DAPI (Cat No. S36938, Invitrogen, Life 
Technologies Corporation, CA, USA) 
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Cell lines 
 
H1 and H7 hESCs from WiCell Research Institute, WI, USA. 
HES-3 hESCs from ES Cell International, Singapore, http://escellinternational.com),  
 
Media and solutions for cell culture 
 
0.25 % Trypsin-EDTA (Cat No. 25200, Invitrogen, Life Technologies Corporation, 
CA, USA) 
24-well non-TCPS plates (Cat No. 351147, Beckon Dickinson, Frankin Lakes, NJ.) 
24-well TCPS plates (Cat No. 142475, NUNC, Denmark) 
2-mercaptoethanol (Cat No. 21985-023, Invitrogen, Life Technologies Corporation, 
CA, USA) 
60 mm center-well organ culture (OCD) dishes (Cat No. 353037, Beckon Dickinson, 
Frankin Lakes, NJ.) 
96-well non-TCPS white-walled transparent bottom plates (Cat No. 265302, NUNC, 
Denmark) 
96-well TCPS plates (Cat No. 167008, NUNC, Denmark) 
96-well TCPS white-walled transparent bottom plates (Cat No. 3610, Corning) 
BD MatrigelTM (Cat No. 354234, Beckon Dickinson, Frankin Lakes, NJ.) 
Collagenase IV, (Cat No. 17104-019, Invitrogen, Life Technologies Corporation, 
CA, USA) 
DMEM high glucose (Cat. No.11960, Invitrogen, Life Technologies Corporation, CA, 
USA) 
DMEM/F12 (Cat No. 11039, Invitrogen, Life Technologies Corporation, CA, USA) 
Fetal bovine serum (FBS) (Cat No. 10270, Invitrogen, Life Technologies Corporation, 
CA, USA) 
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FGF-2 (Cat No. 13256-029, Invitrogen, Life Technologies Corporation, CA, USA) 
Fibronectin (Cat No. F2006 from Sigma Aldrich, MO, USA)  
Iscove’s Modified Dulbecco’s Medium (IMDM) (Cat No. 12440-046, Invitrogen, Life 
Technologies Corporation, CA, USA) 
Knock-out Dulbecco’s Modified Eagle’s medium (KO-DMEM) (Cat. No. 10829018, 
Invitrogen, Life Technologies Corporation, CA, USA) 
Knock-out serum replacer (Cat. No. 10828-028, Invitrogen, Life Technologies 
Corporation, CA, USA)  
Laminin (Cat No. AG56P, Merck Millipore, Darmstadt, Germany) 
L-glutamine (Cat No. 25030-081, Invitrogen, Life Technologies Corporation, CA, 
USA) 
mTeSRTM1 media (Cat No. 05850 from Stem Cell Technologies, BC, Canada)  
Nonessential amino acids (Cat No. 11140-050, Invitrogen, Life Technologies 
Corporation, CA, USA) 
Penicillin-Streptomycin (Cat. No. 15140, Invitrogen, Life Technologies Corporation, 
CA, USA) 
Phosphate buffered saline (PBS) (Cat No. 14190, Invitrogen, Life Technologies 
Corporation, CA, USA) 
Rock inhibitor (Y27632) (Cat. No. 688002, Merck Millipore, Darmstadt, Germany) 
Streptavidin (Cat No. Z02043, Genescript, NJ, USA)  
TrypLETM express (Cat No.12604-021, Invitrogen, Life Technologies Corporation, 
CA, USA)   
Vitronectin (Cat No. CC080, Merck Millipore, Darmstadt, Germany) 
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Preparation of media and solutions 
 
 
MEF culture media 
 
90 % (v/v) DMEM high glucose, 10% FBS, 2 mM L-glutamine, 25 Units/ml 




2 mg of mitomycin C powder dissolved in 2 ml of PBS to generate 1 mg/ml stock 




10 mM Tris, 0.1 % BSA, sterilize through 0.22 M filter and stored in 4 oC. 
 
Collagenase IV solution  
 
Prepare 500 g/ml of collagenase IV in KO-DMEM, 0.22 M sterile filter (Sartorius) 




85 % KO-DMEM and 15 % KO serum replacer supplemented with 1 mM L-
glutamine, 1 % nonessential amino acids, 0.1 mM 2-mercaptoethanol, 25 U/ml 
Penicillin, 25 g/ml streptomycin and 10 ng/ml FGF-2. 
 
mTeSRTM1 media preparation 
 
Thaw 5 x supplement and add into basal medium, 0.22 M sterile filter (Nalgene) and 
stored at 4 oC. 
 
Heparinase digestion buffer (Sigma) 
 
20 mM Tris-HCL, 50 mM NaCl, 4 mM CaCl2 and 0.01 % BSA, pH 7.5. 
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Heparinase digestion buffer (Iduron) 
 




MatrigelTM was thaw at 4 oC overnight and diluted (1:30) in cold KO-DMEM 
 
0.1 % gelatin-coated plates 
 
Weigh out 2.5 g gelatin from porcine skin Type A and dissolve in 25 ml MilliQ water, 
0.22 M sterile filter (Sartorius) and stored at 4 oC.  
 
Low salt affinity chromatography buffer 
 
20 mM phosphate buffer, 150 mM NaCl, pH 7.2 
 
High salt affinity chromatography buffer 
 
20 mM phosphate buffer, 1.5 M NaCl, pH 7.2 
 
0.1 M MES buffer 
 




30 ml 5 M NaCl, 66 ml 1.5 M Tris, 1ml Tween 20 and 990 ml MilliQ water 
 
1 x Transfer buffer 
 
For 1 L, add 24.22 g of Triza® base, 112.6 g glycine and top up with MilliQ water 
 
Standard assay buffer (SAB) 
 
100 mM NaCl, 50 mM NaAc, (v/v) 0.2 % Tween 20, pH 7.2 
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Defining a Threshold Surface Density of Vitronectin
for the Stable Expansion of Human Embryonic Stem Cells
Lynn Y.W. Yap, B.Sc.,1,2 Jian Li, Ph.D.,3 In Yee Phang, Ph.D.,3 Lay Ting Ong, M.Sc.,3
Jo’an Zhu-En Ow, B.Eng.,4 James C.H. Goh, Ph.D.,5 Victor Nurcombe, Ph.D.,1,6 Jonathan Hobley, Ph.D.,3
Andre B.H. Choo, Ph.D.,4 Steve K.W. Oh, Ph.D.,4 Simon M. Cool, Ph.D.,1,6 and William R. Birch, Ph.D.3
Current methodology for pluripotent human embryonic stem cells (hESCs) expansion relies on murine sarcoma
basement membrane substrates (Matrigel), which precludes the use of these cells in regenerative medicine. To
realize the clinical efficacy of hESCs and their derivatives, expansion of these cells in a defined system that is free
of animal components is required. This study reports the successful propagation of hESCs (HES-3 and H1) for
>20 passages on tissue culture-treated polystyrene plates, coated from 5 mg/mL of human plasma-purified
vitronectin (VN) solution. Cells maintain expression of pluripotent markers Tra1-60 and OCT-4 and are kar-
yotypically normal after 20 passages of continuous culture. In vitro and in vivo differentiation of hESC by
embryoid body formation and teratoma yielded cells from the ecto-, endo-, and mesoderm lineages. VN im-
mobilized on tissue culture polystyrene was characterized using a combination of X-ray photoemission spec-
troscopy, atomic force microscopy, and quantification of the VN surface density with a Bradford protein assay.
Ponceau S staining was used to measure VN adsorption and desorption kinetics. Tuning the VN surface density,
via the concentration of depositing solution, revealed a threshold surface density of 250 ng/cm2, which is
required for hESCs attachment, proliferation, and differentiation. Cell attachment and proliferation assays on
VN surface densities above this threshold show the substrate properties to be equally viable.
Introduction
Human embryonic stem cells (hESCs) are self-renewing,pluripotent cells. They are isolated from the inner cell
mass of blastocysts and have the ability to differentiate into
all three germ layers, thus holding the promise of applica-
tions in tissue repair and drug development.1 Early methods
of culturing hESCs relied on co-culture with inactivated
mouse embryonic fibroblasts (MEFs).1 This method, how-
ever, is not suitable for the development of clinical-grade
hESCs, partly due to the xenogenic risks it introduces.
Although human feeders have been reported to successfully
replace MEFs,2,3 these cells may carry-over during hESC
removal and thus adversely affect hESC purity.
Other than cell-based feeder layers, Matrigel, a gelati-
nous basement membrane extract secreted by mouse
Engelbreth-Holm-Swarm tumor cells and distributed by
Becton Dickinson Biosciences, is now routinely used as a
substrate for maintaining the pluripotency of cultured
hESCs. However, a medium conditioned by MEFs is usu-
ally used in combination with Matrigel to maintain plu-
ripotent hESCs. Matrigel is known to contain a diverse
number of factors that include laminin-111, entactin, he-
paran sulfate proteoglycans, and multiple growth factors.4
Importantly, in a move toward a more defined culture
platform, Hakala et al. recently compared the use of Ma-
trigel with different feeder-free hESC culture substrates
(biomaterials, human extracellular matrix [ECM] proteins,
and human and animal sera matrices) and reported that
Matrigel was superior in terms of the maximum passage
number attained, as well as hESC morphology and plu-
ripotent marker expression.5 Despite these advances in
feeder-free systems, the use of Matrigel is limited by batch
to batch variability, complex protein mixtures, and the
possibility of transferring nonhuman sialic acid, Neu5Gc, to
the hESCs.6 Neu5Gc is an immunogenic molecule and can
1Stem Cells and Tissue Repair Group, Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), Singapore,
Singapore.
2Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore, Singapore.
3Institute of Materials Research and Engineering, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
4Stem Cell Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
5Tissue Engineering Program, Department of Orthopedic Surgery, National University of Singapore, Singapore, Singapore.
6Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
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limit the industrial scale up of this technology for clinical
applications. These results have driven the exploration of
several routes to develop a defined system suitable for
culturing hESCs.
Defined model surfaces in the form of immobilized pep-
tide arrays have been used as substrates for hESC adhesion
and expansion.7,8 Although dilution is used to tune the
peptide surface density, the latter is not quantified or oth-
erwise measured. Rather, this study identifies a peptide
surface density threshold that promotes cell adhesion. Fur-
ther, the analysis of hESC pluripotency is limited to detecting
endogenous alkaline phosphatase and OCT-4, without ex-
amining karyotypic stability or differentiation potential of
the expanded hESCs. In a more recent study by Kolhar et al.,
immobilized cyclic arginine, glycine and asparigine (RGD)
peptide sequences where shown to promote hESCs attach-
ment and propagation.9 Using this platform, hESCs were
cultured for >10 passages, without adversely affecting kar-
yotypic stability or differentiation potential. Although an
estimate of peptide surface density (10–30 fmol/cm2) was
obtained from fluorescence measurements and enzyme-
linked immunosorbent assay, no direct quantification of the
peptide surface density or other surface characterization was
carried out.
Recent advances in synthetic surfaces by Melkoumian
et al. describe synthetic peptide-acrylate surfaces that are
able to sustain the propagation of pluripotent hESCs for
>20 passages in a xeno-free environment.10 This study de-
tects surface-immobilized peptides by fluorescence, and
while solution concentration is used to tune the conjugated
peptide surface density, the surface density was not re-
ported. Villa-Diaz et al. report the propagation of hESCs on
a fully synthetic polymer (without immobilized biomole-
cules) with tunable surface wettability and Young’s mod-
ulus.11 This surface successfully propagates H9 hESCs in
StemPro defined medium, but was not reported to be robust
across cell lines and with the mTeSR-defined cell culture
medium.
A further development of a defined hESC culture plat-
form was described by Ludwig et al., who reported that a
combination of human collagen IV, fibronectin, laminin,
and vitronectin (VN) was able to support several passages
of hESCs when combined with a xeno-free culture medium
(TeSR1).12 However, this platform relies on a combination
of four human matrix protein substrates that adds signifi-
cant cost to the scale-up of hESCs. Moreover, the cells were
found to be karyotypically abnormal,12 which may explain
their adaptation to this platform. In other approaches,
hESCs have been shown to propagate on separate matrices
of fibronectin, laminin, laminin-511, and VN,13–16 high-
lighting that a defined, scalable substrate on which to
propagate hESCs may be a realistic possibility. Also, in-
duced pluripotent stem cells (iPSC) have recently been
successfully propagated on plasma-purified VN,17 sug-
gesting that VN, of the various ECM proteins being inves-
tigated, may be universally applicable for the propagation
of pluripotent stem cells.
VN is an abundant glycoprotein that is found in the ECM.
It promotes cell adhesion and spreading, but inhibits the
complement pathway that can compromise hESC viability. It
is secreted as a single molecule (75 kDa),18 which may be
approximated by a cylinder with a radius of 30.3 0.6 A˚ and
a length of 110 A˚.19 Braam et al. reported the successful
culture for at least 10 passages of hESCs on 5mg/mL of re-
combinant VN and identified aVb5 integrin as VN recep-
tor.15 Rowland et al. also reported similar results with 10 mg/
mL of plasma-purified VN with iPSCs.17 However, neither of
these reports determined the threshold amount of VN nec-
essary for the long-term propagation of hESCs. As such,
there is a need to better characterize and quantify VN sub-
strates for hESC expansion so as to provide a defined plat-
form for the scale-up of stem cell cultures.20–22
In the present study, we adsorb VN onto tissue culture
polystyrene (TCPS) and determined the effect of VN surface
density on the adhesion, proliferation, and long-term main-
tenance of hESCs compared to Matrigel.12 This simplified
VN substrate also provided an opportunity to tune the rel-
evant surface properties for promoting hESC adhesion and
propagation. VN surface density was characterized by a
combination of Ponceau S staining, Bradford assay, X-ray
photoemission spectroscopy (XPS), and the physical rough-
ness of the surface determined by atomic force microscopy
(AFM). Although AFM has previously been used to study
VN adsorption on smooth mica surfaces,23 the present study
examined VN adsorbed to TCPS, a surface demonstrated to
be successful for the long-term propagation of hESCs.
We show that the bioresponse of cultured hESCs to ad-
sorbed VN correlates with VN surface density. Further, we
establish a minimum threshold of surface-bound VN that is
required for the maintenance of hESC pluripotency.
Materials and Methods
Biological response
Coating of TCPS with VN or Matrigel. A 5mg/mL
working solution of VN was prepared by diluting stock VN
solution (1mg/mL) (Millipore) with 1phosphate-buffered
saline (PBS). This solution (300 mL) was added into 60mm
center-well organ culture dishes (Becton Dickinson Bios-
ciences), which are made from TCPS. After overnight in-
cubation (15 h) at 48C, the VN-coated plates, referred to as
VN5, were rinsed once with PBS and then immediately used
for cell seeding. For surface characterization, the coated
TCPS substrates were rinsed twice in MilliQ water (Milli Q
Gradient A10; Millipore) and dried under a nitrogen flow.
Matrigel (Becton Dickinson Biosciences), used as a control
cell culture surface, was diluted in cold knock-out (KO)
Dulbecco’s modified Eagle’s medium (Invitrogen) at 1:30
ratio and allowed to coat TCPS overnight at 48C before
washing and cell seeding.
hESCs and matrices. HES-3 (46, XX) and H1 (46, XY)
cells were obtained from ES Cell International and WiCell,
respectively. They were cultured on Matrigel or VN-coated
culture dishes with conditioned medium (CM) from DE-
MEF24 or in mTeSR1 serum-free defined growth medium,
with bovine serum albumin (BSA) as the only animal-
derived component (Stem Cell Technologies) at 378C/5%
CO2. The CM used for culturing hESCs contained 85%
KO-Dulbecco’s modified Eagle’s medium and 15% KO
serum replacer, supplemented with 1mM L-glutamine, 1%
nonessential amino acids, 0.1mM 2-mercaptoethanol, 25U/
mL penicillin, 25 mg/mL streptomycin (Gibco), and 10 ng/
mL fibroblast growth factor-2 (Invitrogen). This medium was
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conditioned overnight on DE-MEF as described above,
sterilized with a 0.22mm filter, and again supplemented
with 10 ng/mL fibroblast growth factor-2 before adding
into hESCs culture. Cells were grown on the matrix for
7 days with a daily change of CM or mTeSR1. mTeSR1
medium was prepared according to the manufacturer’s
instructions.
hESC cultures were passaged following Choo et al.3
Briefly, cells grown on Matrigel were treated with collage-
nase IV (200U/mL) for 5min at 378C and differentiated
cells removed by pipetting. Cells were then dissociated into
small clumps by scraping and repeated pipetting. Har-
vested cells were split at 1:4 ratio and seeded into fresh
Matrigel-coated tissue culture dishes. For cells grown on
VN, mechanical passaging was employed. Colonies that
appeared differentiated were removed by manual pipetting
and the remaining cells scraped into small clumps. Cells
were then seeded into freshly coated VN culture dishes at a
1:6 passage ratio.
Fluorescence-activated cell sorting analysis. Flow cyto-
metry was performed with the cell surface marker Tra1-60
and transcription factor OCT-4 with an appropriate isotype
control for hESCs grown on the various platforms. Cells
were first trypsinized with 0.25% trypsin/ethylenediamine-
tetraacetic acid to a single cell suspension and then fixed and
permeabilized with a Fix and Perm kit (Caltag Laboratories,
Invitrogen), used according to the manufacturer’s instruc-
tions. During the 15min permeabilization step, OCT-4 (1:20;
Santa Cruz) or Tra1-60 (1:50; Chemicon) mouse monoclonal
antibodies were incubated together with the kit’s Reagent B.
Cells were then washed with 1% BSA/PBS followed by
15min incubation in the dark with fluorescein iso-
thiocyanate-conjugated goat anti-mouse antibody at 1:500
dilution (Dako). Finally, cells were washed and resuspended
with 1% BSA in PBS for analysis on a fluorescence-activated
cell sorting (FACS) Calibur (Becton-Dickinson). Results were
analyzed with FlowJo software, with gating selected at the
point of intersection between the marker and isotype control
curves.25
Adhesion assay. Flat-bottom 96-well TCPS plates
(Thermo Fisher Scientific) were coated with VN solutions at
concentrations of 0, 2.5, 5, 10, 15, and 20 mg/mL, as described
above, yielding VN coated TCPS surfaces that are referred to
as VN0, VN2.5, VN5, VN10, and VN20, respectively, (in
triplicates). The wells were then blocked with 2% BSA (1 h,
208C) and a single cell suspension of HES-3 cells (3105 per
well), dissociated with TrypLE (Invitrogen), was seeded
into the wells. The cells were incubated for 45min at 378C/
5% CO2. TCPS substrates coated from the same VN solution
and similarly blocked were used as blanks. After 45min, the
wells were washed three times with Iscove’s modified Dul-
becco’s medium (Invitrogen), supplemented with 0.35%
BSA, and then rinsed once with PBS to remove nonadherent
cells. Cells on TCPS were fixed with 100% ethanol for 5min
and stained with 0.4% crystal violet in methanol for another
5min at room temperature. Cells were then washed with
deionized water three times, followed by the addition of
40 mL of 1% sodium dodecyl sulfate to solubilize the dye. The
plates were left on an orbital shaker until a uniform color in
the well was observed. Cell adhesion was determined by
measuring the optical density at 570 nm with results nor-
malized to Matrigel (100%).
Cell growth. A solution containing 3105 cells was used
to seed the TCPS surface of organ culture dishes, coated
with different concentrations of VN (VN0, VN2.5, VN5, and
VN10), in triplicates. Cells were counted on days 1 and 7.
Briefly, cultures were washed with 1 PBS and cells disso-
ciated with 0.25% trypsin/ethylenediaminetetraacetic acid
(Invitrogen). The total cell number was determined using a
nucleocounter NC-100 (ChemoMetec).
In vitro differentiation assay (embryoid body formation)
and reverse transcribed-polymerase chain reaction analy-
sis. To determine whether HES-3 cells cultured on VN
with mTeSR1 media retain their ability to differentiate into
the three germ layers, confluent HES-3 cells grown on VN
were removed using a cell scraper to form random-sized
embryoid bodies (EBs). These were grown in suspension for
7 days and replated on 0.1% gelatinized plates for 14 days
with a media change every 2 days. Total ribonucleic acid
(RNA) was extracted from EBs after 21 days culture using
an RNA extraction kit (Qiagen) in accordance with the
manufacturer’s instructions. Purity and concentration of
RNA was quantified using an ND-1000 Spectrophotometer
(Nanodrop Technologies). The RNA was reverse tran-
scribed with polymerase chain reaction (RT-PCR) using
oligo dT primers and superscript II reverse transcriptase
(Promega) into complementary DNA. PCR (Biorad) was
carried out with primers specific to the three germ layers.
The endodermal lineage was represented by alpha-feto
protein (AFP), the mesodermal lineage by Msh homeobox
1, heart- and neural crest derivatives-expressed protein 1
(MSX1), and the ectoderm lineage by neurofilament heavy
chain (NFH). OCT-4 (undifferentiated marker) and GAPDH
(house keeping gene) were used as controls (Table 1). In
parallel, RNA was harvested from undifferentiated HES-3
cells for comparison to differentiated cells. The amplified
products were observed with ethidium bromide-stained 1%
agarose gels.
In vivo differentiation assay (teratoma analysis). To
confirm the pluripotentiality of hESCs cultured on the vari-
ous substrates, an intramuscular injection of cells was given
to SCID mice and the formation of tumors determined 10
weeks post injection. Briefly, HES-3 cells cultured on VN for
18 passages with either CM or mTeSR1 media were har-
vested by trypsin, and an intramuscular injection (hamstring
muscle) of 5106 cells in 50 mL of sterile PBS was delivered to
4-week-old female SCID mice with a sterile 22G needle. After
10 weeks, mice were sacrificed and the tumors dissected,
fixed in 10% formalin, embedded in paraffin, and then sec-
tioned and stained with hematoxylin and eosin (H&E). The
presence of germ layers (ectoderm, mesoderm, and endo-
derm) in the tumors was assessed by immunohistochemistry,
using the primary antibodies: polyclonal rabbit anti-
cytokeratin (1:250), Desmin Clone 33 (1:100), and Rabbit anti-
glial fibrillary acidic protein (GFAP) (1:250) (Dako) with
matching undiluted secondary antibodies: EnVisionþHRP
anti-rabbit and EnVisionþHRP anti-mouse (Dako). Sections
were then incubated with Chromogen DAB (Dako) and
counter stained with hematoxylin.
THRESHOLD VITRONECTIN SURFACE DENSITY FOR HESC EXPANSION 195
Karyotypic stability. To assess chromosomal stability of
hESCs cultured on VN for more than five passages, kar-
yotyping of 20 colonies using BrdU/colcemid was per-
formed by the Cytogenetics Laboratories at the Department
of Obstetrics and Gynaecology, Kandang Kerbau Women’s
and Children’s Hospital, Singapore.
Surface characterization
Adsorption and desorption kinetics were measured by
Ponceau S staining. VN-coated organ culture dishes: VN0,
VN2.5, VN5, VN10, and VN20, prepared as described above for
the cell culture substrates, were exposed to Ponceau S staining
solution (Sigma-Aldrich) for 15 h at room temperature.26,27
After three rinses in water and blow-drying, 400mL of 0.1M
NaOH (Goodrich Chemical Enterprise) were added to each
TCPS substrate. The samples were then shaken gently for
20min, allowing desorption of bound Ponceau S stain from
the sample surface.27 TCPS samples were run in triplicates,
yielding six 200 mL aliquots per VN concentration. Each ali-
quot was placed in a flat-bottom 96-well plate and neutral-
ized with 15 mL of 50% acetic acid ( J.T. Baker). Colorimetric
adsorption was measured at 515 nm on an Infinite 200
Multimode Microplate Reader (Tecan). This was compared
with a standard curve generated using Ponceau S concen-
trations ranging from 0 to 10 mg/mL in 5% (w/v) acetic acid.
The Ponceau S solution density was converted into molarity,
which was used to calculate density of stain adsorbed to
TCPS-immobilized VN. Ponceau S staining was similarly
used to determine VN adsorption kinetics at 48C, where
TCPS samples were incubated with 5 mg/mL VN for differ-
ent times. For VN desorption, TCPS samples were coated
with 5 mg/mL VN solution overnight (15 h) at 48C. Samples
were then rinsed once with water and blow-dried. They were
then incubated with 1mL of PBS at 378C at different times
and subsequently stained with Ponceau S, as described
above.
Quantification of VN adsorbed on TCPS by Bradford
assay. VN adsorbed to TCPS was quantified by its de-
pletion from the depositing solution by using a modified
Bradford assay28,29 to measure the VN concentration in PBS
before and after coating of TCPS. Dye reagent was prepared
according to Bradford28 and TCPS substrates were incu-
bated with VN solutions at concentrations of 0, 5, 10, 15,
and 20 mg/mL for 15 h at 48C, as described above. After
coating, 100 mL VN in PBS supernatant from triplicate
samples for each concentration were combined into one
1.5mL glass vial and 1.2mL of Bradford dye reagent solu-
tion was added. The contents were mixed for 5min and six
200 mL aliquots of each solution were then pipetted into a
flat-bottom 96-well plate to measure their absorbance at
590 nm (A590) and 450 nm (A450) on a Tecan plate reader.
This process was carried out within 10–20min, to minimize
nonspecific adsorption of VN during handling of the pro-
tein solution. For each well, the A590/A450 ratio mitigates
fluctuations arising from differences in solution volume.
This was normalized by subtracting the average A590/
A450 value for PBS (0 mg/mL).29 An assay of VN solutions
with concentrations of 0, 5, 10, 15, and 20 mg/mL was used
to plot the standard curve of A590/A450 versus VN con-
centrations. The VN solution concentrations before TCPS
coating were taken as 0, 5, 10, 15, and 20 mg/mL. The A590/
A450 values obtained from VN solutions used to coat TCPS
were compared with the standard curve, yielding the de-
pletion in VN solution concentration. These values were
then used to calculate VN adsorbed to TCPS and its corre-
sponding surface density. For the latter, the coated surface
area of the 60mm center-well organ culture dishes was
estimated at 3.5 cm2, which includes the base and a rim
extending 1.5mm above it.
XPS measurements. VN0, VN2.5, VN5, VN10, and
VN20 were prepared as described above. Their surface che-
mical composition was determined using a Theta Probe X-
ray photoelectron spectrometer (Thermo Fisher Scientific),
equipped with an aluminium anode (15 kV, 100W), and a
quartz monochromator. The latter was set to a 508 take-off
angle, measured from the normal to the plane of the sample
surface, yielding a probing depth of *5 nm. Detailed scans
of the N1s, O1s, and C1s peaks were performed on each
sample, taking data from a 400mm2 spot and using a pass
energy of 40 eV. Detailed scans were repeated as follows: 20
times for C1s, 15 times for O1s, and 20 times for N1s. A wide
scan (binding energy from 0 to 1300 eV) was then performed
with pass energy of 200 eV. Peaks were fitted with a mixed
Lorentz-Gaussian function. Deconvolution of the C1s signal
reveals five peaks: aromatic C (284.8–284.9 eV), C-C (285 eV),
C-NH2 (285.5–286.0 eV), C-O (287.6–288.4 eV), and C¼O
(287.6–288.4 eV).
AFM measurements. Surface topography was assessed
by AFM profilometry, as a measure of the hESC responses to
VN-coated TCPS. Bare TCPS and VN0, VN2.5, VN5, VN10,
and VN20 were measured after blow-drying in ambient
conditions using a Bioscope I microscope equipped with a
NanoScope IIIa controller and a low noise scanner (Digital
Instruments; Veeco Metrology Group). PointProbe Plus
Table 1. Primer Sequences for Reverse Transcribed Polymerase Chain Reaction
Target
gene Ascension no. Forward (50–30) Reverse (50–30)
Size
(bp)
AFP NM_001134 AAA TGC GTT TCT CGT TGC CAG CCT CAA GTT GTT CCT CT 428
MSX1 NM_002448 CCT TCC CTT TAA CCC TCA CAC CCG ATT TCT CTG CGC TTT TC 287
NFH NM_021076 TGA ACA CAG ACG CTA TGC GCT CAG CAC CTT TAT GTG AGT GGA CAC AGA 398
HAND1 NM_004821 TGC CTG AGA AAG AGA ACC AG ATG GCA GGA TGA ACA AAC AC 274
Nanog NM_024865 ACC AGA ACT GTG TTC TCT TCC ACC GGT TGC TCC AGG TTG AAT TGT TCC 330
OCT-4 NM_002701 CGR GAA GCT GGA GAA GGA GAA GCT G AAG GGC CGC AGC TTA CAC ATG TTC 242
GAPDH NM_002046 TGG TAT CGT GGA AGG ACT CA CCT GCT TCA CCA CCT TCT TG 250
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noncontact high resonance frequency (PPP-NCH) silicon
cantilevers (Nanosensors) were used for intermittent-contact
(also known as tapping) mode operation to obtain high-
resolution images of the samples. Scan rates ranged from
0.75 to 1Hz, and free amplitude (A0) setpoint values were
*1.6V. Images of the TCPS surface morphology and the
corresponding VN-coated surfaces were taken at 85%–90%
of the free amplitude. Roughness analysis was performed by
Nanoscope software version v5.12rb. Briefly, two-dimen-
sional AFM height maps can be used to determine the
arithmetic roughness (Ra) of the bare and VN-coated TCPS
surfaces. The arithmetic roughness, Ra, describes the absolute
FIG. 1. Characterization of HES-3 and H1 cells cultured on VN5 in either conditioned medium (CM) or mTeSR1 medium at
passage 15. (A) Representative pictures after 1 week of culture; cells retained the typical stem cells morphology and (B)
fluorescence-activated cell sorting analysis of Tra1-60 surface marker and cells were grown on Matrigel as a positive control.
Shaded bar represents isotype control expression and unshaded bar represents Tral-60 marker expression. Both cell lines
expressed >90% positive for Tra1-60 markers, demonstrating that cells are able to adapt to VN coating.
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value of the surface height, measured relative to a two-di-
mensional plane, set at the average sample height. Ra was
calculated from the entire (44mm) image or several smaller
areas (22mm) within the image. Phase data records varia-
tions in the cantilever oscillation, reflecting changes in sur-
face rigidity and viscoelasticity. This was used to improve
the contrast between adsorbed VN aggregates and the TCPS
substrate surface. Bearing analysis was carried out using
Nanoscope software version v5.12rb.
Colloidal gold staining of VN adsorbed to TCPS. To
evaluate the uniformity of VN adsorbed to TCPS over length
scales of mm–cm, the surface-bound protein was detected by
the Colloidal Gold Total Protein Stain (Bio-Rad). VN0,
VN2.5, VN5, VN10, and VN20 were prepared as described
above. After rinsing and blow-drying, the surfaces were in-
cubated overnight in Colloidal Gold stain at room tempera-
ture. They were then rinsed with water, blow-dried, and
photographed.
Statistical analysis. Data values are reported as a mean
and a standard deviation. Graphs were plotted and data
were transformed using Sigmaplot software. One-way
analysis of variance was applied to compare differences
across the groups and p< 0.05 was considered as significant.
Results
Stable expansion and analysis of HES-3
and H1 cells cultured on VN5
The development of a defined matrix to support long-term
hESC expansion is important for potential therapeutic
applications. To determine whether VN is a suitable sub-
strate, HES-3 and H1 cells were cultured for >10 passages
on VN5 in either CM or mTeSR1 media. Cells grown on
Matrigel in CM served as a positive control. Images of cells
cultured at passage 15 showed that both hESC lines re-
tained an undifferentiated morphology that was character-
ized by the formation of compact colonies with distinct
boundaries and a high nucleus to cytoplasmic ratio (Fig.
1A). Cells cultured with mTeSR1 appeared to have less
distinct boundaries as compared to cells cultured in CM.
However, this difference was not reflected in the expression
level of the pluripotent marker Tra1-60 (Fig. 1B) and OCT-4,
with >90% positive expression after 12 passages (Table 2).
Quantitative RT-PCR of HES-3 cells cultured on VN5 and
Matrigel at passage 20 revealed similar levels of Nanog and
OCT-4mRNA expression, which confirms their pluripo-
tency (Supplementary Fig. S1 and Supplementary Table S1,
available online at www.liebertonline.com). The population
doubling time of HES-3 cells was assessed from the expo-
nential region of a growth curve, measured over 7 days
(Supplementary Fig. S2, available online at www.liebert
online.com). Refer to supplemental materials and methods
section for the description of quantitative PCR and popu-
lation doubling time analysis. Results show that the
doubling times are 32 and 25 h for VN5 and Matrigel,
respectively.
Karyotype analysis was performed on HES-3 (46, XX) at
passage 9 and H1 (46, XY) at passage 5 from the VN5 in
mTeSR1 platform and the cells were found to be of a normal
diploid karyotype (Fig. 2A). Moreover, FACS and karyotype
analyses were also repeated on passage 30 hESC, with >90%
of the cells continuing to express Tra1-60 and OCT-4 with a
normal diploid karyotype (data not shown).
A robust tri-germ layer differentiation potential is also a
hallmark of pluripotent hESCs. After VN propagation for 25
passages, HES-3 cells were induced to differentiate through
EBs and the presence of ectoderm, mesoderm, and endoderm
probed by PCR (Fig. 2B). After 21 days of differentiation,
HES-3 express the mRNA transcripts for AFP (endoderm),
NFH (ectoderm), and MSX1 (mesoderm) that are absent in
undifferentiated cells (Fig. 2B). As expected, expression of
the pluripotent markers Nanog and OCT-4 were suppressed
when the cells were induced to differentiate.
As a final test of pluripotency, the tumorgenicity of HES-3
was investigated in vivo. When cultured on VN5 for 18 pas-
sages in mTeSR1medium and then injected into the muscle of
SCID mice, a teratoma formed contained structures from all
three germ layers, as determined by H&E and immunohis-
tochemical staining (Fig. 2C, D). Ectoderm (neural epithelium
and pigmented epithelium), mesoderm (bone and cartilage),
and endoderm (gut epithelium) were clearly visible by H&E.
Similarly, the presence of GFAP-positive intermediate fila-
ments (ectoderm), desmin-positive muscle (mesoderm), and
cytokeratin-positive epithelium (endoderm) was confirmed
by immunohistochemistry.
Taken together, these data suggest that VN5 com-
bined with mTeSR1 medium is able to support the long-
term propagation of undifferentiated, pluripotent hESCs.
Notably, similar results were also found for induced plu-
ripotent stem cell (IMR90) that could be readily propagated
on VN5 mTeSR1 medium for over five passages (data not
shown).
Table 2. Tra1-60 and OCT-4 Marker Expression for HES-3 on VN5
Tra1-60 OCT-4
Passage Matrigel/CM VN/CM VN/mTeSR1 Matrigel/CM VN/CM VN/mTeSR1
P2 91.0 96.0 97.0 93.8 93.5 96.3
P4 98.9 93.0 98.0 89.8 90.7 91.9
P6 94.2 98.0 95.2 98.8 93.0 95.9
P8 95.0 99.2 98.6 89.4 97.4 92.7
P10 96.0 97.6 97.0 95.3 96.6 96.2
P12 94.0 98.3 99.0 97.1 93.4 95.3
Cells maintain >90% positive for both markers expression for 12 passages.
CM, conditioned medium; VN, vitronectin.
198 YAP ET AL.
Short-term biological response to different
VN surface density
Having established a defined condition for hESC culture,
we sought to assess the variation in bioresponse arising from
changes in the VN surface density. Several VN solution
concentrations were used to coat TCPS by overnight incu-
bation at 48C. Cell attachment on these surfaces was com-
pared across a range of VN densities in CM and mTeSR1
media (Fig. 3A). For all VN surface densities, cells attach in a
VN density-dependent manner, with the highest number of
attached cells resulting from the highest VN density. Notably,
in CM, the cell density plateaus at concentrations above
1.25mg/mL, with approximately two- to four-fold more cells
attached in the presence of mTeSR1 as compared to CM.
As significant differences in cell attachment to VN-coated
TCPS were observed over a 45min period, we next chose to
examine hESC attachment and proliferation at 1 and 7 days
FIG. 2. HES-3 and H1 cells cultured on VN5 with mTeSR1 media were analyzed by karyotyping, embryoid body (EB)
differentiation, and teratoma assay. (A) No chromosomal abnormality was observed in passage 9 and 5 of HES-3 and H1
cells, respectively, and they retained the normal diploid, 46, XY and 46, XX karyotype. (B) Reverse transcribed polymerase
chain reaction analysis of EB-differentiated passage 25 HES-3 cells showed expression of alpha-feto protein (AFP) (endo-
derm), MSX1 (mesoderm), and neurofilament heavy chain (NFH) (ectoderm) genes from the three germ layers that were
previously absent in the undifferentiated cells. OCT-4 marker diminished after 21 days of differentiation and GAPDH as
house keeping gene. (C) Passage 18 HES-3 cells were injected intramuscularly into the rear limbs of SCID mice. Tissues
representing the three germ layers were observed with hematoxylin and eosin staining. Neural epithelium (marked with
arrows) and pigmented epithelium representing ectoderm lineage; bone and cartilage representing mesoderm lineage and
gut epithelium representing endoderm lineage. (D) Teratoma was also stained with antibody for GFAP (ectoderm), desmin
(mesoderm), and cytokeratin (endoderm). Scale bar¼ 100 mm. Color images available online at www.liebertonline.com/ten.
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(Fig. 3B, C). In contrast to the 45min assay, at day 1 no
differences in cell number were observed for both media
treatments. There was, however, a similar VN density-effect
between 45min and 1 day with approximately threefold
more cells in the VN2.5 condition, when compared to
VN1.25. Notably, when hESCs were cultured for 7 days at
various VN densities, VN2.5 was required for maximum
proliferation; however, significant growth differences were
observed between CM and mTeSR1 media, with mTeSR1
significantly outperforming CM (*30%).
The VN density threshold of 2.5mg/mL, capable of sup-
porting hESC attachment and expansion, was also evident
from photomicrographs taken after 1 week in culture (Fig. 3D).
Cells cultured on VN2.5 had the typical mosaic/cobblestone
appearance of confluent hESC, as compared to cells cultured
<VN2.5 that were sparsely attached and failed to grow.
Long-term biological response to different
VN surface densities
To fully evaluate the threshold VN surface density suit-
able for the long-term maintenance of pluripotent hESC,
HES-3 cells were cultured for greater than five passages in
mTeSR1 media. Pluripotency was then assessed by FACS,
EB differentiation, and teratoma formation. Initially, cells
cultured on VN1.25, VN2.5, and VN5 underwent a period
of adaptation,27,28 which was reflected by decreased ex-
pression of pluripotent markers at passage 1 (Table 3). After
subsequent passaging, cultures at passage 2–6 were >90%
positive for Tra1-60 and OCT-4 (Fig. 4A and Table 2). These
levels were similar to those observed for cells maintained
on Matrigel.
Differentiation was then assessed by RT-PCR for germline
markers in EBs. Cells cultured on VN1.25 failed to expand
sufficiently for differentiation assays and were not analyzed
further by either EB or teratoma formation. However, cells
readily expanded on VN2.5, with differentiation assays
showing the presence of mRNA transcripts for AFP (endo-
derm), Hand1 (mesoderm), and NFH (ectoderm) and the
absence of Nanog and OCT-4 genes (Fig. 4B). Importantly,
despite their in vitro differentiation potential, cells cultured
on VN2.5 failed to form a teratoma when transplanted into
the muscle pouch of a SCID mouse (data not shown). As
previously shown in Figures 1 and 2, cells cultured on VN5
FIG. 3. Short-term adhesion assay on different VN-coated TCPS with HES-3 cells. (A) Forty-five minutes of adhesion assay
were done with HES-3 either with CM or mTeSR1. Cell numbers were normalized to cell adhering to Matrigel surface (taken as
100%), as represented by the dashed line. *p< 0.05. (B) About 3105 cells were seeded and a cell count was performed at day 1
after seeding; number of cells attached to <VN1.25 was insignificant as compared to the rest of the conditions. (C) After 1 week
of culture, cell number was similar in VN2.5, VN5, and VN10, but the number of cells from VN1.25 was significantly lower than
the rest. Cultures from VN1.25 did not reach confluence at day 7. *p< 0.05, cells cultured on CM and mTeSR1 media have
significant differences. **p< 0.001, significant differences between cultures from VN1.25 and VN2.5. Data are expressed as
mean standard deviation (n¼ 3). (D) Day 7 representative pictures of HES-3 cells on TCPS coated with different VN con-
centration. VN1.25 did not support robust cell expansion as well as the rest; culture did not reach confluence at day 7.
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maintained all the hESC characteristics of growth, differen-
tiation, and teratoma formation. Further, hESC culture on
VN1.25 and VN2.5 maintained normal karyotypes over five
passages (Fig. 4C, D).
Surface characterization
Results from both the Bradford protein assay and Ponceau
S staining (Fig. 5A and Fig. 5B, respectively) show similar
trends for the adsorbed VN surface density versus the de-
positing solution concentration: a steady increase in surface-
adsorbed VN with increasing solution concentration that
reaches a plateau for >VN10. Adsorption and desorption
kinetics (Fig. 5C, D) were modeled using an exponential time
dependence. Modeling the data with an exponential in the
square root of time, as proposed by Granick,30–32 does not
improve the fit. The associated fitting parameters (Table 4)
indicate an adsorption time constant of *1 h and a desorp-
tion time constant of *4 h. The latter may not accurately
represent surface depletion in actual cell culture conditions,
where VN desorption is influenced by competing adsorption
from other proteins. The y0 parameter physically represents
the VN protein that remains bound to TCPS after a desorp-
tion time of 2 days, and Figure 5D shows that only about
25% of the adsorbed VN is desorbed from the TCPS substrate
after 48 h exposure to PBS. While 75% of VN adsorbed to
TCPS after 2 days may arise from VN re-adsorbed from the
PBS solution, this is mostly attributed to VN remaining du-
rably bound to the TCPS substrate.
XPS detects the surface chemical composition of VN-
coated TCPS, with data showing the presence of nitrogen,
C-NH2, C-O, and C¼O bonds (Fig. 6A). The increasing
signal from N and O atoms with depositing solution con-
centration indicates a monotonic increase in VN surface
density, which reaches saturation for depositing solution
concentrations >VN10, reproduces the same trend as ob-
served with Ponceau S surface staining and Bradford quan-
tification of the surface-adsorbed protein (Fig. 5A, B) and
independently confirming the dependence of surface-ad-
sorbed VN on depositing solution concentration.
AFM height images depict surface profilometry of the cell
culture substrate. Bare TCPS shows an intrinsic, structured
surface roughness, consisting of random line features that are
presumably introduced by the tissue culture plates’ manu-
facturing process. These substrate features are observed
across all samples, from bare to TCPS coated from 0, 2.5, 5,
10, and 20 mg/mL VN (Fig. 6B–G), The TCPS morphology
remains unchanged after exposure to PBS solution alone,
implying that the features associated with VN aggregates, as
observed on VN2.5, VN5, or VN10, are not an artefact gen-
erated by the exposure of TCPS to PBS solution (Fig. 6C). The
surface roughness, Ra, of the bare TCPS substrates was
found to range from 2.7 to 3.2 nm. Deposited VN aggregates,
in the form of spot-like features, are visible on VN2.5 to
VN10 (Fig. 6D–F). AFM phase images offer an enhanced
contrast, improving the visibility of adsorbed VN aggregates,
as seen on VN2.5 (Fig. 6I). A higher magnification of a se-
lected area in Figure 6I (VN2.5) is shown in Figure 6J. The
absence of spot-like features, associated with VN aggregates,
on the AFM phase image of bare TCPS (Fig. 6H) confirms
that these arise from adsorbed VN. Adsorbed VN aggregates
did not significantly increase the Ra value for coated samples
beyond the range quoted above. Finally, the AFM profilo-
metry of VN20 shows a loss in resolution, whose physical
origin remains unexplained.
Colloidal gold staining confirms that the surface density of
adsorbed VN increases with concentration of the depositing
solution (Fig. 6K–P). The sample shown in Figure 6K is in-
distinguishable from the bare TCPS. This demonstrates the
absence of colloidal gold staining on a substrate uncoated
with VN. As the depositing VN solution concentration is
increased, the samples shown in Figure 6L do not show any
stain, whereas Figure 6M, which shows samples coated with
5mg/mL VN solution, shows a barely discernible stain.
Figure 6N–P, which shows samples from VN10, VN15, and
VN20, respectively, shows a discernible and increasing col-
loidal gold stain, whose uniformity indicates that VN ad-
sorbed to the surface of TCPS is homogeneous, when
averaged over length scales ranging from hundreds of mi-
crons to millimeters.
Bearing analysis integrates the height measured by AFM
profilometry over a two-dimensional map of the sample
surface. This may be used to calculate the volume under the
sample surface and thus derive an estimate of the protein
volume required to coat 95% of the surface features.33,34 The
volume required to fill in the TCPS surface roughness,
leaving only 5%, by area, of its highest features exposed was
calculated to be 0.22 mm3 from a typical region of bare TCPS.
Projecting this volume into a film over a two-dimensional
area of 16mm2, this corresponds to an average coating
thickness of 14 nm or a VN surface density of 1.7 mg/cm2
(assuming VN protein density as 1.2 g/cm3).35
Quantification of surface-adsorbed VN
Surface-adsorbed VN is quantified by measuring the de-
pletion of the depositing solution concentration. Completing
Bradford assay measurement of protein solution concentra-
tion within 10–20min, which is an order of magnitude
smaller than the several hours required to saturate nonspe-
cific adsorption of VN on TCPS (Fig. 5C), effectively mini-
mized losses of VN by nonspecific adsorption. This
measurement estimates the surface density of VN deposited
solutions of VN ranging from 5 to 20 mg/mL. These solution
concentrations resulted in surface-adsorbed VN of 250 ng/
cm2 (VN5) to 500 ng/cm2 (VN20), respectively (Fig. 5A).
Analysis of the bioresponse indicates that hESCs do not at-
tach on <VN2.5 and (Fig. 3C, D) and long-term proliferation
is not supported on <VN5. Thus, the minimum threshold
Table 3. Tra1-60 and OCT-4 Marker Expression
for HES-3 Cells Cultured on VN1.25, VN2.5, or VN5
Tra1-60 OCT-4
VN (mg/mL) 1.25 2.5 5 1.25 2.5 5
P1 85.0 83.2 89.3 90.0 76.6 89.0
P2 95.0 95.7 93.4 96.0 91.6 86.2
P3 94.7 99.6 99.7 90.0 92.9 95.7
P4 96.0 98.0 99.3 93.0 92.0 96.0
P5 99.4 99.5 99.8 96.4 96.0 93.1
P6 99.4 99.6 97.3 91.2 95.1 89.0
Cells maintained high levels of expression for 6 weeks.
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VN surface density, which is required for the long-term
propagation of hESCs, is estimated at 250 ng/cm2 (VN5).
Experimental data in Figure 5A allow a simple calcula-
tion of VN depletion from the depositing solution. From the
surface density of VN adsorbed to TCPS, the reduction in
solution concentration may be deduced. Given that 300 mL
of 5 mg/mL solution contains 1.5 mg of VN and that 250 ng/
cm2 of surface-adsorbed VN on 3.5 cm2 of TCPS is 0.88 mg,
*50% of VN in the solution is deposited onto TCPS. This is
the case for VN solution concentrations up to 10 mg/mL. For
higher VN concentrations, the lack of an increase in surface-
adsorbed VN reduces its depletion in solution. For an initial
solution concentration of 20 mg/mL, the final solution con-
centration after VN is deposited on TCPS is *15 mg/mL, or
75% of the initial solution concentration. The staining uni-
formity of surface-adsorbed VN and AFM data indicate that
this may be effectively considered as an average surface
density, over length scales larger than tens of microns.
Discussion
Recent studies have demonstrated the ability of VN to
support hESCs propagation, but they lack details concerning
the characterization and quantification of VN on the culture
surfaces.15,17 In this study, we varied the concentration of VN
in solution and determined the amount that adsorbed to
TCPS with a view to developing a quantifiable platform on
which to expand pluripotent hESC over multiple passages,
and in a stable manner.
We showed that a threshold VN surface density of at least
250 ng/cm2 (VN5) is required for the long-term expansion
(>30 passages) of pluripotent hESCs in a serum-free defined
medium (mTeSR1). Cells cultured at this VN threshold had
sustained expression of Tra1-60 and OCT-4 at levels above
90%. The population doubling time for HES-3 cultured on
VN5 is 32 h. For the same cells cultured on Matrigel, the
doubling time is 25 h. These differences in cell growth rates
are not associated with a loss in pluripotency for hESCs
cultured on VN surfaces. They also retained the potential to
differentiate to the three germ layers through EBs and readily
formed teratomas when transplanted into the muscle pouch
of SCID mice. Importantly, the cells had a normal diploid
karyotype and they maintained a compact morphology. At
VN surface densities below 250ng/cm2 cell attachment and
proliferation were compromised and the cells failed to dif-
ferentiate in EBs and were unable to develop teratomas
in vivo.
Noteworthy is the finding that only 50% of the VN dis-
solved in PBS was able to adsorb to TCPS from VN solution
concentrations 10mg/mL. As the VN surface saturates, this
waste increases, reaching *75% from the higher initial so-
lution concentration of 20 mg/mL. These findings may serve
as process parameters, forming the basis of a scale-up system
for hESCs, with a fully quantifiable, chemically defined cul-
ture conditions.
We also observed that hESCs cultured in mTeSR media
achieved higher cell numbers after 1 week in culture than
cells grown in CM. This observation was supported by Chin
et al., who reported that a defined medium such as mTeSR1
reduces the doubling time of hESCs to *21 h, as compared
to cells cultured in CM that require 28 h.36 Another inter-
esting observation was the absence of in vivo teratoma from
the transplanted cells when cultured on VN2.5 with mTeSR1
media.
Previous studies by Braam et al. reported that VN ad-
sorbed to TCPS from a solution containing 5mg/mL is able to
support hESC cultures and in another study, Rowland et al.
coated TCPS with 10 mg/mL of human-plasma-purified VN
for the culture of iPSCs (IMR90).15,17 In both cases no surface
characterization was performed to quantify the amount of
VN bound to the surface. By comparison, in the present
study we show that a VN threshold surface density of
250 ng/cm2 (VN5) can be used as a xeno-free substrate for
hESC culture. Although VN used in this study was purified
from human plasma, this would serve as a bench mark for
studies done with human recombinant VN in the future.
More recently, Manton et al. demonstrated that a chimeric
VN:insulin-like growth factor 1 complex when added into
serum-free media could maintain pluripotent hESCs; how-
ever, in this study hESCs were cultured on a substrate of
murine laminin that does not fulfill the requirements for a
xeno-free culture platform.37
VN is known to synergize with numerous growth factors
to maintain both embryonic and adult stem cells in an un-
differentiated state.38,39 Indeed, notable differences in the
mitotic rate between embryonic and adult stem cells have
been reported.40 As such, there is a clear need to better un-
derstand the cellular context underlying hESC culture. An
interesting aspect that merits further exploration is how ECM
and growth factor signaling pathways interact in maintain-
ing stem cell pluripotency.
Our characterization studies demonstrate that the long-
term, stable propagation of hESCs is possible with VN5 and
that this defined surface is a viable alternative to Matrigel.
The threshold surface density is estimated at 250 ng/cm2 of
protein by assuming a linear dependence of adsorbed VN
with solution concentration, as predicted by the Langmuir
adsorption isotherm and corroborated by Ponceau S staining
and the Bradford protein assay (Fig. 5A, B). Thus, VN is
effective for promoting cell adhesion and supporting the
expansion of pluripotent stem cells at surface densities well
below its saturation, which is estimated at 500 ng/cm2.
AFM image resolution was limited by the radius of the
AFM probe tip, which is nominally 20 nm. This prevents the
FIG. 4. Long-term analysis of HES-3 cells cultured on TCPS coated from different VN concentration. (A) Representative
Tra1-60 and OCT-4 marker expression by fluorescence-activated cell sorting at passage 5. HES-3 cells on VN1.25, VN2.5, and
VN5 with mTeSR. Shaded bar represents isotype control expression and unshaded bar represents Tra1-60 and OCT-4 marker
expression. Cells expressed >90% positive for these markers. (B) EB in vitro differentiation assay was done for passage 5 HES-
3 cells cultured on VN2.5 with mTeSR1 medium. HES-3 cells were able to differentiate into the three germ layers with
expression of AFP (endoderm), Hand1 (mesoderm), and NFH (ectoderm) genes, downregulation of Nanog and OCT-4 plu-
ripotent markers, and GAPDH as house keeping gene. (C) Karyogram of HES-3 cells cultured on VN1.25 and (D) VN2.5 with
mTeSR1 after five passages. No chromosomal abnormalities were observed in both conditions.
‰
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detection of individual VN molecules, which may be ap-
proximated by a cylinder of radius 3 nm and length 11 nm.19
Larger VN aggregates appear as point-like asperities on the
randomized line-feature background of the TCPS substrate.
Only the height of VN aggregates is cited, since dimensions
in the plane of the surface are convoluted with the tip di-
ameter. Their size is comparable to that reported by Zhang
et al., for VN molecule aggregates adsorbed onto smooth mica
surfaces.23 Lynn et al. describe the formation of VN aggre-
gates in solution and Izumi et al. report the presence of VN
aggregates with a Stokes radius of 6.5 nm in human plas-
ma.19,41 Thus, the observed VN aggregates may have be
adsorbed from solution or may be formed as VN adsorbs to
TCPS. Higher VN solution concentrations may lead to its
adsorption in a different configuration, potentially giving
rise to the observed decrease in resolution when imaging
VN20. This observation correlates with colloidal gold stain-
ing images (Fig. 6K–P). Colloidal gold staining, although not
FIG. 5. (A) Quantification of VN adsorbed to TCPS, deduced from VN depletion in the depositing phosphate-buffered
saline (PBS) as measured by Bradford assay. (B) Surface density of VN adsorbed to TCPS versus concentration of the
depositing solution Ponceau S was used to stain VN on the coated surface. Both Bradford assay and Ponceau S staining
showed that density plateau at VN10. (C) Ponceau S staining of VN adsorption kinetics onto VN5. (D) Ponceau S staining of
VN5 desorption from TCPS. n¼ 3, standard error of the mean.
Table 4. Equations, with x Representing the Ordinate and y, the Abscissa, with Fitting Parameters
for Adsorption and Desorption Kinetics of Vitronectin on Tissue Culture Polystyrene
Data Equation A y0 T
Adsorption y¼A(1 – exp(x/T)) 0.0146 0.0003 1.2 0.2
Desorption y¼Aexp(x/T)þ y0 0.0042 0.0003 0.0118 0.0002 4.2 0.7
Data and fitted curves shown in Figure 6. For adsorption, A reflects the maximum surface density of VN and T is the time constant. For
desorption, A reflects the initial surface density of VN, T is the time constant, and y0 reflects staining of nondesorbed VN.
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quantitative, may be used to discern increases in the ad-
sorbed protein surface density. However, the increase in VN
surface density deposited from solutions 10mg/mL con-
trasts with Ponceau S staining, the Bradford assay, and XPS
data.
An estimate of the minimum protein volume required for
masking the roughness of the underlying substrate is ob-
tained from bearing analysis of the AFM profile generated by
bare TCPS. This yields a VN surface density of 1.7 mg/cm2,
which exceeds the highest quantified VN surface density, of
*0.5 mg/cm2 by a factor of three. Given that the adsorbed
VN is not sufficient to fill in the roughness of the TCPS
substrate surface, it is expected that only spot-like features
associated with adsorbed VN aggregates are discernible.
We note that mTeSR1 is not a completely defined media,
due to the presence of BSA. However, this is not expected to
significantly alter our conclusion of a minimum threshold
concentration of 5mg/mL of VN to achieve a viable platform
for long-term hESCs culture. A further examination of this
threshold may be performed in a completely chemical de-
fined xeno-free medium such as X-VIVO10. Although the
field is moving toward the use of recombinant proteins, these
proteins are cloned and expressed in animal cells that are a
source of foreign antigen (Neu5Gc). Further, animal cells
may provide an inappropriate glycosylation pattern to the
protein of interest and thus render it inactive. Serum-derived
proteins, despite being subject to lot-to-lot variability and
the possibility of contamination from plasma, retain the
biological activity of the protein. Future biotechnological
innovations may provide the means to overcome these con-
tradicting drawbacks in protein synthesis.42
The observation of a minimum VN surface density raises
the issue of its efficiency and cost effectiveness within the
context of large-scale industrial manufacturing processes.
Characterization and quantification of defined substrates
suitable for hESCs expansion will render the translation
of this technology into a scaled-up process for generating
clinical-grade stem cells more feasible and reliable.20–22 As
FIG. 6. (A) X-ray photoemission spectroscopy quantification of surface composition for TCPS coated with VN versus de-
positing solution concentration. Atomic force microscopy profilometry images, representing sample height, of (B) bare TCPS,
(C) VNo, (D) VN2.5, (E) VN5, (F) VN10, and (G) VN20. (H) and (I) are images of phase data from same samples: (B) bare TCPS
and (D) 2.5 mg/mL. Image ( J) shows a closeup of the marked area on image (I). The height range is 0–25 nm; the phase range is
08–158. The scale bar is 1mm on all images except image ( J), where it is 200 nm. Colloidal gold staining of (K) VN0, (L) VN2.5,
(M) VN5, (N) VN10, (O) VN15, and (P) VN20. The diameter of each disk is 15mm. Color images available online at www
.liebertonline.com/ten.
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described above, the nonspecific adsorption of VN on TCPS
results in *50% of VN in solution being deposited on the
surface. Therefore, the production of large quantities of stem
cells may benefit from an optimization of VN binding and
VN bioactivity on these cell culture substrates.
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The standard method for culturing human embryonic stem cells hESC uses supporting feeder
layers of cells or an undeﬁned substrate, Matrigel™, which is a basement membrane extracted from
murine sarcoma. For stem cell therapeutic applications, a superior alternative would be a deﬁned,
artiﬁcial surface that is based on immobilized human plasma vitronectin VN, which is an
adhesion-mediating protein. Therefore, VN adsorbed to diverse polymer surfaces was explored for
the continuous propagation of hESC. Cells propagated on VN-coated tissue culture polystyrene
TCPS are karyotypically normal after 10 passages of continuous culture, and are able to
differentiate into embryoid bodies containing all three germ layers. Expansion rates and pluripotent
marker expression veriﬁed that a minimal VN surface density threshold is required on TCPS.
Further exploration of adsorbed VN was conducted on polymer substrates with different properties,
ranging from hydrophilic to hydrophobic and including cationic and anionic polyelectrolyte
coatings. Despite differing surface properties, these substrates adsorbed VN above the required
surface density threshold and were capable of supporting hESC expansion for 10 passages.
Correlating wettability of the VN-coated surfaces with the response of cultured hESC, higher cell
expansion rates and OCT-4 expression levels were found for VN-coated TCPS, which exhibits a
water contact angle close to 65°. Importantly, this simple, deﬁned surface matches the performance
of the benchmark Matrigel, which is a hydrogel with highly complex composition. © 2010
American Vacuum Society. DOI: 10.1116/1.3525804
I. INTRODUCTION
Human embryonic stem cells hESC are isolated from
the inner cell mass of blastocysts and thus retain the ability
to differentiate into the three primary germ layers endo-
derm, ectoderm, and mesoderm. They offer the potential for
applications in tissue repair and drug discovery.1 Obtaining
signiﬁcant numbers of hESC is a prerequisite for their use in
both research and industrial scale applications. This drives
efforts to explore cell culture environments that are capable
of hESC propagation, which is deﬁned as the expansion of
hESC over multiple passages while preserving their karyo-
typic stability and pluripotency.2 The current standard
method for hESC culture employs a Matrigel™ MG cell
culture substrate,3 which is a commercial product distributed
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by Becton Dickinson. It consists of a gelatinous membrane
extracted from a mouse sarcoma, rich in laminin-111, and
contains collagen, entactin, heparan sulfate proteoglycans,
and several growth factors.3 Several methods also employ a
cell culture medium that is conditioned by exposure to inac-
tivated mouse or human feeder cells.1,4–6 This conditioning,
when supplemented by basic ﬁbroblast growth factor, main-
tains pluripotency of hESC. However, these poorly deﬁned
cell culture environments may be a source of xenogenic risk
and are not suitable for generating clinical-grade cells for
medical applications. Recent efforts have focused on devel-
oping a deﬁned cell culture environment that is capable of
the stable and prolonged expansion of hESC. Hakala et al.
recently showed the performance of MG to be superior to
other cell culture substrates when used to expand hESC in
deﬁned cell culture media.7 As a natural product, MG suffers
from batch-to-batch variability and introduces a complex
protein mixture. It may also expose cultured hESC to non-
human sialic acid, an immunogenic molecule that can limit
its industrial scale-up for clinical applications.
With the aim of deﬁning surface properties that are suit-
able for hESC culture, a study by Derda et al. screened an
array of surface-immobilized short peptide sequences.8 Spe-
ciﬁc surface properties showed promise and the study iden-
tiﬁed a surface density threshold. However, the surface den-
sity threshold was not quantiﬁed and hESC pluripotency was
inferred from expression of the OCT-4 genetic marker, which
is necessary but not sufﬁcient criterion for establishing hESC
pluipotency. A later study demonstrated the stable propaga-
tion of hESC in a deﬁned culture medium on a synthetic
surface consisting of selected peptide sequences covalently
bound to an acrylate polymer matrix.9 Karyotypic stability of
the expanded hESC was veriﬁed and their ability to differ-
entiate into the three germ layers was established in vitro.
Kolhar et al. showed that a cyclic arginine-glycine-aspartic
acid RGD peptide sequence conjugated to amine moieties
presented on tissue culture plastic is capable of supporting
the long-term propagation of hESC and the peptide surface
density was estimated at 10–30 fmol /cm2 from ﬂuores-
cence measurements.10 A full synthetic polymer surface with
tunable wettability and rigidity has been shown to support
hESC expansion in conditioned cell culture medium.11 How-
ever, this surface could not support the long-term propaga-
tion of multiple hESC lines in deﬁned, serum-free medium.
Indeed a recent comprehensive study reports that wettability
may be optimally tuned to enhance hESC proliferation but
integrin engagement with surface-presented vitronectin is re-
quired to promote hESC colony formation and ensure a vi-
able platform.12
To develop a cell culture platform based on deﬁned extra-
cellular matrix ECM proteins, Ludwig et al. used human
collagen IV, laminin, ﬁbronectin, and vitronectin to expand
hESC in a deﬁned cell culture medium.13 Although the
propagated hESC expressed pluripotency markers and were
able to differentiate in vivo, prolonged expansion resulted in
karyotypic instability, which may result from adaptation to
the new platform. Similar studies have found that single-
component matrices provide viable substrates for the stable
propagation of hESC: laminin, ﬁbronectin, laminin-511, and
vitronectin.14–17
With the emergence of a deﬁned substrate as a realistic
possibility, Braam et al. identiﬁed that surface-presented vit-
ronectin VN enables the adhesion of hESC and activates a
key integrin, which is believed to play a role in supporting
the long-term propagation of hESC.16 This study was ex-
tended to the propagation of human induced pluripotent stem
cells cultured on VN by Rowland et al.18 They identiﬁed the
same integrin as mediating cell attachment but added that its
subsequent inhibition enhanced cell proliferation.18 VN is an
ECM protein that promotes cell adhesion and spreading.19 A
recent study by Yap et al. demonstrated the long-term propa-
gation of multiple hESC lines on VN immobilized by ad-
sorption on tissue culture polystyrene TCPS.20 A novel as-
pect of this work was the quantiﬁcation of the adsorbed VN
surface density. Correlation of this data with the response
from cultured hESC established that a threshold VN surface
density of 250 ng /cm2 is required to successfully expand
these cells while preserving their pluripotency.20 Moreover,
VN surface density on TCPS equal to or greater than this
threshold provides a cell culture surface that matches the
performance of MG in both deﬁned and conditioned cell
culture media and provides the opportunity to adapt this plat-
form to the culture of hESC at scale.
Having established that VN adsorbed to TCPS is a viable
substrate capable of supporting the long-term propagation of
multiple hESC lines,20 the present study examines VN pre-
sented by polymer substrates with a variety of surface prop-
erties, namely: bare, coated with cationic and anionic poly-
electrolyte, and rendered hydrophilic from plasma treatment.
Heparin, which presents afﬁnity-binding sites for VN,19 was
also introduced as an anionic polyelectrolyte. Following an
initial screening of these surfaces, with and without VN coat-
ing, the long-term propagation of a single hESC line is tested
on four promising candidates, whose performance is corre-
lated with quantiﬁcation of the adsorbed VN surface density.
The relationship between the surface wettability and the
propagation of hESC was also assessed. The scale-up poten-
tial of these surfaces was probed by measuring the hESC
proliferation rate and estimating the population doubling
time using optical detection followed by a ﬁnal cell count.
II. EXPERIMENT
A. Preparing the cell culture substrates
1. Coating tissue culture polystyrene with varying
vitronectin surface density
TCPS surfaces were coated with human plasma-puriﬁed
VN at different surface densities, as described by Yap et al.20
Brieﬂy, VN solutions of varying concentration were prepared
by diluting 1 mg/ml stock VN solution Millipore CC080
with sterile 1phosphate buffered saline PBS, diluted
from 10PBS Sigma P5493 using pure water
PURELAB® Option Q, Elga to 1.25, 2.5, 5, and 10 g /ml
VN1.25, VN2.5, VN5, and VN10, respectively. These so-
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lutions were used to coat 60 mm center-well TCPS organ
culture dishes, OCD, Becton Dickinson Biosciences by in-
cubating the OCD with 300 l of the solution at 4 °C for 15
h. The VN-coated OCDs were rinsed brieﬂy with PBS before
using them as substrates for cell culture.
2. Preparation of VN-coated polymer substrates with
different surface properties
Biaxially oriented polyethylene terephthalate PET and
polystyrene PS ﬁlms, 100 and 125 m thick, respectively,
were sourced from Goodfellow Cambridge, UK. Circular
disks, 16 mm in diameter, were cut from the ﬁlms and were
cleaned by soaking in isopropanol. These were rinsed in pure
water and blow-dried with nitrogen before use. An in situ
polymerized, grafted polyacrylic acid PAA brush was de-
veloped on PET using the method described by Racine et
al.,21 with a UV activation time of 15 min and a UV poly-
merization time of 5 min. The surface density of the car-
boxylic acid groups on PET-PAA was quantiﬁed by Tolui-
dine Blue O Sigma-Aldrich T3260 staining and titration, as
described by Racine et al.21
Bare PET ﬁlms and PET-PAA ﬁlms were brieﬂy rinsed
with water and dried under nitrogen airﬂow before sterilizing
them for 15 min within 70% ethanol, followed by twice rins-
ing in sterile PBS, in the sterile environment of a biological
safety cabinet NuAire Nu-425-400E. The PET-PAA sur-
faces were activated by a 15 min exposure to a pH 10 buffer
solution, consisting of 0.0214M NaOH Goodrich Chemical
Enterprise, Singapore and 0.05M sodium hydrogen carbon-
ate Merck, which ensured charging of the PAA brush. This
was followed by two rapid rinses in PBS before the surfaces
were coated with poly-L-lysine PLL. The PET and PET-
PAA disks were coated with PLL in an OCD, which was
ﬁlled with 400 l of 50 g /ml PLL Sigma-Aldrich P6282
in PBS solution. The samples were incubated for 20 min
followed by three rinses in PBS. The PLL surface density on
PET was measured by Ponceau S staining, using the method
described by Yap et al.20 Similarly, surfaces were coated with
heparin in an OCD by incubating with 400 l of a
100 g /ml heparin Sigma H3149 solution in PBS for 30
min, followed by three rinses with PBS. Autoclaving was
used to sterilize PBS and the pH 10 buffer solution. PLL and
heparin solutions were sterilized by ﬁltration through sterile
NALGENE® syringe ﬁlter membranes with a pore size of
0.2 m Nalge Nunc International Corporation using a 10
ml sterile Injekt® syringe B. Braun Melsungen AG.
Oxygen-plasma-treated PET and PS ﬁlms PET-plasma
and PS-plasma, respectively were activated in a plasma
chamber Triple P, Duratek, Inc. using a 100 W, 2.45 GHz
radio frequency discharge applied to an oxygen gas pressure
of 3.510−1 Torr for 1 min. These ﬁlms were subsequently
sterilized by a 15 min exposure to the UV light in the bio-
logical safety cabinet.
Coating of PET-plasma, PS-plasma, bare PET, PET
+PLL, PET+PLL+heparin, PET-PAA, PET-PAA+PLL, and
PET-PAA+PLL+heparin disks with VN was achieved by
placing them in sterile as-received OCDs, where they were
weighed down by cylindrical glass rings borosilicate glass,
outer diameter of 17 mm, wall thickness of 1.5 mm, and
height of 10 mm. The surfaces were coated from a 400 l
volume of 5 g /ml vitronectin in PBS by incubating them
for 15 h at 4 °C, followed by a brief rinse with PBS imme-
diately prior to cell seeding.
3. Control cell culture substrates coated with
Matrigel™
Control cell culture plates consisted of OCDs coated with
Matrigel™ Becton Dickinson and Company, Franklin Lakes,
NJ. Cold KnockOut KO medium, consisting of 85% KO-
Dulbecco’s modiﬁed eagle medium Invitrogen 10829-018,
15% KO serum replacement Invitrogen 10828-028, 1 mM
L-glutamine Invitrogen 25030-032, 1% nonessential amino
acids Invitrogen 11140-050, 10 ng/ml FGF-2 Invitrogen
PHG0021, 0.1 mM 2-mercaptoethanol Invitrogen 21985-
023, 25 u/ml penicillin, and 25 g /ml streptomycin Invit-
rogen 15140-122, was used to dilute MG in a 1:30 ratio.
Each OCD was coated with 1 ml of this coating solution for
15 h at 4 °C, followed by a brief rinse in KO medium before
cell passaging.
B. Biological responses of hESC on vitronectin
surfaces
1. Culture of hESC on TCPS coated with different VN
surface densities
HES-3 46, XX cells ES Cell International were cul-
tured in conditioned medium CM, prepared as described by
Yap et al.20 The received cells were ﬁrst cultured at
37 °C /5% CO2 on TCPS dishes coated with MG. They were
then adapted to TCPS dishes coated with VN5 for over ten
passages. Cells from VN5 were then tested on TCPS dishes
coated with VN1.25, VN2.5, VN5, and VN10. In these ex-
periments, the cell culture medium was changed daily and
the cells were passaged weekly, as described by Yap et al.20
The passaging process for HES-3 cells grown on MG
coated TCPS involved the removal of differentiated cells by
pipetting and treatment with collagenase IV 200 u/ml for 3
min at 37 °C. They were dissociated by scraping and re-
peated pipetting into small clumps and seeded into freshly
coated OCD at a 1:5 split ratio. The passaging process for
HES-3 cells cultured on all VN-coated surfaces followed the
one used for MG. The hESC passage is abbreviated as Pn,
where n denotes the passage number e.g., passage 2, P2.
2. Growth tracking of hESC on different matrices
In the ﬁrst set of experiments, 1105 HES-3 cells /cm2
were seeded into TCPS coated with VN1.25, VN2.5, VN5,
and VN10, as well as a MG control. These experiments were
performed over 6 weeks and growth curves over 7 days were
measured at P2, P6, and P7. Samples were run in triplicate at
each passage and for each condition.
Freshly-seeded cells were cultured in an incubator Gal-
axy R, RS Biotech Laboratory Equipment Ltd. for 48 h,
after which the media in the dish was refreshed and the cells
were imaged with the stem cell imaging system SCIS, de-
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veloped by Oh et al.22 The cell culture medium was subse-
quently refreshed daily and the cells were also imaged daily
from day 2 to day 7. SCIS image analysis measured the
surface area covered by cells. A threshold value was set on
the system such that it detected cell colonies observed on the
OCD, without the opaqueness of the different cell culture
substrates impinging on the calculation of the total area cov-
ered by the cells. From the zone of linear cell area expansion,
the expansion rate was calculated as the time-rate increase in
area. Cells harvested on day 7 were resuspended in 1 ml and
counted with a NucleoCounter® NC-100™ ChemoMetec
A/S, Denmark. Cell coverage of the surface and cell expan-
sion rates on the OCD or polymer disks were normalized to
the surface area available for cell attachment within the im-
age or to the inner diameter of the glass ring. These surface
areas in the OCD and on the disk are approximately 2.4 and
2 cm2, respectively.
The second set of experiments used the same procedure as
described above with HES-3 cells that were previously cul-
tured for over ten passages on TCPS coated with VN5.
HES-3 cells were mechanically passaged weekly and seeded
onto PET, PET+PLL, PET-PAA, PET-plasma, or PS-plasma
disks at a split ratio of 1:5. TCPS+VN5 and TCPS+MG
were included as the positive controls in this experiment. At
P13, 2.5104 HES-3 cells /cm2 were seeded onto these
freshly coated surfaces, and their growth rates, maximum
cell numbers, and pluripotent marker expression were moni-
tored in triplicate.
3. Flow cytometry analysis
Flow cytometry, also known as ﬂuorescence activated cell
sorting FACS, was performed by targeting the cell surface
marker mAb 8423 and transcription factor OCT-4, with an
isotype control. After dissociating into a single cell suspen-
sion with TrypLE™ Express Invitrogen, cells are ﬁxed and
permeabilized with reagent A and B Caltag Laboratories,
Invitrogen. During the cell permeabilization step, mAb 84
1:20,23 a cytotoxic antibody to hESC and OCT-4 1:20,
Santa Cruz mouse monoclonal antibodies were added to re-
agent B. Cells were then washed with 1% bovine serum al-
bumin in PBS, followed by incubation with ﬂuorescein
isothiocyanate conjugated goat antimouse antibody 1:500,
DAKO in the dark. They were then washed and resuspended
with 1% bovine serum albumin in PBS and analyzed on a
FACSCalibur Becton Dickinson as described by Yap et al.
Brieﬂy, data were collected from 10 000 cells, and the per-
centage of cells positive for the marker was gated at the
intersection of the control and marker histograms.
4. Spontaneous differentiation and quantitative real
time polymerase chain reaction analysis
Embryoid bodies were generated with HES-3 cells from
P6, which were cultured on VN5 OCD for 1 week, after
which they were scraped off and cultured in an ultralow at-
tachment six-well plate Corning, Inc. in a differentiation
medium, prepared as described in Chin et al.24 Following
their growth in suspension for 1 week, the cell aggregates
were dissociated by repeated pipetting into small clumps and
replated onto an OCD coated with 0.1% gelatin, then cul-
tured for 2 weeks, with differentiation medium replaced ev-
ery 2 days. On day 21 of differentiation, total ribonucleic
acid RNA was harvested from these cells following the
protocol of the RNeasy mini kit Qiagen GmbH, Germany.
For each well of the MicroAmp® optical 96-well reaction
plate Applied Biosystems BV 4306737, 26 ng of total RNA
was converted to complementary DNA using Superscript II
Invitrogen 18064-022. Quantitative real time polymerase
chain reaction qRT-PCR was performed with a SYBR®
green PCR master mix Applied Biosystems BV kit, used in
an ABI PRISM® 7500 Applied Biosystems BV, whose
software analyzed the optical absorption data. The primers
used for qRT-PCR are listed in the supplementary Table S1.25
5. Karyotype analysis
HES-3 cells expanded on TCPS coated with VN1.25,
VN2.5, VN5, and VN10 were harvested following P10 and
grown on an OCD coated with VN5 for 4 days. Karyotype
analysis of these cells was carried out on 20 G-banded
metaphases by the Cytogenetics Laboratories of the KK
Women’s and Children’s Hospital.
6. Screening assay for HES-3 cells cultured on
polymer substrates with and without VN5 coating
The short-term adhesion assay was designed to screen
surfaces for HES-3 cell adhesion and subsequent expansion.
If no signiﬁcant numbers of cell colonies attached within 1
day, the surface was designated as nonviable. This designa-
tion is also applied when cultured cells did not attain sufﬁ-
cient numbers for passaging after 7 days. Continuous passag-
ing of the cells relied on the number of colonies attached to
the surface generating sufﬁcient cells for the next passage.
HES-3 cells were prepared as described above and seeded
onto PET, PET+PLL, PET+PLL+Heparin, PET-PAA,
PET-PAA+PLL, PET-PAA+PLL+Heparin, PET-plasma,
and PS-plasma disks with and without VN5 coating. Surviv-
ing colonies from different surfaces were passaged for up to
8 weeks.
C. Surface characterization
1. Determination of VN surface density on surfaces
by Ponceau S staining
Protein surface density was determined by Ponceau S
staining.20 For this experiment, 400 l VN solutions of 0,
2.5, 5, 10, and 20 g /ml were used to coat PET, PET-PAA,
PET-plasma, and PS-plasma surfaces for 15 h at 4 °C, as
described above for cell culture substrates. The top surface of
the coated polymer ﬁlms was exposed to Ponceau S staining
solution Sigma-Aldrich for 15 h at room temperature. After
three rinses in water and blow-drying, each sample was
placed into a new OCD and 400 l of 0.1M NaOH was
added to each sample. The samples were then shaken gently
for 20 min, allowing desorption of Ponceau S stain from the
sample surface. Samples were run in duplicates, yielding
four 200 l aliquots per VN concentration. Each aliquot was
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placed in a ﬂat-bottom 96-well plate and neutralized with
15 l of 50% acetic acid J. T. Baker. Colorimetric absorp-
tion was measured at 515 nm on an Inﬁnite® 200 multimode
microplate reader Tecan, Switzerland. This was compared
to a standard curve, which was generated using Ponceau S
concentrations ranging from 0 to 10 g /ml in 5% w/v
acetic acid. The Ponceau S surface density was converted
into a VN surface density by establishing a relationship be-
tween the adsorbed Ponceau S stain and the quantiﬁcation of
VN adsorbed to TCPS, using data reported by Yap et al.20
Assuming similar accessibility to Ponceau S stain of VN
adsorbed to PET, PET-PAA, PET-plasma, and PS-plasma
surfaces, the VN surface density was thus inferred from the
Ponceau S stain surface density. The same Ponceau S stain-
ing and its subsequent quantiﬁcation were used to estimate
the PLL surface density on the PET+PLL substrate.
2. Contact angle measurements
The water contact angles w of TCPS, PET, PET+PLL,
PET-PAA, PET-plasma, and PS-plasma surfaces with and
without different VN coating concentrations were measured
at ambient temperature on a manual contact angle goniom-
eter model 100, Ramé-Hart, Inc.. Five 1 l sessile pure
water drops were measured on each sample. The average
contact angle and its standard deviation were determined
from contact angles measured on duplicates of each polymer
surface.
D. Statistical analysis
Data values are reported as mean and standard deviation.
Graphs were plotted and data were transformed with Mi-
crosoft Ofﬁce Excel 2007 software. Student t-tests were per-
formed between experimental and control conditions. P
values0.05 were considered to represent statistically sig-
niﬁcant differences.
III. RESULTS AND DISCUSSION
A. Growth of HES-3 cells on TCPS coated with
different concentrations of VN
Figure 1 shows representative images from triplicate cul-
tures on different VN surface densities at P6. Growth of
HES-3 cells on TCPS coated with VN1.25 and VN2.5 ap-
pears patchier than TCPS coated with VN5, VN10, and the
MG control. Bare patches, devoid of hESC, appear on the
VN1.25 and the VN2.5 samples at day 2 and growth over 7
days appears to be more clustered. In comparison, cells
spread more evenly in the other three conditions. After 7
days’ culture, cells have not fully occupied the surface of
VN1.25. The SCIS quantiﬁes this growth trend by plotting
the total area of the OCD occupied by HES-3 colonies,
showing the most rapid hESC expansion rates on VN5,
VN10, and MG, while VN2.5 and VN1.25 substrates show
progressively lower expansion rates Fig. 1b. Cell culture
images at days 2 and 3 Fig. 1a indicate poorer cell attach-
ment and lower numbers of spreading HES-3 colonies on
VN1.25 and VN2.5. The area expansion rates in Fig. 2a
were derived from the linear growth portion of this data and
similar data at P2 and P7. Although growth rates of HES-3 at
P2 appear similar at all VN concentrations, the images taken
from P6, shown in Fig. 1, indicate that hESC adapted to
lower VN concentrations lose viability, resulting in a sharp
decrease in growth rates of HES-3 cells cultured on TCPS
coated with VN1.25 at P7 Fig. 2a. Indeed, despite the
early signs of viable hESC culture on VN1.25, cells passaged
on this surface all but lose their ability to adhere and expand
by P7, highlighting the importance of testing the robustness
of new culture platforms beyond ﬁve passages. Figure 2b
shows the ﬁnal cell numbers, measured with a cell counter,
which differ slightly from the estimates generated by the
SCIS area measurement. Moreover, the folded layer seen on
day 7 Fig. 1a, which is a consequence of the poor adher-
ence of cells cultured on VN1.25, leads to larger discrepan-
cies between the calculated areas on the TCPS surface and
the ﬁnal cell numbers, as observed for P7 in Figs. 2a and
2b. Despite these differences, ﬁnal cell numbers follow the
FIG. 1. a Images of HES-3 colonies cultured on TCPS coated with MG,
VN1.25, VN2.5, VN5, and VN10, respectively, from day 2 to day 7 of P6.
The diameter of each image circle is 14.5 mm. b Area data representing the
surface covered by HES-3 cells from day 2 to day 7 on the same TCPS
surfaces. These are calculated by SICS from triplicate runs of images similar
to those shown in a.
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trends established from area expansion rates: both param-
eters are signiﬁcantly lower on VN1.25 at P6 and P7 than on
higher VN surface densities and the MG benchmark. More-
over, the VN1.25 OCD surface covered by hESC at day 7 of
P6 is approximately half that of the other TCPS surfaces and
the MG control. These results conﬁrm that TCPS coated with
VN1.25 is insufﬁcient for optimal hESC expansion and that
VN5 provides the required surface density to support hESC
culture without compromise. The latter propagates hESC
with an efﬁciency equal to VN10 and the MG positive con-
trol.
B. Pluripotency of HES-3 cells on TCPS coated with
different concentration VN solutions
Flow cytometry analysis of OCT-4 and mAb 84 pluripo-
tency markers at P10 are shown in Fig. 3. HES-3 cells cul-
tured on TCPS coated with VN2.5, VN5, VN10, and the MG
control surface express an equally high percentage of these
pluripotent markers. Distinctly lower expression levels are
exhibited by HES-3 cultured on TCPS coated with VN1.25,
for which the downregulation of mAb 84 implies a probable
loss of pluripotency. Moreover, visual examination of HES-3
cells cultured on VN1.25 at P10 reveals a more ﬁbroblastic
morphology and loss of the hESC phenotype data not
shown.
HES-3 cells cultured on TCPS coated with VN1.25,
VN2.5, VN5, and VN10 were tested at P6 for their in vitro
differentiation capability. As shown in Fig. 4a, differenti-
ated cells show downregulation of the NANOG and OCT-4
pluripotency markers and upregulation of GATA6, Hand1,
and PAX6, which are representative of the endoderm, meso-
derm, and ectoderm lineages, respectively. This veriﬁes the
ability of cultured HES-3 cells at P6 to differentiate into the
three primary germ layers. Moreover, chromosome analysis
of HES-3 at P10 indicates that the cells retain their normal
FIG. 2. a Area expansion rate during linear expansion phase and b cell
numbers at day 7 for HES-3 cells at P2, P6, and P7 on TCPS surfaces coated
with MG, VN1.25, VN2.5, VN5, and VN10, respectively. At P6 and P7,
TCPS coated with VN1.25 shows a signiﬁcant decrease in growth rate as
compared to the other surfaces. =P0.05.
FIG. 3. FACS analysis of OCT-4 and mAb 84 pluripotent markers for P10 HES-3 cells cultured on surfaces of TCPS+MG, TCPS+VN1.25, TCPS
+VN2.5, TCPS+VN5, and TCPS+VN10. Cells grown on MG were used as a positive control.
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diploid karyotype, as depicted in Figs. 4b–4e. Thus, cells
cultured on TCPS coated with VN, irrespective of the surface
density, retain their ability to differentiate at least up to P6
on VN1.25 and maintain stable karyotype.
C. Growth of HES-3 cells on different polymer
substrates coated with VN5
Preliminary cell adhesion and proliferation were used to
screen the polymer substrate surface properties, bare and
coated with VN5. As reported in Table I, surfaces without
VN coating do not promote HES-3 attachment and cannot
support the formation of viable HES-3 cell colonies, thus
indicating that exogenous VN is required to promote the ad-
hesion and support the expansion of hESC. Moreover, for
surfaces with polyelectrolyte multilayer coatings
comprising4 layers PET-PAA+PLL+heparin+VN5, the
substrate cannot support HES-3 expansion, despite it being
coated from VN5 solution. With a smaller number of multi-
layers, the surface is capable of supporting HES-3 propaga-
tion to at least P13 TCPS+VN5, PET+VN5, PET+PLL
+VN5, PET-PAA+VN5, PET-plasma+VN5, PS-plasma
+VN5, PET+PLL+heparin+VN5, and PET-PAA+PLL
+VN5.
SICS was used to track HES-3 proliferation on model
polymer surfaces coated with VN5. Figure 5a shows im-
ages of P13 cells from day 2 to day 7, indicating that all the
VN-coated surfaces promote cell adhesion and support their
expansion. The increase in area covered by expanding cells,
shown in Fig. 5b, depicts a similar trend across all the
surfaces tested, including the TCPS+VN5 and MG positive
controls. The area expansion rates for the two positive con-
trol surfaces are moderately but distinguishably higher than
those for other surfaces Fig. 5c. The PET+PLL+VN5
surface differs by having an initial high area expansion rate,
followed by a lower area expansion rate after day 4. Figure
5c reports the ﬁnal cell numbers, which are measured inde-
pendently of the SICS data. Again, hESCs cultured on MG
and VN5 show the highest cell densities compared to the
other polymer surfaces at P10 P0.05. Looking more
closely at the day 7 images Fig. 5a, PET+VN5 and
PET+PLL+VN5 appear to grow a thinner layer of HES-3
cells. This observation arises from the absence of brighter
white areas, which are seen on other substrates. It is reﬂected
in the ﬁnal cell numbers, which indicate that these two sur-
faces yield the lowest cell numbers at day 7.
D. Undifferentiated state of HES-3 cells on different
plastics coated with VN5
Flow cytometry measurements of mAb 84 and OCT-4 ex-
pression levels serve to indicate whether P13 HES-3 cells are
differentiating. Figure 6 shows that greater than 50% and
90% of the cells are positive for OCT-4 and mAb 84, respec-
tively, across the different plastic surfaces. Lower OCT-4
levels of expression occur for HES-3 cells cultured on VN-
coated PET and PS-plasma. However, this decrease is not
reﬂected by the levels of mAb 84 expression for these two
surfaces. In general, hESC appear to express pluripotent
markers across all polymer surfaces over several passages,
implying that these substrates may be suitable for long-term
culture.
E. Surface characterization
1. Quantiﬁcation of surface-adsorbed VN
Ponceau S stain adsorbed to VN-coated polymer surfaces
was quantiﬁed following its desorption. Assuming a linear
FIG. 4. Color online a Expression of genetic markers following the in
vitro 21 days’ spontaneous differentiation of P6 HES-3 cells cultured on
TCPS coated with VN1.25, VN2.5, VN5, and VN10. Karyotype maps of
P10 HES-3 cells cultured on TCPS coated with b VN1.25, c VN2.5, d
VN5, and e VN10.
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increase in adsorbed VN surface density for solution concen-
trations below 10 g /ml, the constant relating VN surface
density to Ponceau S was determined to be SVN=22 752SP,
where SP is the Ponceau S surface density in nmol /cm2 and
SVN is the VN surface density in ng /cm2. Figure 7 shows the
adsorbed VN surface density, calculated from Ponceau S
staining data using this relationship.
From Fig. 7, both PET and PET-PAA surfaces adsorb
higher VN surface densities than PET-plasma and PS-
plasma. Quantiﬁcation of VN adsorbed to PET+PLL was not
feasible due to Ponceau S staining of both PLL and VN. For
these polymer substrates, the surface density adsorbed from
VN5 is 250 ng /cm2, which is the threshold established by
Yap et al.20 for culturing hESC on TCPS. This threshold is
corroborated by HES-3 cell expansion rates on TCPS coated
from VN5 Fig. 1. Thus, these polymer substrates immo-
bilize a VN surface density that is expected to be sufﬁcient
for supporting the expansion of HES-3 cells.
2. Effects of surface wettability on the propagation
and pluripotency of HES-3 cells
Substrate wettability can inﬂuence the bioresponse of cul-
tured cells.12,26–28 Figure 8a shows the sessile water drop
wettability of polymer surfaces coated with increasing VN
surface density. Adsorbed VN reduces the wettability of hy-
drophobic PET and increases the wettability of hydrophilic
PS-plasma. As the VN surface density reaches saturation, the
wettability of these two substrates converges to 47°–48°. For
TCPS and PET-plasma, adsorbed VN gives rise to a modest
rise in contact angle, from 58° to 66° and from 49° to 58°,
respectively. Similarly, for PET-PAA and PET+PLL, the wa-
ter contact angle increases from 52° to 67° and from 60° to
68°, respectively. With saturating VN adsorption, we may
consider that the polymer substrate is fully coated with ad-
sorbed protein molecules. Atomic force microscopy mea-
surements reported by Yap et al.20 discern aggregates of ad-
sorbed VN molecules but are unable to resolve individual
molecules, which are presumed to coat the intervening re-
gions of the polymer substrate.
TCPS consists of plasma-treated PS, which has been
stored and shipped, probably over several weeks or months.
Given that bare PS exhibits a water contact angle approach-
ing 90° and that freshly plasma-treated PS is fully wettable,
the 58° measured contact angle of as-received TCPS reﬂects
the evolution of this surface since its fabrication. The wetta-
bility increase following plasma treatment is due to the free-
radicals and polar groups that were generated by polymer
chain scission. During storage, these groups partially resorb
into the bulk polymer, giving rise to a progressive decrease
in wettability.29 Even after their long-term storage, TCPS
surfaces present polar groups within a surface layer of 3–5
nm.
29 Freshly plasma-treated PET and PS expose randomly
charged hydrophilic polar moieties, such as CuO, CvO ,
OuCvO, and Ou CvOuO components.29,30 In con-
trast, PET+PLL exposes a cationic polymer with uNHu
and uNH2 moieties, and PET-PAA presents an anionic
grafted polymer brush, with a carboxyl acid group
uCOOH surface density of 11.51.4 nmol /cm2. PET
+PLL exhibits a Ponceau S density of 0.230.4 nmol /cm2,
which is comparable to that of a saturated VN coating on
FIG. 5. a Representative images of HES-3 from day 2 to day 7 of P13 on
the following surfaces: TCPS+MG, TCPS+VN5, PET+VN5, PET+PLL
+VN5, PET−PAA+VN5, PET-plasma+VN5, and PS-plasma+VN5, re-
spectively. Diameter of the image circles is 14.5 mm. b Area covered by
HES-3 cells on these surfaces from day 2 to day 7 at P13. c Area expan-
sion rate of HES-3 cells at P13 and total cell numbers on day 7 at P13. The
data on the area expansion rate and HES-3 cell numbers are calculated by
SICS from triplicate runs of images similar to those shown in a. =P
0.05, which applies only to the area expansion rate data.
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TCPS.20 Thus, polymer substrates without an overriding net
surface charge are hydrophobic bare PET, hydrophilic PET-
plasma and PS-plasma, and TCPS and PET-plasma, both of
which have intermediate wettability. VN adsorbed by hydro-
phobic interactions is expected to expose hydrophilic groups.
Conversely, VN coated on a hydrophilic surface may expose
hydrophobic segments of the protein, thus decreasing the
surface wettability.31 While this may explain the convergence
in wettability when VN adsorbs to bare PET and to PS-
plasma substrates, the mere presence of a saturated VN coat-
ing may account for the observed wettability change. Simi-
larly, VN adsorption to PET+PLL and PET-PAA is
dominated by charge interactions and the adsorbed VN mol-
ecules contribute to the ﬁnal surface wettability.
Given the surface charge presented by PET+PLL and
PET-PAA, the HES-3 response to these VN-coated surfaces
may also be inﬂuenced by the protein’s conﬁguration. VN
FIG. 6. FACS analysis of OCT-4 and mAb 84 surface marker for HES-3 cells at P13 cultured on the following surfaces: TCPS+MG, PET+VN5, PET
+PLL+VN5, PET-PAA+VN5, PET-plasma+VN5, and PS-plasma+VN5, with MG used as a positive control.
FIG. 7. Adsorbed VN surface density vs the concentration of the depositing
solution for PET, PET-PAA, PET-plasma, and PS-plasma surfaces.
FIG. 8. a Water contact angles of VN-coated surfaces as a function of the
depositing VN solution concentration. These surfaces include the following:
TCPS, PET, PET+PLL, PET-PAA, PET-plasma, and PS-plasma. b Total
cell numbers and expression of the OCT-4 pluripotency marker for HES-3
cells at P13. These are plotted vs the water contact angle of the following
surfaces: TCPS+VN5, PET+VN5, PET+PLL+VN5, PET-PAA+VN5,
PET-plasma+VN5, and PS-plasma+VN5.
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contains a similar number of negatively 66 and positively
56 charged residues ExPASy, human VN: P04004, which
allow it to adsorb to both cationic and anionic surfaces, with
similar efﬁciency but via different domains. The bare PET
and PS-plasma surfaces represent the hydrophobic and hy-
drophilic extremes, respectively, of underlying substrate
properties and are not expected to carry a strong net charge.
When coated with VN5, these surfaces adsorb the highest
and lowest levels of VN, which differ by almost a factor of 2
Fig. 7. From Schvartz et al.,19 the integrin-binding domain
lies at the opposite end of the VN molecule, with respect to
the heparin-binding domain. The latter is presumed to be
cationic, adsorbing more favorably to PET-PAA. The
collagen-binding domain, adjacent to the integrin-binding
segment, may be expected to bind more favorably to PET
+PLL. Thus, it is surprising that VN adsorbed to different
surfaces is capable of promoting the adhesion and supporting
the expansion of hESC. This is likely due to the protein’s
ﬂexibility and the presence of several redundant RGD-
binding sequences,32 which facilitates their accessibility.
Long-term culture on these polymer substrates gives rise
to different HES-3 proliferation rates and levels of pluripo-
tency. Given that these surfaces are coated with a VN surface
density250 ng /cm2, above the threshold for the HES-3
bioresponse, this leads to an examination of how their wet-
tability may inﬂuence the expansion of HES-3 cells. Data
from Figs. 5c and 6 are plotted versus surface wettability
Fig. 8a to yield Fig. 8b. VN-coated PS-plasma and PET
exhibit the highest wettability and give rise to the lowest
levels of OCT-4 expression for cultured HES-3 cells Fig.
8b. These surfaces, with underlying substrates that repre-
sent the uncharged extremes of the wettability spectrum, also
generate lower ﬁnal cell numbers. The highest efﬁciency for
HES-3 culture, as measured by ﬁnal cell number and OCT-4
expression level, is obtained on VN-coated TCPS with a con-
tact angle of 63°. Lim et al. found that the adhesion efﬁ-
ciency of human fetal osteoblastic cells correlates strongly
with substrate wettability, obtaining high rates of cell attach-
ment on relatively hydrophilic surfaces and low rates on hy-
drophobic surfaces, with w=65° as the deﬁned
boundary.12,28 For the cationic and anionic surfaces: PET
	PLL	VN5 and PET-PAA	VN5, OCT-4 expression re-
mains high but total cell numbers fall with respect to VN-
coated TCPS. These data indicate that, the VN-coated
polymer substrate properties, including surface wettability,
inﬂuence the rate of HES-3 cell proliferation and their pluri-
potency.
The data reported in the present study and by Yap et al.20
provide a clear indication that the TCPS substrate coated
from VN5 provides an performance equivalent to MG, which
is the current industry standard and benchmark.7 Given that
Matrigel is a water-swellable coating and contains a number
of ECM proteins and polysaccharides,33 it is interesting to
note that VN-coated TCPS, which is a comparatively rigid
substrate coated with only one ECM protein, is equally ca-
pable of supporting the expansion of multiple hESC lines.
This efﬁciency has been measured by cell pluripotency,
karyotype stability, and cell proliferation rates.
IV. CONCLUSIONS
The perspective of hESC manufacturing in respect of
clinical-grade requirements for therapeutic applications
drives the replacement of MG with a deﬁned substrate that
supports the stable propagation of hESC. VN-coated polymer
surfaces were used for the long-term expansion of HES-3
cells in CM. TCPS coated with solution concentrations
VN5 provides a viable substrate, capable of expanding
these cells for over ten passages. Cells maintain karyotypic
stability and are able to spontaneously differentiate in vitro,
where embryoid bodies show evidence of the three primary
germ lineages. HES-3 cells cultured on TCPS coated with
VN2.5 show a slight decrease in their cell expansion rate, as
measured by SICS at P6. When cultured on VN1.25, the cells
initially appear viable, but show a marked decrease in their
adherence to the cell culture substrate at P6, terminating in a
sharp reduction in the number of viable cell colonies at P7.
This adaptation of the cells is also reﬂected in a decrease in
their expression of the OCT-4 and mAb 84 pluripotency
markers, which are expressed normally in HES-3 cultured on
higher VN surface densities.
Other forms of VN surface presentation were pursued us-
ing diverse polymer surfaces, ranging from hydrophobic to
hydrophilic, with the inclusion of anionic and cationic poly-
electrolyte coatings. An initial screening conﬁrmed that all
these polymer substrates require a VN coating to promote the
adhesion and support the expansion of HES-3 cell colonies.
The only exception was a four multilayer coating
PET-PAA+PLL+heparin+VN5, which did not support the
growth of HES-3 colonies. Coatings of 
3 multilayers were
able to support HES-3 expansion over at least 13 passages,
indicating that VN adsorbed to these surfaces with different
properties is capable of the long-term expansion of hESC.
The performance of simple model surfaces TCPS, PET,
PET+PLL, PET-PAA, PET-plasma, and PS-plasma coated
with VN5 was correlated with their wettability to sessile wa-
ter drops. From the expression of OCT-4 and mAb 84 mark-
ers at P13, VN-coated PET and PS-plasma exhibit a higher
wettability and generate a potential loss in HES-3 pluripo-
tency. Cationic and anionic PET+PLL and PET-PAA, re-
spectively, give rise to slower expansion rates at P13. The
highest expansion rates and pluripotency marker expression
levels are observed with VN-coated TCPS, which exhibits a
contact angle of 65°, a result that compares favourably with
data generated by Mei et al.12
TCPS+VN5 and the benchmark MG matrix show equal
performance, both for the proliferation rate and the expres-
sion of pluripotency markers in HES-3 cells. These surfaces
are capable of the long-term expansion of multiple hESC
lines,20 while preserving karyotypic stability and pluripo-
tency. This similarity in performance between VN-coated
TCPS and Matrigel is remarkable, given that the former is an
adsorbed ECM protein, while the latter is a hydrogel coating
of complex composition.
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